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Abstract 
Multiple Sclerosis is the most common non-traumatic cause of neurological disability in 
young people. Until recently few treatments existed for Multiple Sclerosis and Interferon 
beta was the first and remains the most commonly prescribed. As a biological product it 
induces antibodies to the protein which may abrogate the efficacy of the drug (neutralising 
antibodies - NAbs). Testing for these antibodies has been problematic as biological assays 
are difficult to standardise, time consuming and expensive. In the experiments described 
here we sought to develop a novel cell-based reporter-gene assay to reliably test for Nabs, 
to explore the relationship between NAbs, treatment efficacy, biological activity and 
correlate NAb titres with in vivo biomarker induction to establish guidelines to interpret 
results. The work presented in this thesis describes the development and validation of the 
luciferase assay and has shown that subjects who develop NAbs experienced increased 
relapse rates, (which lag behind the appearance of NAbs). Evaluating the in vivo biological 
response to IFNβ injection it was established that in subjects with NAbs there was titre 
dependent loss of bioactivity with reduced myxovirus resistance protein A (MxA) level in 
those with  titres 100 – 600 NU and absent response in those with titres > 600 NU. Opinion 
amongst neurologists (UK, USA, Canada and Austria) regarding NAbs was evaluated and 
revealed uncertainty of their significance in the clinical setting, and the reluctance of some 
neurologists to incorporate NAb testing into routine practice. Results were similar in the 
countries surveyed in that 90 – 100% were aware of NAbs and thought they abrogate 
clinical efficacy, yet few routinely tested for them, particularly in the UK. The validated 
luciferase assay has since been dissemintated to 9 countries. Since it’s launch in the UK in 
2006 over 4,000 patients have been tested for NAbs. This work directly translates into 
clinical practice and provides a useful service to aid management of subjects with MS.  
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Chapter 1  
                                                         Multiple Sclerosis
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 Multiple Sclerosis 
 
1 Introduction 
Multiple Sclerosis (MS) is the most common inflammatory demyelinating disorder of 
the central nervous system. It is a chronic disabling disease largely affecting young people 
with onset between 20 – 40 years of age; onset of the disease is rare in children and those > 
50 years of age. MS is typically characterised by episodes of neurological deficit followed 
by periods of remission. MS has an incidence of approximately seven per 100,000 per year 
and a lifetime risk of 1:400. Worldwide it is estimated that MS affects 2.5 million people 
(approximately 100,000, i.e. ~1:600 people in the UK) and its economic impact is 
considerable [Compston and Coles 2002; Compston and Coles 2008]. Overall life 
expectancy is reduced by about 7 years and living with chronic disability is the major 
burden of the disease [Ragonese et al. 2008]. Despite the strong genetic linkage and 
clustering of MS in some families the concordance rate between monozygotic twins is less 
than 30% [Willer et al. 2003; Mumford et al. 1994 ; French Research group on MS 1992 ; 
Ristori et al. 2006]. It is likely that an interaction between genetic factors and the 
environment causes the disease. The female to male ratio is ~2:1 worldwide, but recent 
evidence suggests this may be increasing [Orton et al. 2006]. This sex bias is 
conventionally attributed to MS being a putative autoimmune disorder, but may be due to 
hormonal and/or due to other unidentified environmental factors. The trigger or triggers 
have not been identified to date but attention is focused on infectious and other 
environmental agents [Marrie 2004]. 
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Over the last fifteen years a number of new treatments which modulate the course of MS 
have emerged and treatment options continue to increase.  An overview of current concepts 
of the aetiology, immunology and pathology of MS will be given to provide a framework 
for explaining the mechanisms by which these new agents modulate the immune system in 
MS.  I will also summarise the efficacy and adverse effects of these agents and discuss how 
best to treat people with MS using interferon beta. 
 
1.1. Epidemiology 
Epidemiological observations have consistently described an effect of geography and 
latitude on the risk of MS.  The incidence of MS is higher in regions beyond a latitude of 
42° North or South of the equator [Kurtzke 2005]. MS predominantly affects people of 
Northern European extraction, with lower rates in the USA, Australia and New Zealand. 
Countries close to the equator have a much lower incidence of MS. Migration studies have 
shown that children migrating before adolescence (generally < 15 years of age) assume a 
risk close to that of the destination country [Gale and Martyn 1995; Martyn and Gale 
1997]. Several cohorts have described increased incidence of MS in the offspring of 
migrants to a high risk area; in Israel the frequency of MS in native born Israelis of African 
/ Asian origin is equal to that in those of European / American origin rather than the lower 
rate of their forebearers [Kahana et al. 1994]. Similarly children born in the UK to 
immigrants from the Indian subcontinent acquire the risk of the native population [Elian et 
al. 1990]. Recent reviews question this, and migration prior to the age of 15 is no longer 
considered the crucial time, rather somepoint within the first two decades of life 
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[Hammond et al. 2000]. It is now thought that primary exposure to a particular agent after 
puberty or during adult life may be the trigger. There is evidence suggesting that viral 
infection may play an important role in pathogenesis [Gilden 2005]. The occurrence of 
mini-epidemics and clusters of MS, such as that in the Faroe Islands, support the 
hypothesis that an environmental – possibly infectious – agent plays a role in the initiation 
and possibly perpetuation of the disease [Kurtzke and Heltberg 2001; Kurtzke 2002]. The 
rising incidence of MS in some regions seems to be particularly amongst women and the 
rate at which this occurs indicates that genetic factors are unlikely to be solely responsible 
rather environmental factors are implicated and may also be influenced by increased 
ascertainment and altered diagnostic criteria [Noonan et al. 2002]. 
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1.2. Aetiology 
Epidemiological evidence suggests that MS is caused by interplay between genes and 
the environment and thus can be considered a complex trait disorder. The genes responsible 
for complex diseases such as MS are not due to individual gene mutations and the 
production of abnormal proteins but are normal polymorphisms, each acting independently, 
exerting a small contributory effect on some as yet undefined structure or physiological 
function [Compston and Coles 2008]. Twin studies indicate a genetic susceptibility with a 
concordance rate of ~ 20 – 30% between monozygotic twins [French research group on MS 
1992; Mumford et al. 1994; Willer et al. 2003] and increased risk of MS in those who have 
an affected relative [Dyment et al. 1997]. Susceptibility genes have been identified using 
population studies, candidate gene studies and whole genome linkage screens. These have 
elucidated susceptibility genes including HLA class II alleles (DRB1*1501, DRB5*0101 
and DQB1*0602) [Olerup and Hillert 1991] and more recently specific alleles of the IL2 
and IL7 receptors [Hafler et al. 2007] Since this time several genome wide association 
studies have been performed and 14 genes have been identified including CLEC16A, 
TNFRSF1a (CD120a), IRF8, RPL5/EVI5, CD226, TYK2, CD6, CD40 amongst others 
[Burton 2007, Baranzini 2009, ANZgene 2009]. The geographical distribution of people 
with MS, may be partially accounted for by genetic factors and homogenous populations 
but cannot be accounted for on the basis of genetics alone, but rather suggests a 
contributory role of an environmental agent in the pathogenesis of MS. It is unclear if the 
role of an external trigger is in initiating the disease only, or whether it also modifies the 
disease course. Several infectious agents have been proposed as triggers of MS, including 
Epstein Barr virus (EBV), human herpes virus 6 (HHV6), canine distemper virus, human 
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endogenous retroviruses (HERV) and Chlamydophila.  However, none of the above has so 
far stood up to rigorous investigation [Giovannoni et al. 2006].  Despite inconclusive 
results, exposure to an infectious agent (or a sequence of agents) at a vulnerable age is 
currently considered an important element for MS to develop in an individual carrying 
specific susceptibility genes. 
 
 
1.3. Immunology and Pathology 
The hallmarks of MS pathology are sharply defined lesions in the CNS, which are 
characterised by inflammation, demyelination, relative axonal preservation, and gliosis 
[Hohlfeld and Wekerle 2004].  These lesions (plaques) may develop in any part of the 
CNS, though they have a tendency to accumulate near the periventricular and outer 
surfaces of the brain and spinal cord. The lesions are usually round to oval, and are 
centered on one or several medium sized vessels [Lassmann and Wekerle, 2006]. Apart 
from MS plaques in the white matter (WM), studies carried out as early as 1890 have 
shown that plaques can also be found in the grey matter (GM) [Dawson 1962; Brownell 
and Hughes 1962], including the cerebral and cerebellar cortex, the basal ganglia and the 
spinal cord [Kutzelnigg et al. 2005; Kutzelnigg et al. 2007; Gilmore et al. 2006].  Usually, 
WM lesions in samples of MS brain can be macroscopically identified and vary in size 
(from less than one mm to several centimetres), shape and number.  They have a pink or 
grey opaque appearance.  Whereas lesions in the WM are pathognomonic of MS 
pathology, changes are also seen in the non-lesional WM, including astrocytic 
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proliferation, perivascular inflammation, blood brain barrier leakage, a certain degree of 
sclerosis of blood vessels and occasional demyelination [Allen and McKeown 1979; Albert 
et al. 2007; Miller et al. 2003].  Despite the relative preservation of axons and neuronal cell 
bodies in MS lesions, damage to both does occur, and this damage probably determines the 
long-term clinical manifestations of the disease [Trapp et al. 1998; Peterson et al. 2001].  
Although demyelinated lesions are the most characteristic feature of MS pathology, 
changes also occur in non-lesional brain tissue, so-called normal appearing white matter 
(NAWM) [Zeis et al. 2008] and normal appearing grey matter (NAGM) [Albert et al. 
2007]. 
 
1.3.1. Lesion formation 
Current concepts of MS lesion formation are often based on findings derived from 
experimental allergic encephalomyelitis (EAE), an animal model that resembles certain 
features of MS [Mix et al. 2008].  Against this backdrop MS has been described as a 
disease that is primarily mediated by autoreactive T-cells (CD4+), which target specific 
epitopes in the CNS. It has been postulated that by crossing the blood brain barrier and 
coming into contact with target antigens, a cell mediated inflammatory reaction is initiated. 
Putative autoantigens include myelin basic protein (MBP), proteolipid protein (PLP), 
myelin oligodendroctye glycoprotein (MOG), myelin associated glycoprotein (MAG) and 
αB crystallin [van Sechel et al. 1999; Pender and Greer 2007]. Once activated, T-cells 
produce an array of pro-inflammatory cytokines, which stimulate other T-cells, B-cells, 
natural killer cells, macrophages and microglia that in turn augment and perpetuate the 
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inflammatory process. These cytokines promote increased permeability of the blood brain 
barrier, alteration of adhesion molecule expression, production of antibodies and 
recruitment of other cells of immune function into the CNS.  The presence of macrophages 
and T cells (both CD4+ and CD8+) has been shown in the brain parenchyma of MS 
patients [Sospedra and Martin 2005] and clonotypic CD8+ T cells have also been described 
in the CSF [Jacobsen et al. 2002]. The environment in MS lesions is complex with roles for 
T cells (Th1, Th2 and Th17 CD4+ cells), cytotoxic CD8+ cells, macrophages, NK cells and 
microglia. Secretion of both pro and anti-inflammatory molecules; proteases, nitric oxide 
derivatives, reactive oxygen species, cytokines – IL-6, TNFα, IL-4 and IL-10, may occur in 
the same lesion and cytokines may be essential in CNS repair [Hohlfeld et al. 2007]. The 
discovery of Th17 cells (CD4+ subset) has further advanced understanding of T cell 
regulation. These cells, stimulated by IL-23, secrete IL-17 along with IL-6 and TNFα, and 
EAE evidence suggests they play an important role in inflammation and lesion formation 
[Bowman et al. 2006].  
 
 
1.3.2. Neurodegeneration 
Whilst demyelination is the most obvious feature of the MS lesion, neurodegeneration 
has also been initially described 140 years ago [Charcot M 1868].  Damage to axons may 
be mediated directly by cytotoxic T-cells, macrophages, antibodies, loss of trophic support 
by oligodendrocytes and oxidative stress [Sospedra and Martin 2005; Sayre et al. 2008].  
Axonal transection in MS lesions is well described in pathological studies, the frequency of 
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which appears to be related to the degree of inflammation in lesions [Trapp et al. 1998]. 
Loss of trophic support for axons and exposure to toxic metabolites leads to degeneration 
of axons. Redistribution of Na+ channels, mitochondrial failure and Ca2+ mediated toxicity 
may all contribute to axonal degeneration in MS [Waxman 2006a; Waxman 2006b]. 
 
1.3.3. Lesion classification 
Several histological staging systems have been proposed to classify MS lesions in the 
WM. Commonly used classifications include the one that resulted from the Vienna 
consensus conference [Lassmann et al. 1998] and the staging system by van der Valk and 
de Groot [Van der Valk and De Groot 2000].  As a rule, demyelinated lesions in the WM 
are classified as active, chronic active or inactive. The relationships between remyelination 
(shadow plaques) [Prineas et al. 2001]) of formerly demyelinated lesions and lesion 
activity has yet to be clarified [Van der Valk and De Groot 2000].  Lesions in the MS grey 
matter have been variably classified – largely according to their location – into three, four 
or seven subtypes [Kidd et al. 1999; Peterson et al. 2001; Bo et al. 2003].  
Recent pathological studies have promoted the hypothesis of lesion heterogeneity in 
MS with several lesion subtypes being described. The Lassmann/Luchinetti/Bruck 
collaboration described four different patterns of actively demyelinating lesions. Pattern 1 
is characterised by a predominantly T cell and macrophage infiltrate, pattern 2 by antibody 
and complement deposition, pattern 3 by oligodendrocyte apoptosis and pattern 4 by non-
apoptotic oligodendrocyte loss [Lucchinetti et al. 1996; Lucchinetti et al. 2000; Lucchinetti 
et al. 2004].  Whether these four patterns indeed allow distinction between four categories 
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of patients (based on their lesion pathology), and whether the described lesion types are – 
as their exponents claim – unequivocally homogenous within a given patient, however, 
remains controversial [Esiri et al. 2009].  Another challenge to traditional views of lesion 
formation has emerged from the observation of oligodendrocyte apoptosis (in the relative 
absence of an inflammatory infiltrate), which has been interpreted as an early or initial step 
in lesion formation [Barnett and Prineas 2004]. According to this research oligodendrocyte 
apoptosis would secondarily lead to microglial activation and subsequent phagocytosis of 
dying/apoptotic oligodendrocytes. The immunoglobulin and activated complement 
deposited on myelin could also activate microglia, which in turn initiate a secondary 
immune response. Apoptotic bodies were only found in a minority of lesions and generally 
in those from subjects with early disease, which may reflect it being present either very 
early in lesion formation or a factor illustrating the heterogeneous nature of MS pathology. 
This hypothesis is however supported by reports of cortical demyelination in the absence of 
leukocyte infiltration [Peterson et al. 2001]. Axonal loss, which correlates more closely 
with disability, has been noted in the absence of focal inflammatory lesions [Lassmann et 
al. 2001].  Whether or not the axonal loss is independent of focal inflammation or due to 
Wallerian degeneration in response to inflammatory lesions along the axonal pathway has 
yet to be determined.  Evidence in support of the latter hypothesis has recently been 
produced [Tallantyre et al. 2009; Frischer et al. 2009]. 
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1.3.4. Remyelination 
Remyelination, a reparative process mediated by oligodendrocytes depends on 
numerous factors, including switching the balance of the inflammatory process in favour of 
production of immunomodulatory cytokines and growth factors such as IL-4, IL-10, Brain 
Derived Neurotrophic Factor (BDNF) and Transforming Growth Factor -β (TGFβ).  
Factors such as those mentioned above play a role in remyelination, which may, at least in 
part, underpin remission of symptoms and clinical signs between relapses. Research 
involving stem cell transplantation suggests there may be a need for a certain degree of 
inflammation to facilitate remyelination [Foote and Blakemore 2005]. Understanding the 
mechanisms underlying remyelination is key to developing treatments that will have an 
effect not only on the inflammatory but also on the neurodegenerative component of MS, 
and repair [Hartung et al. 2004; Hemmer et al. 2002; Franklin and Ffrench-Constant 2008]. 
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1.4. Clinical Features 
The clinical presentation of MS reflects the impaired function at affected sites. 
Demyelination interferes with conduction of action potentials along axons, which results in 
the symptoms and neurological deficits experienced by patients. The conduction block 
caused by partial demyelination may be intermittent, which accounts for intermittent 
recrudescence of symptoms, for example in response to rises in body temperature 
(Uhthoff’s phenomenon) [Saul et al. 1995].  The disease course is highly variable between 
subjects with 85-90% of patients experiencing a relapsing/remitting course, which over 
time becomes secondary progressive in the majority of patients. In a minority (10 -15%) 
the disease course is progressive and without “attacks” from the onset (primary progressive 
MS). Some patients (<5%) with an apparent primary progressive course will go on to 
experience superimposed relapses after a progressive onset (progressive-relapsing MS). A 
typical relapse frequency is between 0.8-1.2 per year, but this can be highly variable. Over 
time the relapse frequency declines [Compston and Coles 2008]. However, in all clinical 
subtypes disability eventually accrues over time. Fixed disability arises from either 
incomplete recovery from relapses, or insidiously in the non-relapsing primary or 
secondary progressive forms of the disease. 
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Figure 1-1 Clinical Course of MS 
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1.4.1. Diagnosis 
The diagnosis of MS requires demonstration of dissemination of the disease process in 
both time and space, and exclusion of other causes. The diagnosis is made clinically with 
the use of paraclinical tools, such as MRI [Figure 1-2], CSF analysis (showing intrathecal 
synthesis of oligoclonal bands or IgG) [Figure 1-3], visual, brainstem or somatosensory 
evoked potentials.  The introduction of the McDonald criteria (2001) and subsequent 
revision have enabled an earlier diagnosis of MS following a single clinical event 
[McDonald et al. 2001; Polman et al. 2005]. Many patients initially present with an acute 
monosymptomatic episode of neurological dysfunction due to a single lesion, known as a 
clinically isolated syndrome (CIS) [Miller et al. 2008]. Most of these patients (~80%) will 
eventually develop MS [Fisniku et al. 2008].  The limited pathological examinations 
carried out on patients with CIS suggest that histological changes are similar to those in 
MS.  
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Figure 1-2 MRI is a useful tool in diagnosing MS 
Hyperintense lesions in the brain and spinal cord (indicated by red arrows) are characteristic of MS  
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Figure 1-3 Immunoblot of oligoclonal bands 
C represents CSF, S represents serum. Working from left to right blots are shown with (i) negative 
CSF and Serum (C- S-), (ii) matched bands in CSF and serum (C+ S+), (iii) CAF bands more 
numerous than serum bands (C++>S+) denoting central and systemic production and (iv) Unmatched 
bands in CSF not present in serum (C++ S-) which is typical of OCBs in subjects with MS 
 
 
  
Figure 1-4 Visual evoked potentials. 
Recordings of a subject with optic neuritis due to MS. The conduction is seen to be delayed in the lower 
panel which is consistent with demyelination 
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1.5. Treatment 
First line disease modifying treatments (i.e. the beta interferons and glatiramer-acetate) 
have now been available in the UK for about 15 years.  These drugs are on average 
partially effective in reducing the number of relapses by about one third and possibly 
delaying disease progression. Current opinion favours starting treatment early in the course 
of the disease, as neurodegeneration (for example brain atrophy) can be detected from the 
very first manifestations of the disease, and at least a proportion of these degenerative 
changes may be secondary to inflammation [Frischer et al. 2009a]. Hence, starting 
treatment early could potentially reduce the occurrence of relapses and subsequent 
development of disability [Jacobs et al. 2000; Kappos et al. 2007; Comi et al. 2001; 
Clerico et al. 2008]. Emerging treatment strategies take into account the different 
pathological mechanisms that have been identified in MS, in particular strategies to protect 
against demyelination and axonal loss. Treatments predating interferons generally and non-
specifically suppressed the immune response, with sub-optimal outcomes. Although in 
hindsight the majority of clinical trials performed in the pre-interferon era were 
underpowered. Potential targets for treatment include immune dysfunction, permeability of 
blood brain barrier, components of the inflammatory cascade, putative autoantigens, 
demyelination, axonal loss (neuroprotection) and remyelination and regenerative processes 
(growth factors).  
 
The complexity of decision making with respect to treatment choices in MS, continues 
to increase. The number of products on the market is steadily increasing. The effects of the 
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currently used first-line agents are modest but they have a very good safety profile that 
seems to have stood the test of time (IFNβ & Glatiramer Acetate).  Two drugs that have 
more recently been licensed for use in MS are potentially more efficacious, but their use is 
limited by unfavourable adverse effect profiles (Natalizumab, Mitoxantrone).  
The currently licensed disease modifying treatments for MS are: 
• Interferon-β 1a IM (Avonex – Biogen-Idec) 
• Interferon-β1a SC (Rebif - Merck-Serono)  
• Interferon-β 1b SC ( Betaferon- Bayer-Schering) 
• Interferon-β 1b SC ( Extavia- Novartis) 
• Glatiramer Acetate SC ( Copaxone- Teva-Aventis)  
• Natalizumab IV (Tysabri™ - Biogen-Idec) 
• Mitoxantrone IV (Novatrone® - Merck-Serono USA or generic product in UK)  
 
Other agents used in MS, but not specifically licensed for this disorder, include: 
Corticosteroids, Cyclophosphamide (Cytoxan), Azathioprine (Imuran), Methotrexate 
and intravenous immunoglobulin (IVIg). Reducing relapse rate probably prevents the 
acquisition of permanent disability caused by incomplete recovery from relapses, but this 
does not necessarily have an effect on the insidious progression that occurs independently 
of attacks. IFNβ and GA have both been shown to reduce relapse rates and MRI measures 
of disease activity. Although they are well tolerated their effectiveness is only partial, and 
none has been shown to be effective in primary progressive MS [Wolinsky 2004; Leary et 
al. 2003; Montalban 2004]. 
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1.5.1. Interferon beta 
Interferons are a family of proteins which stimulate inter- and intra- cellular responses 
to regulate viral infections, modulate the immune response and cell survival. Type 1 
interferons were originally developed as therapeutic agents in MS because of their anti-
viral activity [Borden et al. 2007] and although this may partially explain their 
effectiveness in MS, they have numerous other immunomodulatory activities including 
altering the Th1/Th2 balance [Hussien et al. 2001], antagonising pro-inflammatory 
cytokines (IFNγ, IL-12 and TNFα), down regulating MHC class II expression - affecting 
antigen presentation [Yong et al. 1998], anti-proliferative effects on T cell expansion, 
differentiation and increased T cell apoptosis [Sharief et al. 2001; Yong 2002]. There is 
also evidence that type 1 interferons inhibit transmigration of immune cells across the 
blood-brain barrier (BBB) [Leppert et al. 1996]. Production of IFNs is a transient response 
to microbes including viruses, bacteria and protozoa. [Akira et al. 2006]. Interferons 
mediate their response by binding to their high affinity cell surface receptors and initiating 
a signalling cascade. The type 1 IFN receptor is composed of two subunits IFNAR1 and 
IFNAR2 which are associated with cytoplasmic tyrosine kinases TYK2 and Janus Kinase 1 
(JAK1) [Uze et al. 2007]. The IFN molecule usually binds to IFNAR2 which then recruits 
IFNAR1 and induces autophosphorylation of JAK1 and subsequently STAT (signal 
transducers and activators of transcription). These inturn activate nucleotide sequences or 
interferon stimulated response elements (ISRE) in the promoters of several genes [Platanias 
2005]  [Figure 1-5]. 
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Figure 1-5 Interferon molecule interacting with IFN receptor  
 
 
Two types of recombinant IFNβ products have been synthesised; IFNβ-1a is produced 
in Chinese hamster ovary (CHO) cells and is genetically identical to the human form of 
IFNβ.  IFNβ-1b is produced in E. Coli, is truncated and contains one amino-acid sequence 
that differs from the human form, and is non-glycosylated. Several separate trials have 
been conducted for each agent, and more recently head-to-head trials have been published. 
On average all IFNβ products have been shown to reduce the annualised relapse rate by 
approximately one third [MS study Group 1993; Jacobs et al. 1996; PRISMS 1998]. MRI 
indices are also favourable with a 50 – 70% reduction in disease activity using 
conventional MRI markers of disease activity (Gd-enhancing T1 lesions and new or 
enlarging T2 lesions). Efficacy regarding disability measures has been variable, with some 
trials showing an effect, others being inconclusive, and others that did not include disability 
as an outcome measure [PRISMS 1998; PRISMS-4 2001; Jacobs et al. 1996]. The IFNβs 
have generally been well tolerated, and side effects included flu-like symptoms, injection 
site reactions, myalgia and – in a few cases – possibly depression. Various strategies have 
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been proposed to manage these side effects [Munschauer, III and Kinkel 1997]. Further 
adverse effects include abnormal liver function tests, anaemia, leukopenia and 
thrombocytopenia, all of which can be monitored with regular laboratory tests.  
One of the most significant problems of IFNβ treatment is the production of drug 
specific antibodies. Up to 45% (mean ~ 25%) of patients develop neutralising antibodies 
(NAbs) to IFNβ products. NAbs may abrogate the clinical efficacy of IFNβs. Antibodies 
are more frequently induced by IFNβ-1b than 1a [Malucchi et al. 2004; Bertolotto et al. 
2003; Cook et al. 2001; Panitch et al. 2002]. Of the two IFNβ-1a products the 
subcutaneous IFNβ-1a (Rebif®) is more immunogenic than intramuscular IFNβ-1a 
(Avonex®). The development of NAbs is a significant factor contributing to treatment 
failure, and the reduction in relapse rate in subjects who remain NAb negative may be as 
high as 50% [IFNbeta MSSG 1996]. In order to define the role of IFNβ in treating patients 
with MS, the impact of NAbs, and the response of neurologists treating MS patients with 
IFNβ to NAb status, it is important to be aware of the alternative therapies for MS, their 
efficacy and safety profiles. NAbs to IFNβ will be discussed in detail in the section 
following DMTs [chapter 1.6]. 
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1.5.2. Glatiramer Acetate. 
Glatiramer Acetate (GA, Copaxone), is a mixture of synthetic polypeptides that 
quantitatively resembles MBP, a putative autoantigen in MS.  GA was found to suppress 
MBP-induced EAE [Teitelbaum et al. 2004]. Its mode of action is unclear but it has been 
shown to compete with MHC binding of MBP and limit activation of MBP reactive T-
cells. A broad T-cell response is seen after GA injection, and it is therefore likely that GA 
also mimics antigens other than MBP. GA leads to a shift in the T-cell population towards 
a Th2 cytokine response profile [Miller et al. 1998; Kim et al. 2004]. It has been proposed 
that these Th2 cells migrate through the BBB into the brain parenchyma, where they are 
activated. As a result they produce immunomodulatory cytokines that counteract the pro-
inflammatory Th1 response, an effect called “bystander suppression”. GA reactive T-cells 
have also been shown to secrete brain derived neurotrophic factor (BDNF), which has anti-
inflammatory and neuroprotective functions [Stadelmann et al. 2002; Ziemssen et al. 
2002]. In animal models of MS it has been shown that GA reactive T cells cross into the 
CNS and produce these factors [Aharoni et al. 2003]. Most of the described effects have 
been demonstrated in in vitro studies, and a number of questions with regard to GA’s 
mechanism of action remain as yet unanswered. In the pivotal trial 20 mg of GA SC daily 
was shown to reduce relapse rates by ~ one third and also had a favourable effect on MRI 
outcomes; Gadolinium enhancing lesions and measures of brain atrophy however a 
significant effect was not seen on T2 lesions [Johnson et al. 1995, Ge et al. 2000].  
Subsequent studies showed significant reduction of T2 lesions [Comi et al. 2001] and 
reduction of T1 black holes [Filippi et al. 2001]. Regarding adverse events injection site 
reactions are common with GA and lipodystrophy has been described [Drago et al. 1999]. 
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The most common side effect (~ 15%) however is an idiosyncratic self limiting reaction of 
chest tightness, flushing, dyspnoea and palpitations which can be quite frightening for the 
individual but generally resolves quickly and spontaneously. 
 
 
1.5.3. Natalizumab 
Natalizumab (TYSABRI, Biogen-Idec/Elan) is a humanised monoclonal antibody, 
which targets α4-integrin, acting as a selective adhesion molecule inhibitor. The 
glycoprotein α4β1 integrin is also known as very late antigen 4 (VLA4). It is expressed on 
the surface of lymphocytes and monocytes and plays an important role in cell adhesion and 
trafficking across the blood-brain and other endothelial barriers. VLA4 also acts as a 
regulator of activation of the immune system in areas of inflammation [Frenette and 
Wagner 1996a; Frenette and Wagner 1996b]. Natalizumab is given as a monthly infusion at 
a standard dose of 300mg.  It is not clear exactly how Natalizumab exerts its clinical effect 
but is thought to be due to the significantly reduced migration of leukocytes into the CNS 
parenchyma. 
Two phase III trials of Natalizumab have shown significant reduction in relapse rate 
and disease progression: The first trial (AFFIRM) involved treatment naive patients 
randomised to placebo (n=315) or 300mg Natalizumab (n=627) every 28 days for up to 28 
months.  The second trial (SENTINEL) involved patients who were established on IFNβ 1a 
30µg IM once weekly (Avonex) and had experienced one or more relapses in the 
previous year. Patients continued Avonex therapy and were randomised to either 300mg 
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Natalizumab (n=589) or placebo (n=582) infusions every 28 days. In the AFFIRM study 
patients treated with Natalizumab had a 66% reduction in relapse rate compared with 
placebo, 96% of subjects receiving Natalizumab had no new Gd enhancing lesions as 
compared with 68% on placebo [Polman et al. 2006; Miller et al. 2007]. A reduction in 
new and enlarging T2 lesions was also found. In the SENTINEL study patients on both 
Avonex and Natalizumab had a 54% reduction in annualised relapse rate as compared to 
placebo. With regards to MRI outcomes 96% of the combined treatment group had no 
enhancing lesions as compared with 76% of the Avonex only group. Similarly, fewer 
patients developed new or enlarging T2 lesions, on combination therapy [Rudick et al. 
2006]. 
  
However, at the end of February 2005 the use of Natalizumab was temporarily 
suspended after two patients receiving Natalizumab in combination with IFNβ-1a 
(Avonex®) developed progressive multifocal leukoencephalopathy (PML) one of whom 
subsequently died. A third subject with Crohn’s disease whose death had been attributed to 
glioma was also confirmed as having PML. Since this time Natalizumab was relaunched in 
June 2006 and several patients have subsequently developed PML (43 as per March 2010) 
and many have been naïve to prior immunomodulatory treatments. Emerging evidence 
suggests that subjects treated for > 2 years are at highest risk (European medicines agency 
Jan 2010). Although many patients are now treated with Natalizumab worldwide, vigilance 
is required with regards to its safety profile. Other side effects include anaphylactic 
reactions (~0.8%) and other hypersensitivity reactions, increased risk of infection, 
headache, depression, arthralgia and rash. Approximately 10% of patients receiving 
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Natalizumab develop antibodies, which are neutralising in vitro, with about 6% persisting 
beyond 12 months of treatment [Calabresi et al. 2007]. Therapeutic effectiveness was 
reduced in those who remain persistently antibody positive and relapse rates returned to 
that of those on placebo in both trials. Infusion reactions were also found to be more 
frequent and severe in those remaining antibody positive. Consideration of the safety 
profile and immunogenicity of Natalizumab as another biological agent to treat MS are 
factors to consider in its use. 
 
1.5.4. Corticosteroids. 
Corticosteroids are commonly used to treat acute relapses in patients with MS. They 
have potent anti-inflammatory, immunosuppressive and membrane-stabilising properties. 
They act by preventing disruption of the BBB, alter cell migration expression of adhesion 
molecules, decrease the production of pro-inflammatory cytokines and also promote 
apoptosis of auto-reactive T cells. All of these actions help restore the integrity of the BBB 
and reduce local inflammation and demyelination. A number of studies have shown that 
administration of high dose steroids (>500mg IVMP for at least 3 days) accelerates the 
recovery of disability, but does not influence the final outcome after a relapse or the risk of 
recurrent relapses [Brusaferri and Candelise 2000; Miller et al. 2000; Kapoor et al. 1998]. 
MRI studies have shown decreased number of T1 Gadolinium- enhancing lesions 
following steroid treatment [Barkhof et al. 1991; Miller et al. 1992]. A dose response effect 
has been noted, with high dose Methylprednisolone having more effect than low dose 
(<500mg/day) [Oliveri et al. 1998]. The beneficial effect of a single acute course of 
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corticosteroids lasts for a relatively short period of time, with MRI and other markers 
returning to baseline after approximately 2 months. Regular long-term administration of 
corticosteroids has recently shown a beneficial effect in RRMS and SPMS by reducing the 
accumulation of disability and MRI activity [Zivadinov et al. 2001; Goodkin et al. 1998].  
High dose IVMP given at time of relapse to patients treated with IFNβ, shows sustained 
reduction of Gadolinium-enhancing lesions as compared to steroids alone [Gasperini et al. 
1998].  
Recently studies have explored the effect of corticosteroids in preventing the 
development of neutralising anti-IFNβ antibodies (NAbs) or minimising their levels. It has 
been shown that treatment with concomitant steroids delays the appearance of NAbs and 
reduces the eventual titre. Concomitant use of immunosuppressive therapies in 
combination with various biological products is associated with a lower titre or the reversal 
of NAbs. In an open labelled study of 161 MS patients, receiving IFNβ-1b (Betaferon®, 
8MIU s.c. on alternate days), randomized to receive either intravenous methyl-
prednisolone 1g monthly for 12 months compared to no corticosteroids the prevalence of 
NAbs at 15 months in the prednisone treated group was 12.1% compared to 26.8% in 
untreated group, a relative reduction of 54.9% [Pozzilli et al. 2002a]. The beneficial effect 
of short-term steroid administration in acute relapse justifies their use, but their modest 
long-term benefits are outweighed by an unacceptable side-effect profile, which includes 
reduced bone density, cataracts, weight gain, hypertension, diabetes, avascular bone 
necrosis and propensity to infection. 
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1.5.5. Immunosuppression 
1.5.5.1. Mitoxantrone 
Mitoxantrone (Novantrone, Merck-Serono) was originally designed as a 
chemotherapeutic agent and is most commonly used in treating breast cancer. It is an 
anthracenedione, which inhibits topoisomerase-2 preventing the successful unwinding of 
DNA. It was shown to be effective in EAE [Lublin et al. 1987] and in both active RRMS 
and SPMS [Edan et al. 1997; Hartung et al. 2002; Le Page et al. 2008]. It is currently 
licensed in some countries (not the UK) for use in patients with aggressive relapsing MS 
who have failed first-line therapy. The mechanism of action of Mitoxantrone in MS may be 
mediated on a number of levels. It is immunosuppressive, inhibiting the proliferation of T 
cells, B cells and monocytes and reducing secretion of pro-inflammatory cytokines [Fidler 
et al. 1986], however it is non-specific in its immunosuppressive action. It is typically 
administered as IV pulses of 12mg/m2 every 3 months for two years (Hartung protocol) or 
20mg monthly for 6 months (Edan protocol). It has several serious side effects; most 
notably it is cardiotoxic and warrants monitoring of cardiac function [Ghalie et al. 2002]. 
In view of its cardiotoxicity the maximum recommended lifetime dose is 140mg/m2. There 
have been several reports of therapy-related acute myelogenous leukaemia in patients with 
MS who have received Mitoxantrone [Brassat et al. 2002; Ghalie et al. 2002]. Typically 
therapy related leukaemia, with topoisomerease II inhibitors such as mitoxantrone develops 
within 2-4 years after chemotherapy has been started, and the prognosis is generally poor 
amongst the breast cancer patients, those with MS appear to fare better. Initially it was 
reported to occur in 0.07% patients receiving Mitoxantrone but recently Merck-Serono 
have released data describing two cases in 802 MS patients (0.25%) [Edan 2005], and more 
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recently other studies have described the risk as 1 – 2 % [Le Page et al. 2008]. The post 
marketing data in breast cancer has shown a higher risk in patients who have had a 
combination of chemotherapeutic agents. It has therefore been advised that strict adherence 
to blood count recommendations should be followed including complete blood count, white 
cell differential and platelets prior to each infusion (Prescribing information 
NOVANTRONE- MerckSerono). There is also a risk of premature ovarian failure or 
infertility, which may be permanent. Transient amenorrhoea occurs in ~12% of patients 
and persistent amenorrhoea in ~10% of patients. The risk of persistent amenorrhoea is 
higher in woman older than 35 years (14%) and lower in women less than 35 years of age 
(6.5%) [Edan 2003]. 
 
 
1.5.5.2. Azathioprine 
Azathioprine (Imuran FARO Pharmaceuticals, Inc.) is a purine analogue which 
interferes with DNA synthesis. It’s exact mechanism of action is unknown but it is 
relatively T cell specific due to their lack of salvage pathway. It was previously widely 
used off-license to treat MS however, since the emergence of IFNβ and Glatiramer Acetate 
it is used less commonly. It is relatively T-cell specific but also suppresses both cell-
mediated and humoral immunity non-specifically. Much of the data concerning its efficacy 
is inconclusive as many of the studies performed were on heterogeneous populations in the 
pre-MRI era. Meta-analyses of published studies show a trend of reduced relapse rates and 
slowing of disability [Yudkin et al. 1991; Palace and Rothwell 1997]. In general 
Azathioprine cannot be recommended for use in MS because of doubts about its efficacy. 
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The Avonex Steroids Azathioprine trial compared three treatment arms evaluating the use 
of add on oral methylprednisolone +/- azathioprine in patients who had failed first line 
treatments. Participants were followed for 3 years with a one year extension phase. An 
effect was found was the reduction in ARR in the triple therapy group vs dual-placebo arm 
(0.73 vs 1.05 p <0.05) and regarding T2 lesion volume at 2 years, but this effect was not 
sustained at 5 years [Hardova et al. 2009]. It may however have a role in combination with 
other therapies, for example IFNβ to treat or prevent the development of NAbs. 
 
1.5.5.3. Cyclophosphamide 
Cyclophosphamide (Cytoxan Bristol-Myers-Squibb) is an alkylating agent and a 
potent cytotoxic and immunosuppressive drug which is commonly used in oncology but 
also in autoimmune conditions (vasculitis, lupus). Pulsed IV cyclophosphamide has been 
used in patients with evidence of active inflammatory MS however results have been 
conflicting. Early studies included a heterogenous group of MS patients and did not show 
significant benefit. Other trials however involving patients with very active disease showed 
significant improvement in relapse rate during treatment [Weiner and Cohen 2002]. Recent 
trials using pulsed IV Cyclophosphamide with IFNβ, showed significant clinical 
improvement during treatment and in the 18-month follow up period. Relapse rate declined 
significantly and was maintained for the follow-up period. MRI parameters also improved 
[Smith et al. 2005; Patti et al. 2001]. Due to its toxicity and risk of malignancy (transitional 
cell bladder carcinoma), it is only used as a second line agent. In general, the off-license 
use of cyclophosphamide for MS has been replaced by the licensed drug Mitoxantrone.  
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1.5.5.4. Methotrexate  
Methotrexate (Rheumatrex Lederle Pharmaceuticals) is an anti-metabolite with 
immunosuppressant properties. It confers its action by competitively inhibiting 
dihydrofolate reductase activity preventing thymidine synthesis and ultimately DNA 
synthesis. Its use in MS has been investigated in a number of small clinical trials and has 
been shown to slow disease progression in subjects with advanced chronic progressive 
(secondary and primary progressive) MS [Goodkin et al. 1995]. There remains a need for 
definitive placebo-controlled trials however with the advent of other oral therapies this is 
unlikely to occur. 
 
1.5.5.5. Intravenous Immunoglobulin (IVIg) 
IVIg is widely used in immune mediated systemic and neurological disorders and has been 
found to be of benefit in some aspects of MS [Achiron et al. 2004; Dalakas 1998]. A 
number of open label studies were initially performed followed by four randomised-
placebo controlled trials. Most have addressed its use in relapsing remitting MS and one 
more recently in SPMS. The four placebo controlled trials did show a reduction in relapse 
rate and number of gadolinium enhancing MRI lesions [Achiron et al. 1998; Sorensen et al. 
1998; Fazekas et al. 1997 & 2008].The European Immunoglobulin in MS group recently 
concluded a study involving patients with SPMS and no clinical or paraclinical benefit was 
found [Hommes et al. 2004]. IVIg was also investigated with regards to long-term visual 
outcome in patients with acute optic neuritis and no difference in outcome was found 
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[Roed et al. 2005]. The use of IVIG is not recommended in MS in view of the uncertainty 
about its impact on the more objective MRI-based outcome measures, in comparison to its 
apparent effect on relapse rate, and its relatively high cost and limited availability. 
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1.6. Binding and Neutralising antibodies 
The production of anti-drug antibodies has been described during treatment with a 
variety of biological products. This phenomenon is well described with agents such as 
Insulin [Fineberg et al. 1983], Factor VIII [Bray et al. 1994], erythropoietin [Casadevall et 
al. 2002], botulinum toxin [Goschel et al. 1997] and also with interferon alpha and beta 
[Antonelli et al. 1996; Vallbracht et al. 1981]. Naturally occurring proteins, which are 
genetically altered or synthesised in non-mammalian cells, may have subtle changes in 
their structure, which trigger a loss in immune tolerance. The rate at which these occur is 
related to the immunogenicity of the protein – defined as the ability of a protein to evoke 
an immune response against it. The antibodies induced can be binding or neutralising. A 
neutralising antibody (NAb) binds to the biological agent preventing its interaction with its 
receptor (or – in the case of enzymes - its active site), thus inhibiting or neutralising the 
biological action of the drug/protein.  A binding antibody (BAb) does not significantly 
affect the action of the molecule and, hence, is therefore commonly called non-neutralising 
antibody. Non neutralising auto-antibodies are thought to possibly function as carriers, 
preventing the rapid elimination of cytokines from the circulation, thus increasing their 
bioactivity [Durelli and Ricci 2004] or in the case of some molecules increasing their 
elimination. 
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1.6.1. Anti-Interferon Beta Antibodies 
As described in section 1.5.1 IFNβ is an endogenous cytokine which is secreted by a 
variety of cells – T cells, B cells, macrophages, endothelial cells and fibroblasts, in 
response to microbes (viruses and bacteria in particular). It alters the expression of 
numerous genes and this confers its anti-viral, anti-proliferative and immunoregulatory 
activities. There is some redundancy in its activities which may also be mediated by other 
cytokines [Borden and Wadler 1996]. Low levels of naturally-occurring antibodies directed 
against cytokines are found in the circulation of individuals who have never been exposed 
to a biological therapy and are thought to play a regulatory role in the intensity and 
duration of the immune response [Morgensen 1981, Fomsgaard 1989, Ross 1990, Bendtzen 
1994]. As with the majority of biological products IFNβ can also induce the production of 
antibodies. BAbs can be detected in 50 – 80% of treated patients [Scagnolari 2002, 
Deisenhammer 1999, Kivisakk 2000]. The reasons that some subjects develop NAbs and 
others only BAbs are unclear. Those who develop NAbs – but not all cases – tend to have 
higher BAb levels indicating that qualitatively NAbs differ from BAbs, in that BAbs bind 
with lower affinity to the IFNβ molecule than NAbs [Gibbs and Oger 2008]. 
There has been much controversy with respect to the significance of these antibodies in 
patients with multiple sclerosis treated with IFNβ and how to manage them [Hartung and 
Munschauer, III 2004; Farrell and Giovannoni 2007]. The therapeutic efficacy of IFNβ has 
been shown in trials to be diminished by the presence of neutralising antibodies, which 
form in 2-45% of patients, depending on the product used. Neutralising antibodies may be 
detected as early as 3 months after commencement of therapy, but usually appear between 
6 –18 months.  Binding antibodies occur earlier. It has been shown in numerous trials that 
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patients who become antibody positive, have higher relapse rates, lesion activity on MRI 
and also higher rate of disease progression (this is discussed in more detail in later 
sections). 
 
1.6.2. Immunological mechanisms underlying NAb development 
Factors which affect the development of antibodies remain obscure but may include 
production and purification methods, dose and frequency of administration and potentially 
heterogeneity of the immune response in subjects with multiple sclerosis. IFNβ-1a 
preparations (Avonex IM, Rebif SC) are synthesized in hamster ovary and 
glycosylated, as is the endogenous human form; the specific glyosylation pattern, however, 
may differ. IFNβ-1b (Betaferon, SC) is synthesized in Escherichia coli and has a 
different amino acid sequence to the human form with deletion of methionine at position 
one and a cysteine to serine mutation at position 17 and is non-glycosylated.  These 
changes lead to it being less hydrophilic and more prone to aggregation, resulting in a 
higher dose required to achieve bio-activity similar to the IFNβ-1a preparations. These 
differences are likely to play a role in the relatively high immunogenicity of IFNβ-1b 
compared to IFNβ-1a. However, the above mentioned differences do not explain the 
difference in immunogenicity between IFNβ-1a products. Other issues such as production 
methods, purification, storage and dose also contribute. There is no clear evidence that the 
route of administration impacts on immunogenicity. Perini et al conducted a study, which 
compared IFNβ-1b 250µg (8 miu) IM once weekly vs. SC every other day. The rate of 
antibody production was slower in the IM group and NAb titres were lower [Perini et al. 
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2001]. However, higher frequency of dosing and cumulative weekly dose in the SC group 
could have affected this. Another study which compared 22µg Rebif IM once or twice 
weekly with 22µg Rebif SC three times weekly showed no difference in NAb frequencies 
[Bertolotto et al. 2002]. Other studies have addressed these issues but have used different 
products to compare IM and SC routes and thus results are difficult to interpret [Ross et al. 
2000]. 
 
1.6.3. Frequency of NAb production 
1.6.3.1. Avonex 
Avonex IFNβ-1a (30µg IM once weekly) has the lowest rate of NAb production; rates 
are generally between 2 and 6% [Panitch et al. 2002; Clanet et al. 2002; Jacobs et al. 
1996]. The original formulation used in the pivotal trial was more immunogenic than the 
commercial products that are currently on the market.  It is unclear why this was the case, 
but it probably relates to modifications to its synthesis, purification and formulation. The 
rate of NAbs in the EVIDENCE trial using the freeze-dried Avonex preparation was 2% 
[Panitch et al. 2002]. Currently Avonex is available as a freeze dried vial 30µg which is 
reconstituted with 1mL sterile water or as a prefilled syringe 30µg in 0.5 ml. The 
immunogenicity of the new prefilled syringe preparation was assessed in a recent study; at 
2 years 2% of patients had developed NAbs, which is similar to the data using the freeze-
dried product are the same Table 1-1[Phillips et al. 2004].  
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1.6.3.2. Rebif 
The PRISMS trial using freeze-dried Rebif IFNβ-1a (22 µg or 44 µg SC three times 
weekly) found that the NAb rate on high dose or 44 µg Rebif was lower than patients on 22 
µg (12.5% on Rebif 44 µg vs. 23.7% Rebif 22 µg after 2 years); at the end of the 4 year 
extension phase 24% of patients on Rebif 22µg had developed NAbs as compared to 14% 
Rebif 44 µg, by their last visit [Francis et al. 2005j]. Subjects who had originally been 
treated with placebo and subsequently switched to either 22 µg or 44 µg arms had similar 
rates on NAb during years 3-4 (both ~ 28%) however persistent antibodies were noted in 
24% of patients receiving 44 mcg tiw and in 23/83 (28%) patients receiving 22 µg tiw 
[Oger et al. 2005]. The earlier OWIMS study, published in 1999, showed a dose response 
in that patients receiving Rebif 44µg once weekly developed NAbs sooner and had a higher 
rate of positivity at the end of the trial; 5% of patients on Rebif 22µg were NAb positive as 
compared with 16% on Rebif 44µg once weekly [OWIMS 1999].  However this study was 
only 48 weeks duration and was probably too short to evaluate the natural history of NAbs 
or their impact on disease course. NAb frequencies vary between 15 to 25% in most 
studies.  
Efforts have been made to reduce the immunogenicity of Rebif by altering its 
production methods - free from human serum albumin and produced without fetal bovine 
serum, called Rebif new formulation (RNF). Recently RNF and EVIDENCE studies have 
published NAb rates with NAbs at both 24 and 48 weeks of 2.5% (95% CI, 0.9-5.5) and 
14.3% (95% CI, 10.7-18.6), respectively [Giovannoni et al. 2007]. In the 96 weeks results 
the proportion of neutralizing antibody-positive (NAb +ve) patients at week 96 was 17.4% 
(exact 95% confidence interval [CI]: 13.0-22.5), compared with 21.4% (95% CI: 17.2-
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26.2) in the EVIDENCE study, and 27.3% (95% CI: 22.8-32.1) in the subsequent 
REGARD study. These results suggest that RNF had a lower immunogenic potential 
compared with the approved IFNβ-1a formulation assessed in the EVIDENCE and 
REGARD studies [Panitch et al. 2002; Mikol et al. 2008]. 
 
1.6.3.3. Betaferon 
Betaferon has generally shown the highest rates of NAb formation (25-47%). In the 
IFNβ study group (1993) after three years patients on low dose IFNβ 1b (1.6 MIU) had 
NAb rates of 47% and those on higher dose (8 mIU) had a rate of 45% [MS study Group 
1993]. Further data published in 1993 compared IM and SC routes with 8 mIU/AD and 
NAb rates were 35% in the SC group and 41% IM [1996]. Therefore it did not show a clear 
dose or route dependent effect. The more recent European trial using an MxA assay 
showed NAb rates of 27.8% in the 8 mIU / AD SC dose group as compared to placebo 
[Table 1-1].  
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Trials Product/dose Assay method NAb positivity % positive 
[Jacobs et al1996] 
(MSCRG) 
 
30µg Avonex IM 
OW 
Not reported No definition 
given 
22%. Production 
altered afterwards. 
[Rudick et al. 
1998a] (MSCRG) 
 
Avonex 30µg IM 
OW 
CPE ≥ 20 x 1 titre 6% 
[Jacobs et al 
2000] (CHAMPS) 
 
Avonex 30µg IM 
OW 
CPE ≥ 20 x 1 titre 2% 
[Clanet et al  
2002] 
Avonex 30µg IM 
OW. 
Avonex 60µg IM 
OW. 
 
CPE ≥ 20 x 1 titre 2.3% 
 
5.8% 
[PRISMS 1998b] Rebif 22µg SC 
TTW. 
Rebif 44µg SC 
TTW. 
CPE Titre ≥20 at end of 
study. 
23.8% 
 
12.5% 
 
[EVIDENCE 
1999] 
 
Rebif 22µg SC 
OW. 
Rebif 44µg SC 
OW 
 
CPE 
 
Titre ≥20 
 
5.3% 
 
16.3% 
 
[PRISMS 4 2001] 
 
Rebif 22µg SC 
TTW. 
Rebif 44µg SC 
TTW. 
Placebo group 
Rebif 22µg SC 
TTW from year 3 
Rebif 44µg SC 
TTW from year 3 
 
CPE 
 
Titre ≥ 20 at end 
of trial. 
 
 
 
23.7% 
 
14.3% 
 
27.7% 
 
28.0% 
 
 
 
[Interferonβ  MS 
study group 1996] 
 
 
 
Betaferon. 
1.6MIU SC AD 
8MIU SC AD 
 
CPE 
 
1 Titre ≥ 20 
 
 
47% 
45% 
[Interferonβ  MS 
study group 1996] 
 
 
 
Betaferon 
1.6MIU SC AD 
8MIU SC AD 
8MIU IM AD 
CPE 2 consecutive 
titres      ≥ 20. 
 
42% 
35% 
41% 
[European study 
Group 1998a] 
Betaferon. 
8 MIU SC AD 
MxA protein 2 consecutive 
titres     ≥ 20 
27.8% 
Table 1-1 Frequencies of NAbs in the pivotal and dose comparison trials 
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1.6.4. Comparing NAb frequencies 
Frequencies of NAbs in pivotal studies are shown in [Table 1-1]. However, comparing 
rates of NAb development between individual studies poses several problems. The 
recommended weekly dose of IFNβ-1a IM (Avonex) is 6 mIU as compared to 12 mIU 
IFNβ-1a SC three times weekly (Rebif 44 µg - total 36 mIU weekly) and 8 mIU IFNβ-1b 
every other day (250 µg Betaferon – total 28 mIU weekly). There are large differences in 
the potency of each preparation and the amount of protein delivered in each dose. 8 miu 
Betaferon contains 250 µg, 6 mIU of Rebif contains 22 µg and 6 mIU Avonex 30 µg of 
protein. The specific activity of a protein describes the relationship between the absolute 
weight of the protein and its biologic activity and is measured in IU/weight. The specific 
activity of Betaferon is 32 mIU/mg, Rebif 273 mIU/mg and Avonex 200 mIU/mg 
[Deisenhammer et al. 2000]. The IU given by the manufacturers may not be comparable as 
they are measured using different IFN standards. This was illustrated by Deisenhammer et 
al who directly compared the potency of each product by quantifying each preparations in 
vivo activity in patients treated with IFNβ without NAbs. They found a significant increase 
from baseline of MxA expression with 10 IU/mL Betaferon as compared to requiring 100 
IU/mL of Rebif or Avonex to achieve a similar response. However, if this was adjusted 
relative to IFNβ weight Rebif had the highest specific activity (called 100%), Avonex 93% 
of this and Betaferon 71-80% [Deisenhammer et al. 2000].  
It is difficult to compare the rate of NAb positivity between studies as different assays 
and acceptance criteria have been used to define antibody positivity. It is therefore 
important to consider the results of comparative trials [Table 1-2]. 
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Comparative 
trials 
Product/dose Assay method NAb positivity % positive 
[Panitch et al 
2002] 
Avonex 30µg IM 
OW 
Rebif 44µg SC 
TTW 
NR Titre ≥ 20 at any 
time. 
2% 
25% 
 
[Ross et al 2000] 
 
 
 
 
 
Avonex 30µg IM 
OW 
Rebif 22µg SC 
OW  
or TTW 
Betaferon 8MIU 
AD 
 
CPE. 
Varying amount 
IFN added altered 
sensitivity of 
assay 
  
Depended on 
sensitivity of 
assay 
Betaferon > Rebif 
> Avonex. 
 
[Bertolotto et al. 
2002a] 
 
Avonex 30µg IM 
OW 
Rebif 44µg SC 
OW  
or TTW 
Betaferon 8MIU 
AD 
 
CPE 
 
2 x titre ≥ 20 
 
2% 
 
15% 
 
31% 
 
[Kivisakk et al. 
2000] 
 
Avonex 30µg IM 
OW 
Betaferon 8MIU 
AD 
 
CPE 
 
Titre  ≥ 20 
 
5% 
44% 
Table 1-2 Frequencies of NAbs in comparative studies 
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1.6.5. Effect of anti-IFNβ NAbs on efficacy in MS - Clinical 
outcomes and MRI  
There is ongoing debate about the clinical significance of Nabs amongst the MS 
community. Studies, which are of short duration, may not detect the negative effect NAbs 
have on IFNβ efficacy. However, there is now sufficient evidence in the literature to 
support the view that NAbs reduce or eliminate the in vivo bioactivity of IFNβ – termed 
antibody mediated decreased bioactivity. The appearance of NAbs generally occurs 
between 6 and 18 months after commencing IFNβ therapy. Their impact on clinical 
efficacy lags further behind and is generally not seen in trials of less than 2 years duration. 
The findings of the pivotal trials are discussed below. 
Two papers were published by the MS Study group showing efficacy of IFNβ-1b in 
reducing relapse rates and disease activity on MRI [MS study Group 1993; Paty and Li 
1993]. A follow up paper was published to discuss the impact of NAbs in more detail. In 
the treatment arm 35% of subjects became NAb +ve by 18 months. Those who were NAb 
+ve had higher annualised relapse rates from month 13 – 36 than those who remained NAb 
–ve (1.08 vs. 0.56 p < 0.05). No difference in sustained progression (using EDSS) was 
found. With regards to MRI parameters those who were NAb +ve had higher accumulation 
of new lesions than NAb –ve during the 3rd year (1.03 vs. 0.4 p<0.05). In this paper the 
authors’ concluded that NAbs did reduce the clinical efficacy of IFNβ.  
The more recent BECOME study compared efficacy of IFNβ-1b with Copaxone and 
included analysis of the effect of NAbs on MRI outcomes. The incidence of NAbs and 
effect of NAbs on bioactivity were consistent with previous studies. MRI outcomes in 
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patients with NAbs at levels high enough to abolish bioactivity relative to patients without 
NAbs were analysed. Those who had preserved bioactivity, the ratio of enhancing lesions 
per scan decreased from 7.6 in the pretreatment period to 2.6 in the post-treatment period, 
which was a 66% decrease. For the lost bioactivity group, the reduction was only from 8.5 
to 5.8, a 32% decrease. Thus, lost bioactivity from high levels of NAbs resulted in reduced 
therapeutic efficacy of IFNβ-1b as manifested by diminished reductions in enhancing 
lesions on MRI [Pachner et al. 2009a].  
The 4-year extension phase of the PRISMS study showed a significant reduction in 
relapse rate and MRI activity in the patient group on high dose Rebif. This effect was lost 
in those who developed NAbs [PRISMS-4 2001]. The relapse rate was 0.5 for Rx 44µg 
(Rebif treatment dose) patients who were NAb -ve and 0.81 in those NAb +ve (increase of 
62%). There was also a significant difference in the number of T2 lesions on MRI. Median 
number of lesions was 0.3 in those who were NAb -ve and 1.4 in the NAb +ve group. This 
annual increase in the T2 burden of disease (BOD) was similar to that seen in the 2-year 
placebo arm of the study.  
Further analysis of this data evaluated 368 of the original patients with regards to NAbs 
[Francis et al. 2005]. In this analysis the majority of NAbs developed within the first 12 
months of treatment. Thirty percent of Rx 22µg group and 19% of Rx 44µg group had a 
positive NAb result. At 12 months relapse rates were the same at ~ 0.9, thereafter the NAb 
-ve cohort showed a steady linear decline in relapse rates over the next 36 months to 0.35. 
The NAb +ve group however, had a fluctuating course with relapse rates consistently 
higher than NAb -ve and similar to the placebo group. With regards to time to confirmed 
progression by one point on the EDSS scale, in the NAb +ve group 44% had confirmed 
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progression compared to 40% of the NAb -ve cohort.  
Using interval positive analysis, however, a significant difference was found between 
the groups: NAb +ve /NAb -ve progression rate ratio 1.50, 95% CI 1.03 – 2.17 p = 0.03. A 
significant difference was also seen in T2 MRI lesion load between NAb -ve and NAb +ve 
groups. Median lesion load was 0.3 (mean 0.1) in the NAb –ve group and 1.4 (3.2) for the 
NAb +ve group. The median cumulative percentage change in T2 lesion burden from 
baseline to years 2 and 4 was -7.2% and -8.5% in the NAb –ve group receiving 44µg tiw 
and 12.5% and 17.6% for the NAb +ve patients. 
The finding that NAb +ve subjects tend to have fewer relapses in the first 6 months 
has also been described in an independent longitudinal study. They describe a similar 
finding of reduced RR in the first 6 months in the NAb positive cohort but that after 6 
months this reverses and they experience higher RR [Sorensen et al 2007]. This finding is 
interesting as it implies that those who develop NAbs may do better in the first year of 
treatment than those who remain NAb -ve in the longer term. This would suggest a 
difference in the immune response of subjects, who develop NAbs, to treatment. An 
association has been described between NAb development and a MHC class II allele 
(DRB1*0701) and indicates a role for T cell activation in IFN-beta immunogenicity 
[Barbosa et al. 2006], however further investigation is required. The other hypothesis is 
that BAbs, which precede the development of NAbs may extend the half-life of circulating 
IFNβ thereby increasing its bioavailability [Sorensen et al. 2007] 
The European dose comparison trial evaluated the clinical significance of NAbs (IFNβ 
1a 30µg vs. 60 µg IM OW) [Kappos et al. 2005]. Patients were followed from baseline and 
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at three monthly intervals for 48 months. Samples were evaluated for BAbs and NAbs (in 
BAb positive patients). They found a higher proportion of NAb +ve patients in the high 
dose Avonex group. NAb +ve patients had higher (39%) relapse rate from months 12 to 48. 
NAb positive patients EDSS score progressed by a mean of 0.89 over 4 years compared to 
0.29 in the NAb negative group. With regards to MRI findings, both T1 and T2 lesion load 
was higher in the NAb +ve group from 24 months to the end of the study. This study is 
very important as it further clarifies the significance of NAbs. It also highlights the need to 
design long-term studies as the clinical impact of NAbs appears to become more apparent 
with time and lags behind the initial appearance of NAbs.  
 
1.6.6. Use of Biomarkers in monitoring IFNβ activity 
IFNβ affects the expression of several hundred genes and their downstream products. 
Many of these can also be induced by other factors. Some, however, have been identified 
as being relatively specific to type 1 IFNs. MxA is a good example of this [Deisenhammer 
et al. 2000c; Pachner et al. 2003b,c]. Others include Oligoadenylate synthetase (OAS) 
[Pachner et al. 2003b], Neopterin [Cook et al. 2001] and TRAIL (tumor necrosis factor 
apoptosis inducing ligand) [Wandinger et al. 2003; Gilli et al. 2006], but these are not 
exclusively induced by IFNβ.  These have been used to show that the presence of NAbs 
reduces the bioactivity of IFNβ in vivo. A significant rise in MxA mRNA and protein has 
been shown in response to IFNβ administration and that this response is lost in the 
presence of NAbs [Bertolotto et al. 2003; Gilli et al. 2005]. In the case of mRNA levels, 
this response has been shown to be maximal at 12 hours. Similarly the MSCRG (1998) 
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showed failure to induce neopterin in the NAb positive cohort [Rudick et al. 1998].  
Other biomarkers such as β-2 microglobulin and neopterin have been measured in 
relation to NAbs and in the presence of NAbs failed to show any significant response to 
IFNβ [Francis et al. 2005h]. Another study measured the in vivo response to IFNβ by 
measuring pre and post dose levels of MxA mRNA, neopterin and β2- microglobulin. 
Responses were compared between NAb +ve and NAb – ve cohorts. Both pre and post 
dose levels were lower in NAb +ve subjects and a significant inverse correlation was found 
between NAb titre and pre dose levels in particular. The shows that the steady state levels 
are significantly suppressed in NAb +ve patients and in a titre dependent fashion 
[Scagnolari et al. 2007].  
TRAIL [Wandinger et al. 2003]  and OAS [Pachner et al. 2003b] have also been shown 
to produce a reliable response to IFNβ and failure of induction has been found in subjects 
who are NAb +ve [Bertolotto et al. 2003; Deisenhammer et al. 1999; Malucchi et al. 2004; 
Pachner et al. 2003c;Vallittu et al. 2002]. This loss of response to IFNβ predates any 
clinical evidence of loss of efficacy and could thus be used as a predictor or biomarker of 
impending treatment failure in those patients who show persistent antibodies. 
The Impact of Neutralizing Antibodies on Interferon Responsive Genes Highlights 
Biomarker Response (INSIGHT) study was specifically established to examine the effect of 
antibodies to IFNβ on in vivo response of highly specific biomarkers for IFNβ binding to 
IFNAR: MxA, viperin, and Interferon-induced protein with tetratricopeptide repeats 1 
(IFIT-1) [Pachner et al. 2009b]. In this study 718 patients with MS treated with any IFNβ 
for at least 12 months were included - IFNβ-1a 30 µg once weekly, subcutaneous (SC) 
IFNβ-1a  22 µg or 44 µg 3 times weekly, or SC IFNβ-1b 250 µg every other day. Binding 
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antibodies were evaluated using the capture ELISA (cELISA) and NAbs were measured 
using the viral cytopathic effect assay. Biomarker induction was compared between those 
who were BAb +ve / NAb +ve (n=149) vs. BAb –ve/ NAb -ve (n = 498) vs. BAb +ve/ 
NAb  –ve (n = 71). MxA, IFIT 1 and viperin responses were all significantly lower in the 
BAb +ve NAb +ve groups as compared with those in the BAb -ve / NAb –ve arm. The 
reduced bioactivity was also found to be titre dependent with complete suppression of 
biomarker response in those with titres > 100 NU (CPE assay). This study confirmed in a 
large cohort the findings of other groups who have correlated NAb titres with biomarker 
induction or IFNβ gene induction [Sominanda et al. 2008; Hesse et al. 2009]. 
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1.6.7. Measurement of BAbs and NAbs 
1.6.7.1. Binding antibody assays 
Neutralising antibodies are by definition also binding antibodies and as screening for 
BAbs was generally considered less troublesome, it was recommended that one should 
screen for BAbs before testing neutralising activity. There are several ways to screen for 
BAbs; ELISA, western blotting, radio-immunoprecipitation (RIA) or affinity 
chromatography. ELISA is the most commonly used method and this can be performed in 
two ways, with and without a capture antibody. Recently these methods have been 
compared in a cohort of 325 patient samples. Capture and direct ELISAs performed equally 
well, however the capture ELISA had a better correlation with NAb titres [Gneiss et al. 
2008]. These assays and findings are described in more detail in chapter 2. 
 
1.6.7.2. Neutralising antibody assays 
IFNβ has diverse actions in vivo altering the expression of many genes at the nuclear 
level which confers antiviral, anti-proliferative and immunological actions. Neutralising 
assays are therefore based on quantifying these functions and their inhibition in the 
presence of NAbs. IFNβ binds to its cell surface receptor causing it to dimerise and activate 
the intracellular signaling mechanism. These transcription factors translocate to the nucleus 
where they bind to and activate the interferon stimulated response element (ISRE), which 
induces the transcription of numerous genes whose end products can be measured, such as 
MxA, neopterin, OAS, TRAIL and β2 microglobulin. In the presence of NAbs, it is 
proposed that IFNβ fails to bind to and activate its receptor and thus the downstream 
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effects are lost. Therefore, the antiviral effect or the IFNβ induced gene products can be 
used in assays to measure the bioactivity of IFNβ. Problems, however, exist with regards to 
reliable measurement of neutralising antibodies. At the time this work was commenced no 
standardised assay, which could be applied reliably in all laboratories existed. The “gold 
standard” assay to measure NAbs was the Cytopathic Effect Assay (CPE) recommended by 
the World Health Organisation [WHO expert committee on Biological Standardisation 
1985]. Guidelines have been developed by the EFNS task force, which recognise the 
validity of a cell based assay measuring MxA mRNA or protein which may be more widely 
used in the future [Sorensen et al. 2005a].  
 
1.6.7.3. Cytopathic Effect Assay 
This assay makes use of the anti-viral effect of IFNβ. Virus sensitive cells are seeded in 
micro titre plates and a known amount of IFNβ is added with serial dilutions of the 
patient’s serum. This is incubated for 12 to 24 hours, after which the virus is added. After a 
further 24 hours viable cells are quantified by staining with crystal violet in 20% ethanol. 
The ability of IFNβ to inhibit viral replication is measured. The antibody titre is calculated 
using the Kawade method [Kawade 1986]. The unit of measurement is the lab unit (LU), 
which is defined as the amount, which reduces the cytopathic effect of the virus by 50%. 
The dilution of patient’s serum, which reduces the activity of 10LU/mL of IFNβ to 
1LU/mL, is then determined. The reciprocal of this value is the neutralisation titre of the 
serum. A concentration value of ≥ 20 LU/mL is generally considered a positive titre 
although this is an arbitrary figure [Grossberg et al. 2001 a & b].  
In an attempt to standardise this assay the WHO have recommended the use of human 
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lung carcinoma cells (A549) and encephalomyocarditis virus (EMCV). Use of different 
cells and viruses has meant that results cannot be directly compared between labs. 
Variation in the amount of IFNβ used in the assay also alters the sensitivity of the assay 
[Ross et al. 2000; Sorensen et al. 2003a]. Adding too much will reduce the sensitivity and 
too little will increase the sensitivity of the assay. It is therefore crucial that the amount of 
IFNβ added reflects the in vivo environment. It is not clear what that level should be but 
the WHO currently recommends 10 LU/mL. Another difficulty is that the assay is not 
specific. If any other factor with antiviral properties is present it may cause the reduction in 
the cytopathic effect of the virus instead. The CPE assay is also relatively time consuming 
and prone to inter assay variability. 
 
1.6.7.4. Quantification of Biomarkers 
More recently assays which quantify either MxA protein or MxA mRNA have been 
developed and validated in relation to the CPE assay. These assays make use of the fact 
that certain proteins are induced, in response to IFNβ, in a dose-dependent manner. 
Therefore, after stimulating the cells with a known amount of IFNβ, the amount of MxA 
protein or mRNA produced is measured. MxA protein can be measured by sandwich 
ELISA, chemoluminesence [Kob et al. 2003] or fluorescence activated cell sorting (FACS) 
[Pachner et al. 2003c; Vallittu et al. 2002]. Cells are pre-incubated with serial dilutions of 
patient’s sera. The presence (and titre) of neutralising antibodies is quantified by 
measurement of the MxA produced, by ELISA or alternatively MxA mRNA is quantified 
by PCR. Whilst less time consuming than the CPE assay this is also subject to the problem 
of inter-assay variability.  
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Results comparing three PCR methods to measure MxA mRNA and evaluate response 
to IFNβ have been published. PBMCs were isolated from blood and RNA extracted and 
reverse transcribed to generate cDNA. Quantitative competitive PCR, real time PCR and 
semi-quantitative PCR were used and NAb titres compared with the CPE assay. All three 
methods showed high specificity for MxA analysis [Gilli et al. 2004].  Bertolotto et al have 
modified this assay mixing patient’s serum with IFNβ (known amount) and adding in serial 
dilutions to a plate seeded with cells. This is incubated for 6 hours, cells are then lysed and 
MxA mRNA extracted. cDNA is produced and quantified by real time PCR. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is also measured as a housekeeping 
gene at the same time to account for any cytotoxic agents, which may inhibit/lyse the cells. 
This new assay is less time consuming and has been validated with respect to the CPE 
assay and MxA protein assay [Bertolotto et al. 2007]. It is however expensive to perform, 
which could potentially limit its accessibility to clinical practice. 
 
1.6.7.5. Titre Calculations 
Most titres are calculated using a specific eponymously named method: the Kawade 
method. To date no consensus has been achieved to define what constitutes a clinically 
relevant titre. Generally the cut off is ≥ 20 neutralising units, but a variety of endpoints 
have been used in trials. It has also been shown that the bio-efficacy of IFNβ may be 
reduced with a NAb titre < 20 [Pachner et al. 2003b].  Guidelines regarding NAb testing, 
assay validation and clinical implications of a positive result have failed to form a 
consensus regarding a significant titre. The European group recommended in 2005 that 
measurements of binding and neutralising antibodies to IFNβ should only be performed in 
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specialised laboratories. Use of a validated CPE assay is still the gold standard assay and 
A549 cells should be used with a fixed amount of IFNβ which should be the same product 
that the patient is using. The stimulated cells can be challenged with the EMC virus or 
MxA production measured. Standard curves should be included using increasing amounts 
of IFNβ until saturation is reached. Titres above 20-60 are associated with loss of IFNβ 
bioactivity (using CPE assay and IFNβ-1b). In these guidelines however a recommendation 
is made to switch or stop treatment in subjects with persistent titre > 100 NU. It has also 
been acknowledged that there still remains a need for simpler assay methods such as 
quantifying the in vivo biological response [Sorensen et al. 2005a].  
 
1.6.8. Not all neutralisation is due to NAbs 
A small number of patients exhibit neutralisation of IFNβ activity in the absence of 
antibodies to IFNβ. This has been associated with high levels of circulating soluble IFN 
receptors. Among 256 enrolled patients, 11 (4.3%) showed a significant inhibition of the 
IFNβ activity in vitro, but no measurable BAbs. As a whole, in vivo bioactivity was 
inhibited in 9/11 (82%) of these patients. A minority of IFNβ treated patients have a non-
antibody mediated neutralising activity, which competitively inhibits the bioactivity both in 
vitro and in vivo. This has been attributed to the circulation of soluble IFN receptors 
(IFNAR) and has mostly been described in subjects treated with Rebif. If this is the case 
using the BAb assay as a screening tool will fail to detect a proportion of non-responders to 
IFN therapy and there is a strong argument to alter current guidelines to initially detect 
bioactivity. 
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1.6.9. Reversion to NAb negativity 
Over time ~ 30% of NAb positive patients will revert to negative status  This occurs 
most commonly in patients with low to moderately positive titres and those treated with 
IFNβ-1b [Bellomi et al. 2003; Gneiss et al. 2004; Petkau et al. 2004; Rice et al. 1999; 
Sorensen et al. 2005b; Sorensen et al. 2003]. In the pivotal IFNβ-1b trial, 60% of those 
who had a NAb +ve test subsequently reverted to negative status [MS study Group 1993]. 
Rice et al performed NAb assays in the Canadian cohort, of those included 25 of 59 
subjects (42.4%) developed NAbs [Rice et al. 1999]. They were followed for a median of 7 
years and all but 3 reverted to NAb negative status in this time. Subsequently a longitudinal 
study was performed to analyse the development of NAbs in patients treated with IFNβ-1a 
and 1b. Gneiss et al followed 28 NAb positive patients for mean of 57 months after 
commencing IFNβ therapy, 16 patients received treatment with IFNβ-1a and 11 received 
IFNβ-1b.  They found that patients who were likely to revert to NAb negative status 
reached their peak titre earlier and had lower peak titres (< 75 – 100NU) than those 
persistently positive [Gneiss et al. 2004].   58% of patients treated with IFNβ-1b reverted to 
NAb –ve status whereas only 27% of those treated with IFNβ-1a were reverters. 11 of the 
12 reverters had titres < 75 NU and only one of those who did not revert had titres < 75. 
During the NAb positive period, patients are seen to revert to placebo status with regards to 
induction of biomarkers.  
The Danish MS group has collected data on all of their patients since IFN-β therapy 
was licensed. In a study using samples which were taken over 6 years, 455 patients were 
included receiving different IFNβ preparations. Of these 52.3% remained NAb -ve, 40.9% 
were definitely NAb +ve and the remainder fluctuated. Patients on Avonex had the lowest 
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frequency of NAbs and frequencies were similar in the Rebif and Betaferon groups, 
specific frequencies however were not published in this paper at this time. Of the 277 
(60.8%) of patients who were NAb -ve at 18 months only 19 (6.5%) became persistently 
NAb +ve. At 24 months the rate of conversion was only 3%. If a patient reaches 24 months 
and has been persistently NAb -ve it is unlikely for them to subsequently seroconvert. Of 
those who developed persistent NAbs 33% subsequently became definitely NAb -ve. The 
chance of reverting was higher in those on Betaferon than the other products. 52% of 
patients who were NAb +ve treated with IFNβ 1b reverted to NAb -ve status compared 
with 19% of those NAb +ve treated with IFNβ-1a. In this study they were unable to 
differentiate between NAb titres of 200 and those much greater. Due to this they were 
unable to comment on titre predicting reversion to NAb- status [Sorensen et al. 2005b]. An 
earlier study investigated the persistence of NAbs in 42 patients treated with IFNβ and 
found that almost all subjects reverted to NAb negative status over a 6 year period. Those 
who remained persistently positive had high titres of Nabs [Bellomi et al. 2003]. 
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1.7. Competitive Environment and Health Economics. 
The high incidence and long duration of MS means that even cheap (but efficacious) 
treatments could have significant effects on health care provider budgets. Government 
funding of interferons and glatiramer acetate as treatments for MS has been controversial in 
many countries. The unpredictable course of MS and its potential to cause severe disability 
underpins the high demand for disease-modifying agents.  Funding bodies, on the other 
hand, have highlighted the lack (as yet) of unequivocal long-term evidence of clinically 
effective drugs. Health economic evaluations performed to date have demonstrated poor 
cost-benefit ratios of these drugs [Whetten-Goldstein et al. 1998].  Research and 
development and production costs contribute to the high prices charged for the currently 
available DMDs. The cost of drugs may be further increased by administration costs where 
treatments have a short shelf-life, and require regular IM or SC administration. Patients on 
such treatments require regular follow-up, which add to health-care provider costs. 
Medical and non-medical costs relating to treatment (direct costs) are relatively easy to 
measure, however to calculate the financial savings arising from delayed disease 
progression is less straightforward.  In accounting terms, future financial benefits are 
usually discounted at an annual rate of up to 6% with further adjustments made for health 
service price inflation. However, no trial has directly investigated the potential of DMDs’ 
to reduce the high costs of hospitalisation or nursing-home admission. Such benefits might 
mitigate high drug acquisition and administration costs. 
The long-term effect that MS DMDs might have on salaried and non-salaried 
employment (indirect or production costs) has similarly not been investigated. MS is a 
disease that typically develops in young people, and in societies where unemployment is 
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low, the potential production benefits associated with delaying disability are likely to be 
very high [Prosser et al. 2004]. A further saving that might offset high drug costs are those 
arising from improved quality of life (intangible costs). These are very difficult to measure 
in financial terms. Recently pharmaco-economic studies of DMDs in MS have attempted to 
derive likely quality adjusted life year (QALY) benefits due to treatment, but have failed to 
demonstrate a convincing case for their widespread use [Gold et al.1996]. Though the 
QALY may not be the most appropriate measure in chronic, slowly progressing, diseases 
such as MS alternative measures of quality of life are equally or even more controversial. 
In the UK in 2002, the National institute of Clinical Excellence (NICE) issued 
guidelines on treatment stating  
 
              “A recommendation to use these medicines cannot, presently, be justified, taking 
both benefits and costs into account. “ 
 
However, many patients were already receiving IFNβ treatment post licensing of IFNβ 
in Europe as a result of the pivotal trials. Thus NICE conceded that: 
 
              “People who are currently taking beta interferon or glatiramer acetate to treat 
MS could suffer loss of well being if their treatment was stopped when they did not 
expect it. Because of this, all NHS patients who are on therapy at the date of 
publication of this guidance should have the option to continue treatment until they 
and their consultant consider it is appropriate to stop, bearing in mind the criteria 
established for withdrawal from treatment in the Guidelines of the Association of 
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British Neurologists published in January 2001. This advice about continuing 
treatment also applies to all participating patients at the end of a clinical trial 
(regardless of whether they were receiving placebo or active drug) and to women 
whose therapy has been interrupted by pregnancy. “ 
 
Updated guidelines are anticipated but have not yet been issued. Future DMDs will be 
required to demonstrate their cost-effectiveness before approval by national licensing and 
funding authorities. High prices may be off-set by low administration costs (for example 
once monthly rather than daily dosing), clear clinical benefit in patient sub-groups in terms 
of reduced disability and quality of life, and data demonstrating reduction in economically 
relevant outcomes such as hospitalisation, nursing home admission, and employment. In 
view of this resolution of the issues surrounding the clinical significance of NAbs, cost 
effective assays and standardised reporting of titres is required.  
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1.8. Rationale for the research underpinning this thesis 
IFNβ is currently the most commonly prescribed first line therapy worldwide for 
relapsing MS. Evidence supporting the significance of NAbs in abrogating or at least 
reducing the clinical efficacy of IFNβ has been conflicting and many studies are inadequate 
for the purpose of assessing their impact. As routine NAb testing was not available in the 
UK at the time this work began, the purpose of the experiments and studies described here 
were to:  
• establish a validated BAb assay in our laboratory 
• develop and validate a novel cell based reporter gene (Luciferase) assay to reliably 
and cost effectively measure NAbs to IFNβ 
• to evaluate the frequency of BAbs and NAbs in patients attending the National 
Hospital for Neurology and Neurosurgery (NHNN) London, using the Luciferase 
assay and to correlate NAb titres with clinical data – relapse rates, side effects, 
treatment cessation  
• to develop guidelines to interpret NAb results obtained with the Luciferase NAb 
assay using in vivo biomarker data to set “cut-points” of significance 
• to evaluate maturation of the immune reponse to IFNβ 
• to evaluate current opinion among neurologists regarding NAbs to IFNβ, the 
uncertainty about their significance in the clinical setting, and the perspective of 
neurologists in the UK , Europe and the US on incorporating NAb testing into 
routine practice. 
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Chapter 2 
Binding Antibodies 
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2 Binding antibodies 
2.1. Antibodies to IFNβ 
Endogenous proteins which are synthesised and used as biological treatments are 
known to induce an immune response to the protein. The resulting antibodies that are 
produced may or may not alter the action of the drug. In the case of IFNβ those which bind 
to the protein but do not appear to alter the bioactivity of the drug are termed binding 
antibodies and those which reduce or neutralise the biological effect are called neutralising 
antibodies [Giovannoni and Goodman 2005]. These observations, however, are restricted 
to ex vivo bioactivity. The in vivo effect of BAbs in relation to the biological compound is 
complex; in some cases they may extend the half-life of the circulating protein and in other 
circumstance reduce the half-life [Durelli and Ricci 2004]. Extending the circulating half-
life of interferon-beta is one of the hypotheses put forward to explain the observation that 
patients destined to develop NAbs tend to do better clinically in the intitial 6 months of 
therapy [Chapter 1.6.5].  
Several factors are thought to contribute to the immunogenicity of the different 
commercial products including amino acid sequence, glycosylation, dose, production 
methods and individual patient factors. Binding antibodies have been described to occur in 
the majority of treated patients 50 – 80% depending on the assay used and its sensitivity 
[Durelli and Ricci 2004]. Many studies reporting on NAbs do not report BAb frequencies. 
It is also difficult to compare results due to different assays used.  
There are several hypotheses to try to explain why some antibodies act as inhibitors of 
IFNβ function and others do not. These include immunoglobulin (Ig) class – IgM or 
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subtype IgG1 vs. IgG2 and IgG4 [Deisenhammer 2001, Sorenson 2007], low vs. high 
affinity antibodies [Gneiss 2006], epitope recognition pattern resulting in binding to 
epitopes which are not involved in receptor interaction [Bendtzen 1990, PRISMS 1998]. 
There remains significant debate as to the significance of BAbs and it is suggested that low 
affinity BAbs protect IFNβ from clearance or degradation. In the majority of publications 
the presence of BAbs in the absence of NAbs is not associated with a reduced efficacy of 
treatment with IFNβ or abrogation of serum biomarker responses [Francis et al. 2005; 
Rudick et al. 1998; Pachner et al. 2009 b,c; Zang et al. 2000].  
 
 
2.2. BAb measurement 
There are several ways to screen for BAbs; ELISA [Brickelmaier et al. 1999; Pachner 
2003a], Western blotting [Gneiss et al. 2008], radio immunoprecipitation or affinity 
chromatography [Bendtzen et al. 2000; Lawrence et al. 2003].  
 
2.2.1. Capture ELISA 
This method involved coating a microtitre plate overnight with a mouse / rabbit 
monoclonal anti IFNβ antibody or phosphate buffered saline (PBS) alone in control wells. 
Plates are decanted and then blocked with milk protein. At this point IFNβ is added to the 
plate and incubated. A standard curve is made with doubling dilutions of a known BAb 
positive sample. Control and test sera are then added in duplicate. Antibodies which bind to 
the IFNβ molecule are detected by adding a horseradish peroxidase (HRP) conjugated anti-
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human IgG and detected colorimetrically by adding developing solution 
(Tetramethylbenzidine TMB or o-phenylenediamine OPE). By attributing arbitrary values 
to the points on the standard curve titres can be generated for the samples which are tested 
[Brickelmaier et al. 1999; Pachner 2003a],.  
 
 
2.2.2. Direct ELISA 
The direct ELISA is similar to the cELISA but directly coats microtitre plates with 
1:5000 IU solution of commercial IFNβ in 100µL PBS. Control wells were filled with PBS 
alone and incubated overnight. After blocking the plates test sera were added to the wells in 
doubling dilutions. The plate was then washed and HRP conjugated anti-human IgG added. 
After further washing this was detected by adding a developing solution (3, 3’, 5, 5’-
tetramethylbenzidine (TMB) or O-phenylenediamine (OPE )). The reaction was stopped by 
adding HCl and reading in a spectrophotometer. As with the cELISA a standard curve may 
be used to generate BAb titres [Gneiss et al. 2008]. 
 
2.2.3. Western Blotting 
This method involves separation of IFNβ by SDS-PAGE (sodium dodecylsulphate 
polyacrylamide gel electrophoresis) and transfer of protein to a nitrocellulose membrane. 
The membrane is blocked with milk protein and dried. Strips of the membrane were 
incubated with test sera 1:1000 dilution, negative control sera and a mouse monoclonal 
anti-human IFNβ antibody as positive control. These were incubated with either anti-
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human IgG or anti-mouse IgG. These were detected by adding p-nitro blue tetrazolium 
chloride and 5-bromo-4-chloride-3-indolyl phosphate. Samples were considered positive 
when the band detected at the level of the mouse anti-IFNβ, was stronger than the negative 
control. A disadvantage of this technique is relatively high levels of false negatives and that 
no relative quantification can be made merely weak or strongly positive. 
 
2.2.4. Radioimmuno Assays 
Human IFNβ is radioiodinated (I-r) with purified and validated tracers which are known 
to be stable. Serum samples are preincubated with 125I-rIFNβ and the amounts of free and 
IgG-bound tracer are determined by protein G Sepharose affinity chromatography. The 
bound IFNβ is eluted and cpm detected in the supernatant. This was used to calculate the 
amount of 125I-IFNβ in the mixture. This assay has not been widely adopted and hence 
validated across multiple laboratories. In addition, it is not as simple to perform as ELISA 
[Lawrence et al. 2003].  
 
Recent studies have compared these assays and ELISA appears to be the preferred 
method. The capture and direct ELISAs performed equally well, but the units obtained with 
the capture ELISA had a better correlation with NAb titres [Gneiss et al 2008]. The direct 
ELISA had higher rates of false positive and false negative results which have been 
attributed to the fact that IFNβ when bound directly to the plate undergoes conformational 
changes in the IFNβ molecule which results in it being presented in non-native form 
whereas in the cELISA IFNβ is bound to the capturing antibody in the liquid phase 
preventing such conformational change [Svenson et al. 1993; Brickelmaier et al. 1999]. 
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Thus the consensus opinion is that the cELISA is the most reliable and efficient screening 
tool in use to detect BAbs. In view of this, for the purpose of this study, the capture ELISA 
was used [Pachner 2003a]. 
 
The aim of this chapter was to:  
1. Validate a pre-existing BAb assay in our laboratory  
2. Test the samples in the cohort of subjects attending the affiliated hospital.  
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2.3. BAb Capture ELISA 
2.3.1. Analytical principles 
The cELISA method is sandwich immuno-assay that utilises an IFNβ specific 
monoclonal antibody bound to the surface of a polystyrene 96-well microtitre plate to 
capture and immobilise the IFNβ protein.  IFNβ specific IgG antibodies in the serum that 
bind to the anchored protein are detected using a horseradish peroxidase (HRP) labelled 
polyclonal donkey anti-human IgG. The amount of bound conjugate is determined 
colorimetrically by monitoring the oxidation of TMB which leads to production of a blue 
colour, the intensity of which depends on the quantity of HRP conjugate present. The 
reaction is stopped by adding 1M hydrochloric acid HCl (which changes the colour of the 
solution from blue to yellow) and the optical density is measured at 450 nm. A reading at 
750 nm is also taken to correct for differences in volume of solution in each well. A 
standard curve is created using a highly positive reference serum sample and BAbs are 
quantified in arbitrary Units (U) based on the linear detection range of the standard curve. 
The method described here is based on that published by Pachner et al. 2003a. 
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Figure 2-1 Capture ELISA  
The first well shows capture antibody coating base of well, Interferon-β is added and is bound 
to the capture antibody. Subjects sera containing anti-Interferon antibodies (BAbs) bind to the 
IFNβ molecule. HRP conjugated anti human IgG is added which binds to BAbs and is detected 
by addition of TMB. 
 
 
2.3.2. Materials 
Monoclonal capture antibody specific for Human IFNβ Clone #B-02 Yamasa SAM-
260871-1, IFNβ-a (Avonex) Biogen Idec, Donkey anti-human IgG -HRP conjugate 
Jackson Immuno-research #709-035-1, TMB Microwell Substrate Kirkegaard & Perry 
Labs 50-76-06, 96-well Microtitre Plates ICN 76-381-04,  Microtitre Plate Covers 
Corning-Costar 3095, Micro Pipette Tips VWR,  Reagent Reservoirs Labcor 730-001,  
Sodium Chloride S3014, Potassium Chloride P9541, Sodium Diphosphate S7907, 
Postassium Monophosphate P0662, Sodium Carbonate S1641, Sodium Bicarbonate S8875, 
HRP 
TMB added 
Colour change 
Detector added 
Anti-human IgG 
HRP conjugated 
Capture antibody 
HRP 
Interferon bound Patient sera added Babs bind 
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Polyoxyethylene sorbitan monolaurate (Tween 20) P1379: all from Sigma, Instant Non-Fat 
Dry Milk Pathmark,  Sulphuric Acid CEM SX1244-3 
 
2.3.3. Preparation of solutions 
All solutions were prepared prior to the day of the assay except the blocking buffer and 
the sample dilution buffer which were prepared on the day of the assay. 
 
2.3.3.1. Carbonate buffer 
A 0.1M solution was made with 4.2g Sodium Bicarbonate added to 500mls distilled 
water. This was poured into a large beaker. The 0.1M sodium bicarbonate solution was 
made with 3.18g Sodium bicarbonate added to 300mls distilled water. This was slowly 
added to the Sodium Bicarbonate until pH reached 9.6. The buffer was stored at room 
temperature for up to 1 month. 
 
2.3.3.2. 10 X PBS Solution 
80g NaCl, 2g KCl, 11.5g NaH2PO4 (dibasic), 2g KH2PO4 (monobasic) were brought to 
1L with distilled water.  
 
2.3.3.3. Blocking buffer 
0.25g non-fat, dried, milk powder was added to 5mls of 10XPBS and 50 mls distilled 
water. This was prepared fresh each day the assay was being performed. 
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2.3.3.4. Wash buffer 
0.05% Tween 20 in PBS. 5 ml Tween was added to 200ml 10xPBS and volume 
brought to 2L.  
 
2.3.3.5. Sample dilution buffer 
0.05% Tween 20 & 0.5% milk in PBS. 1.25g non-fat dry milk powder was added to 
250ml wash buffer. This was prepared on the day of the assay. 
 
2.4. Methods 
2.4.1. Day 1: cELISA 
The appropriate number of microtitre plate wells were coated with 55µL/well of BO2 
capture Ab at 2 µg/ml: To prepare 1 plate: 28 µL BO2 stock was diluted in 5.5 ml 
carbonate buffer. Plates were incubated overnight at 4°C. 
 
2.4.2. Day 2: cELISA 
Blocking buffer and sample dilution buffer (SDB) were prepared as described above 
(2.3.3.5). The coated microtitre plates were taken from the refrigerator and washed 3 times 
with PBS-TWEEN wash buffer by filling the wells to the brim and then decanting the 
entire volume and blotting on paper towel. Using a multi-channel pipette, the plates were 
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blocked with 300 µL/well blocking buffer and placed on a shaker for 1 hour at ambient 
temperature. The IFNβ solutions were prepared using sample dilution buffer: 20 µL stock 
IFNβ (Avonex®) + 4 ml PBS-TWEEN-20/Milk = 0.15 ug/mL (volume for 1 plate). The 
blocking buffer was decanted and plate inverted and tapped sharply on paper towels to 
remove excess buffer. Using a multi-channel pipette, 50 µL/well of IFNβ or diluent (for 
neg. control wells) was added to the appropriate wells [Figure 2-2] and this was further 
incubated on the shaker for 1 hour at ambient temperature. 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A BO2 + IFN BO2 + diluent BO2 + IFN BO2 + diluent BO2 + IFN BO2 + diluent 
B BO2 + IFN BO2 + diluent BO2 + IFN BO2 + diluent BO2 + IFN BO2 + diluent 
C BO2 + IFN BO2 + diluent BO2 + IFN BO2 + diluent BO2 + IFN BO2 + diluent 
D BO2 + IFN BO2 + diluent BO2 + IFN BO2 + diluent BO2 + IFN BO2 + diluent 
E BO2 + IFN BO2 + diluent BO2 + IFN BO2 + diluent BO2 + IFN BO2 + diluent 
F BO2 + IFN BO2 + diluent BO2 + IFN BO2 + diluent BO2 + IFN BO2 + diluent 
G BO2 + IFN BO2 + diluent BO2 + IFN BO2 + diluent BO2 + IFN BO2 + diluent 
H BO2 + IFN BO2 + diluent BO2 + IFN BO2 + diluent BO2 + IFN BO2 + diluent 
Figure 2-2 Coating of plate with IFNβ or diluents (sham well). 
 
 
2.4.3. Preparation of Calibrators, controls and samples 
The standard curve was prepared using a known positive serum sample which was 
diluted 1:400 in doubling dilutions to 1:12,800. Several samples were evaluated for use as 
the standard which had low background reactivity and had a high level of BAbs. Arbitrary 
units were assigned to each point on the standard curve – see table 2-1. A negative control 
sample and samples for testing were prepared by diluting 1:100 with SDB 5 µL of sample 
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added to 500 µL of sample diluent buffer. The plate was emptied, blotted on paper towels 
and washed 4 times. All standards, controls (buffer and negative) and samples were added 
in duplicate 50 µL / well. This was incubated on the shaker for 2 hours at room temperature 
[Figure 2-3]. 
 
 
 
Dilution Serum or diluted 
serum 
Vol 
required Vol SDB 
Dilution 
Factor 
Assigned 
units 
1 Positive standard 
serum 
5 µL 2000 µL 1:400 100 U 
2 1:400 1000 µL 1000 µL 1:800 50 U 
3 1:800 1000 µL 1000 µL 1:1600 25 U 
4 1:1600 1000 µL 1000 µL 1:3200 12.5 U 
5 1:3200 1000 µL 1000 µL 1:6400 6.25 U 
6 1:6400 1000 µL 1000 µL 1:12,800 3.125 U 
Table 2-1 Preparation of standards 
 
 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A buffer control buffer control test sample #1 test sample #1 test sample # 9 test sample # 9 
B negative control negative control test sample #2 test sample #2 test sample#10 test sample#10 
C PSC dilution 6 PSC dilution 6 test sample#3 test sample#3 test sample#11 test sample#11 
D PSC dilution 5 PSC dilution 5 test sample #4 test sample #4 test sample#12 test sample#12 
E PSC dilution 4 PSC dilution 4 test sample #5 test sample #5 test sample#13 test sample#13 
F PSC dilution 3 PSC dilution 3 test sample #6 test sample #6 test sample#14 test sample#14 
G PSC dilution 2 PSC dilution 2 test sample #7 test sample #7 test sample#15 test sample#15 
H PSC dilution 1 PSC dilution 1 test sample #8 test sample #8 test sample#16 test sample#16 
Figure 2-3 BAb ELISA - Application of samples to the plate. 
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The HRP conjugated detector antibody was prepared by adding 0.5µL donkey anti-
human IgG HRP-conjugated antibody and 8 µL goat anti-human IgG and adding to 11.65 
mls SDB (per plate). The samples were decanted from the plate and washed 4 times, plates 
were blotted after each wash on paper towel. 100 µL of detector antibody solution was 
added to each well and incubated for 1 hour on the shaker at room temperature. 
This was decanted and washed 4 times with wash buffer and 100 µL of TMB added to 
each well. This was incubated at room temperature in the dark until the colour of the 
highest concentration standard was sufficiently developed to the naked eye (~ 5 – 10 
minutes). The reaction was stopped by adding 50 µL of 1M HCl to each well. The plate 
was then read at 450 nm and 750 nm using the Wallac Victor2 1420 plate reader [Figure 
2-4]. 
 
 
Figure 2-4 Photograph of BAb cELISA plate 
Layout of standards and samples is as described in Figure 2-3 
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2.4.4. Calculation of results 
The OD 750 nm readings were subtracted from the OD 450 nm readings; this corrected 
for subtle variations in volume. The mean of each duplicate was obtained and the CVs of 
each duplicate were calculated to ensure variation was < 10%. The mean readings without 
IFNβ were subtracted from those with IFNβ to correct for background levels. To create a 
standard curve, Units were plotted on the x-axis vs. corrected A-450 values of the five 
doubling dilutions of the positive control sera on the y-axis (both log 10 scale). A linear 
regression analysis was performed on the x-y points of the curve to obtain slope and y-
intercept. Using these values and the background corrected A-450 values of the test 
samples as y values, the x value (Units) was calculated for each test sample using the 
following formula: 
 
Test Sample Units = [(test sample background-adjusted A-450) – y-intercept] / slope 
 
2.4.5. Reference ranges 
Reference ranges were established previously by measuring the OD and thus mean 
units in subjects (n=10) who were treatment naïve and thus BAb negative. The mean OD + 
3 SD was used as the cut off for negative / low positive and results were categorised as 
follows: 
 
Units  Interpretation  
< 3.5 U Low Negative 
3.5-8 U Moderate Positive 
8.0-55 U High Positive 
> 55 U Very High Positive 
                                 Table 2-2 Result interpretation. 
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2.5. Testing patient samples 
 
Several NAb+ve samples were selected and used at varying dilutions to generate a 
standard curve. Those with background < 0.15 were stored for use. The plate below shows 
the typical OD values obtained. Columns highlighted in red are wells coated with IFNβ and 
those highlighted in green without (control for background) Figure 2-5 and Figure 2-6. 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A buffer control  buffer control test sample #1 test sample #1 test sample # 9 test sample # 9 
B negative control negative control test sample #2 test sample #2 test sample#10 test sample#10 
C PSC dilution 6 PSC dilution 6 test sample#3 test sample#3 test sample#11 test sample#11 
D PSC dilution 5 PSC dilution 5 test sample #4 test sample #4 test sample#12 test sample#12 
E PSC dilution 4 PSC dilution 4 test sample #5 test sample #5 test sample#13 test sample#13 
F PSC dilution 3 PSC dilution 3 test sample #6 test sample #6 test sample#14 test sample#14 
G PSC dilution 2 PSC dilution 2 test sample #7 test sample #7 test sample#15 test sample#15 
H PSC dilution 1 PSC dilution 1 test sample #8 test sample #8 test sample#16 test sample#16 
Figure 2-5 BAb cELISA Plate layout 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.162 0.143 0.135 0.155 0.504 0.518 0.556 0.536 0.391 0.366 0.377 0.404 
B 0.437 0.414 0.392 0.407 0.436 0.440 0.363 0.343 0.456 0.445 0.477 0.476 
C 0.285 0.262 0.142 0.162 0.781 0.786 0.840 0.813 1.278 1.310 0.357 0.394 
D 0.272 0.256 0.107 0.115 0.385 0.365 0.426 0.410 0.364 0.380 0.368 0.381 
E 0.331 0.306 0.093 0.094 0.607 0.648 0.389 0.380 0.325 0.316 0.396 0.358 
F 0.471 0.470 0.092 0.090 0.595 0.625 0.308 0.282 0.405 0.469 0.365 0.303 
G 0.677 0.704 0.128 0.134 0.728 0.719 0.943 0.863 0.468 0.436 0.301 0.329 
H 1.135 1.124 0.162 0.152 0.374 0.394 0.493 0.460 0.165 0.161 0.189 0.197 
Figure 2-6 OD from positive standard curve and patient samples.  
 98 
2.5.1. Standard Curve 
The mean of each dilution of the positive standard, negative control and diluents in 
wells with or without IFNβ was calculated. These values were subtracted to give the 
corrected value [Table 2-3]. Dilutions 1 – 6 of the PSC were assigned unit value, which 
were plotted against corrected absorbance at 450nm to generate the standard curve [Figure 
2-7]. 
 
 
Mean 
IFNβ 
Mean 
no 
IFNβ 
corrected units SD IFNβ CV % 
SD no 
IFNβ CV % 
dil 0.152 0.145 0.008  0.0137 9.0 0.0143 9.9 
c neg 0.426 0.400 0.026  0.0159 3.7 0.0106 2.7 
6 0.273 0.152 0.121 3.125 0.0164 6.0 0.0143 9.4 
5 0.264 0.111 0.153 6.25 0.0112 4.2 0.0052 4.7 
4 0.318 0.094 0.225 12.5 0.0182 5.7 0.0010 1.1 
3 0.470 0.091 0.379 25 0.0007 0.1 0.0012 1.3 
2 0.690 0.131 0.559 50 0.0191 2.8 0.0047 3.6 
1 1.129 0.157 0.972 100 0.0077 0.7 0.0077 4.9 
Table 2-3 Data analysis to derive standard curve  
 
 
Units of each dilution plotted against corrected absorbance @ 450nm 
 
Figure 2-7 BAb standard curve 
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To calculate the titre of the unknown samples the OD was corrected and inserted as the 
y value in the equation of the standard curve. Thus x (sample titre) was calculated. In the 
data provided below the background values of sample 3 and 7 were > 0.6 therefore these 
results were not accepted and required retesting. Samples 5, 6 and 11 were positive and 
sample 15 was a low positive, all others were regarded as negative 
 
               
Sample IFNβ no IFNβ Corrected Result SD IFNβ CV 
SD no 
IFNβ CV 
1 0.511 0.546 -0.035 -20.4 0.0098 1.9 0.014 2.6 
2 0.438 0.353 0.085 -4.4 0.0026 0.6 0.014 3.9 
3 0.784 0.827 -0.043 -21.5 0.0035 0.4 0.019 2.3 
4 0.375 0.418 -0.044 -21.6 0.0138 3.7 0.012 2.8 
5 0.627 0.384 0.243 16.6 0.0288 4.6 0.007 1.7 
6 0.610 0.295 0.315 26.2 0.0212 3.5 0.018 6.2 
7 0.723 0.903 -0.180 -39.8 0.0063 0.9 0.057 6.3 
8 0.384 0.477 -0.093 -28.1 0.0143 3.7 0.023 4.9 
9 0.378 0.391 -0.012 -17.4 0.0183 4.8 0.020 5.0 
10 0.451 0.477 -0.026 -19.3 0.0079 1.7 0.001 0.2 
11 1.294 0.375 0.918 106.6 0.0226 1.7 0.026 6.9 
12 0.372 0.374 -0.002 -16.1 0.0108 2.9 0.009 2.5 
13 0.320 0.377 -0.056 -23.3 0.0068 2.1 0.027 7.1 
14 0.377 0.334 0.043 -2.0 0.0452 8.3 0.044 7.1 
15 0.452 0.315 0.137 2.5 0.0224 5.0 0.020 6.4 
16 0.163 0.193 -0.030 -19.7 0.0028 1.7 0.006 2.9 
Table 2-4 Typical BAb results with BAb capture ELISA  
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2.5.2. Evaluation of protocol performance 
To evaluate performance of the assay each plate has a standard curve of dilutions of a 
known positive sample. Each plate also contains control wells (containing buffer alone) 
and control negative serum. After identification of known BAb +ve sample and untreated 
BAb –ve sample these were aliquoted in small volumes and frozen at –80oC for use in each 
assay. A sample was considered negative when the A-450 values were <0.4 prior to 
background correction and less than 0.15 after correction. The positive control serum was 
serially diluted as previously described, each dilution should have A-450 values curve 
ranged from 0.2 to 1.0 after correction for background (background levels < 0.4 were 
accepted). The dilutions were plotted on a log scale and the adjusted R value for the linear 
regression of the standard curve should be >0.95 to accept the plate. Serial standard curves 
were monitored for performance and plates which did not fulfil criteria were discarded and 
repeated. Figure 2-6 shows the plot of ten sequential “accepted” standard curves with 95% 
confidence intervals of each dilution point. Using repeated measures ANOVA no 
difference was found between the OD at each point (p=0.093). 
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Figure 2-8 Plot of BAb standard curve. 
Mean OD of ten sequential standard curves with 95% CI.  
 
 
 
2.6. Limitations 
The sensitivity of the assay was 3.5 U. Samples with background corrected A450 
values out of the linear range of the standard curve (i.e. above the top value or below the 
lowest value of the curve) could not be quantified accurately. To obtain a more accurate 
Unit value samples were re-tested in the next assay using a higher dilution if above top end 
of curve (e.g. 1:500 or 1:1000) or lower dilution when below bottom value of curve (e.g. 
1:25 or 1:50). Samples with background levels >0.6 A-450 were also retested. Accession of 
samples less than 6 hours after IFN-β injection can theoretically result in falsely low values 
due to quenching, by IFNβ, of the binding to antibodies in the circulation. 
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2.7. Conclusions 
The cELISA is accepted as the optimal screening assay for BAbs thus we sought to 
establish it as the BAb assay in our laboratory and to use this as a screening tool to evaluate 
subjects treated with IFNβ in the affiliated hospital prior to NAb testing. We found this 
assay simple to establish in the laboratory but many samples required retesting due to high 
backgrounds. In this way ~700 samples were tested with respect to BAb status (details of 
these results are given in chapter 4). In this way we could identify samples which should be 
NAb -ve and also those potentially with neutralising capacity. These samples could be used 
in developing and validating a novel NAb assay (chapter 3). The cELISA was simple and 
relatively time efficient to perform. Difficulties were experienced related to the sourcing 
and expense of the capture antibody which required shipping from Japan. Each 96-well 
plate had capacity to test only 16 sera and thus high throughput screening would be very 
labour intensive in the absence of a robot to apply samples or a plate washer. This may 
make the assay less accessible for some laboratories / countries.  
 
 
 
 
 
 
 
 103 
 
Chapter 3 
Development and validation of a novel cell based 
anti-Interferon beta neutralising antibody assay 
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3 Development and validation of a novel cell based anti-
IFNβ neutralising antibody assay. 
 
3.1. Introduction 
The development of NAbs has an important impact on the use of IFNβ in the treatment 
of people with MS. The objective of this chapter was to develop a novel bioassay to 
accurately detect neutralising antibodies to IFNβ, which was easy to perform, reliable and 
utilised commercially available products and to validate it against existing assays in other 
European Laboratories.  
The firefly - Lampyridae of the beetle order Coleoptera, also called lightning bugs or 
gloworms are winged beetles which are capable of producing a cold light. The enzyme 
luciferase acts on luciferin, in the presence of magnesium ions, ATP (adenosene 
triphosphate), and oxygen to produce light [Figure 3-1]. Luciferase genes can be 
synthesised and inserted into organisms or transfected into cells. Mice, silkworms, and 
potatoes are amongst the organisms that have already been engineered to produce the 
protein. The gene has been incorporated into many cell systems to provide a sensitive, 
rapid means to assay transcriptional activity of regulated activation sequences of DNA 
when fused to the protein coding sequence of the luciferase gene. In biological research, 
luciferase commonly is used as a reporter to assess the transcriptional activity in cells that 
are transfected with a genetic construct containing the luciferase gene under the control of a 
promoter of interest [Fan and Wood 2007]. 
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Figure 3-1 Diagram of firefly reaction with substrate - beetle luciferin to yield light. 
 
The premise to this work was to use a human cell line which was stably transfected 
with the firefly luciferase gene under transcriptional control of the ISRE. There are a 
number of cell lines available using the luciferase reporter gene system, thus we sought to 
evaluate two cell lines – a fibrosarcoma cell line (ATCC HT 1080 - HL 116 clone) 
developed by Gilles Uze, University of Montpellier France [Uze et al. 1994] and also a 
human embryonic kidney cell line - HEK293 (ATCC CRL-1573™).  The HL 116 clone 
was isolated in after co-transfection of the human HT 1080 [Pellegrini et al. 1989] cell line 
with p6-16 luciferase and pBB3 which contains the Eco GPT gene (glutamic-pyruvate-
transaminase) [Bourachot et al. 1982]. When interferon binds to its receptor, the reporter 
cassette is activated by the JAK/STAT intracellular signalling mechanism and luciferase is 
expressed within a few hours [results 3.7.1]. In the presence of Nabs this response is 
inhibited [Figure 3-1] (courtesy of Dr Susan Goelz – Biogen Idec). The HEK293 (ATCC 
CRL-1573™) cell line was donated by Biovation Ltd. who had transfected the cell line 
with the luciferase gene. The signaling reporter vector pISRE–TA-luc containing the firefly 
Luciferase gene was under the control of the ISRE. This cassette was transferred to the 
mammalian episomal expression vector pREP4 (Invitrogen) to create pREP-ISRE 
 106 
which was subsequently transfected into HEK293 cells. Stable transfectants were selected 
with hygromycin creating a stable HEK293-ISRE cell line [personal correspondence from 
Biovation].  
 
Figure 3-2  Mechanism of action of IFNβ 
Diagram of interaction of INFβ molecule with its cell bound receptor. activating JAK/STAT cell 
signalling mechanisms which in turn cause activation of the ISRE and transcription of downstream 
nuclear genes including the transfected luciferase gene. In the presence of NAbs this effect is lost.  
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3.2. Principles of assay development and validation 
The process by which a specific bioanalytical method is developed, validated and 
transferred to routine use divides into three main stages (i) reference standard preparation, 
(ii) bioanalytical method development and establishment of assay procedure and (iii) 
application of validated method to routine sample analysis and acceptance criteria 
(www.fda.gov/cder/guidance). A reference standard is a substrate of known identity and 
purity and should be used to prepare solutions of known concentrations, which would be 
used in the standard curve. For our purposes we utilised readily available IFNβ standards 
(NIBSC 3rd International Standard Interferon Beta 00/572) and therapeutic products 
(Avonex IFNβ-1a (Biogen Idec Ltd), Rebif IFNβ-1a (Merck-Serono) and Betaferon IFNβ-
1b (Schering)), and NIH antiserum to IFNβ (NIH anti-IFNβ antibody standard #G038-501-
572). The cell line used was an established line in the public domain and all other materials 
were obtained from verified suppliers. In developing the method fundamental parameters 
needed to be addressed including: accuracy, precision, calibration curve, robustness and 
system suitability. Accuracy is the closeness of agreement between the measured value and 
that which is accepted as the true value. This requires a “gold standard” or method to which 
the new method may be compared. Accuracy is determined by replicate analysis of the 
same samples using > 5 determinations at a variety of titres. Precision describes the degree 
of agreement among individual measures when a single sample is repeatedly measured. 
This should also be performed using at least 5 determinations of >3 samples at a range of 
concentrations. Acceptance criteria of coefficients of variation (CV) < 25 % should be 
applied to a biological assay. The standard curve is the relationship of known amounts of 
standard and the cells – a predictable dose response curve. A sufficient number of standard 
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samples should be used to adequately define this relationship and it should be reproducible. 
Anchoring points beyond the established upper and lower limits of quantification may be 
employed. The robustness of a procedure is the capacity of the method to remain 
unaffected by small but deliberate variations in the method parameters and provides an 
indication of its reliability in normal use.  In a cell based assay this includes: cell bank 
(beginning, middle or end of freeze), cell passage level, seeding density, stock density 
(days in culture), incubation time, different plates and varying reagent sources. If the assay 
method meets these validation criteria it can then be used to test routine samples.  
In the case of NAb assays a specific technique is used to calculate the titre to correct for 
changes in the bioactivity of the IFNβ protein used in the assay [Grossberg et al. 2001 a & 
b]. Rather than employing the international unit assigned by the IFNβ producer a Lab Unit 
(LU) is assigned by the laboratory performing the assay and this denotes activity as 
measured by any given IFN bioassay method in that lab, without reference to a standard. 
The LU is expressed per unit volume (LU/mL) as the IFNβ dose response is concentration 
dependent. In a bioassay the dose response forms a sigmoidal curve with upper and lower 
asymptotes and the endpoint of any assay is taken as the midpoint of the straight line 
portion of the dose response curve [Fig 3.3]. In the luciferase assay, the lower limit was set 
as the minimum amount of light the cells without any IFNβ stimulus emit under the 
established conditions of the assay. The upper limit was taken as the maximum amount of 
light emitted by cells maximally stimulated by a concentration of IFNβ that is considered to 
be saturating the transfected cell line. 
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Figure 3-3  Graph of luminescence in response to stimulating cells with IFNβ 
 
The Kawade technique defines the neutralisation potency of serum as the titre that 
reduces IFNβ bioactivity by ten-fold, i.e. the serum titre that reduces the activity of IFNβ 
from 10 LU/mL to 1 LU/mL.  The concentration of IFNβ at the 50% endpoint is defined as 
being 1 LU/mL and is the point at which 50% of the biological effect of IFN-beta is lost. 
To calculate the ten-fold Reduction Units (TRU)/ml, the formula  t = f (n-1) / 9 is used, 
where t equals the titre, n the number of LU/ml of IFNβ applied to the samples actually 
measured in the assay on this occasion (originally assumed to be 10), and f the dilution of 
antibody at the 50% endpoint.  One LU/ml is subtracted from n because that is the 
endpoint, not zero (there is no IFN to measure at zero), and therefore 9 is used as the 
divisor (difference between 10 and 1). This calculation method will be described in 
subsequent passages detailing calculation of n and the titre [Chapter 3.4.9]. 
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3.3. Materials and Methods 
3.3.1. Materials 
Flasks 80 cm2, sterile, with filter cap, Nunc (VWR, 734-2131).  96-well TC treated 
microtitre plate, black with clear bottom, sterile (Greiner Bio-One Ltd, 655097). 
Microplate lid, sterile (Greiner Bio-One Ltd, 656170). 10mL Stripette (Sigma, CSL 4488). 
Eppendorf combitips (2.5 mL) (VWR, 613-3531). 50  mL centrifuge tubes (Fisher, CFT-
900-011L). 15 mL centrifuge tubes (Fisher, FB55950). 5 mL syringes (VWR, 7008169). 
Sterile syringe filters 0.2µm (VWR, 514-4011).   
ATCC HT -1080 HL-116 clone (Gilles Uze, University of Montpellier, France,), bank 
of cells stored in liquid nitrogen. Dulbecco’s Modified Eagle Medium (DMEM) 
(Invitrogen Ltd. 11960-044) stored at 4oC. Fetal bovine serum, heat-inactivated (FBS) 
(Invitrogen Ltd. 10108-165). L-Glutamine solution 200 mM, sterile filtered (Sigma, 
G7513). HAT Media Supplement (50x), Hybri-Max, γ-irradiated (Sigma. H-0262). 
Antibiotic-Antimycotic αM (Sigma, A5955).  Hank’s Balanced Salt Solution (HBSS) 
(Sigma, H-6648). Dimethyl sulfoxide, (DMSO) Biotechnology Performance Certified, 
sterile-filtered (Sigma, D2438). Trypsin-EDTA Solution, 10x concentration (Sigma, T-
4174). Trypan Blue (Sigma). Steady-Glo Luciferase Assay System (Promega, E2550).  
Avonex IFNβ-1a  (Biogen Idec Ltd). NIBSC 3rd International Standard Interferon Beta 
00/572.  Sheep anti human IFN-beta antibody (Serotec AHP294Z). NIH anti-IFNβ 
antibody standard #G038-501-572 .  
Tissue culture facilities: 37oC incubator with 5% CO2, laminar flow hood water bath, 
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set at 37oC refrigerated bench centrifuge (set at 2000rpm, 5min, 4oC). Microscope cell 
counting chamber and counter liquid nitrogen cell storage facility Pipettes: 10 µL, 200 µL, 
1000 µL, 30-300 µL multichannel adjustable volume pipettes - Eppendorf Research®.   
Aluminium foil, ELISA plate shaker, ELISA plate reader (Wallac Victor2 1420 Multilabel 
Counter Plate Reader), set to read luminescence. 
 
3.3.2. Solutions and Media 
3.3.2.1. Complete culture medium 
Culture medium  without αM Volume 
DMEM 500 mL 
FBS 57 mL 
Glutamine 6 mL 
Sterile 7.5 % w/v NaHCO3 solution 6 mL 
HAT 1 vial 
  
Culture medium with αM Volume 
(DMEM-αM as prepared above) 100 mL 
1% Antibiotic-Antimycotic 1 mL 
Table 3-1 Preparation of culture media 
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3.3.2.2. Calibration solutions 
Preparation of stock solution – 10 LU/mL IFNβ-1a (Avonex) [Table 3-2]. Ten LU/mL 
of IFNβ-1a was generally equivalent to about 15 IU/mL of Avonex (10 – 20 IU/mL). Stock 
solutions were made on this basis.  The actual concentration of IFNβ-1a in LU/mL used to 
stimulate the cells was calculated and adjusted on each plate in line with the Kawade 
technique. A vial of Avonex (IFNβ-1a) was dissolved in fresh DMEM-αM to give a final 
volume of 6.0 mL and a concentration of 1 million IU/mL. This was equivalent to 
approximately 500,000 LU/mL. The solution was diluted with DMEM-αM, to give a final 
IFNβ-1a concentration of 500 LU/mL (ie take 1mL of the 500,000LU/mL solution and add 
to 9 mLs of DMEM, then take 1mL of this solution (50,000 LU/mL) and add to 9 mLs 
DMEM to create the 5,000 LU/mL solution, finally take 8mLs of the 5,000 LU/mL 
solution and add to 72mLs of DMEM to create the working solution of 500 LU/mL [Table 
3-2]. 
 
 
IFNβ-1a – 500 LU/mL    Stock solution. 
[IFN] LU/mL IFN (mL) DMEM-αM (mL) Final [IFN] LU/mL 
500,000 1 9 50,000 
50,000 1 9 5000 
5000 8 72 500 
 
Table 3-2 Preparation of IFNβ stock solution. 
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3.3.2.3. Promega Steady-Glo Luciferase Assay System 
Substrate was reconstituted as described in the manufacturers’ protocol and aliquots 
(5.3 mL) were prepared in foil covered tubes and frozen at -20˚C ready for use. Each 
aliquot contained sufficient substrate for one complete 96 well plate. 
 
3.4. Cell Culture 
The HL-116 cells were stored in complete DMEM in 1.5 mL aliquots at a density of 4 
million cells / mL in liquid nitrogen and thawed for use as required.  
Complete DMEM+αM (12 mL) was added to an 80 cm2 culture flask and incubated at 
37oC, with 5% CO2 for ~15 minutes prior to the cells being thawed.  A vial of cells was 
removed from liquid nitrogen storage and thawed rapidly at 37oC in a water-bath. The 
thawed cells were added to culture flask. Cells are cultured for ~ 4 hours to allow the viable 
cells to adhere to the flask and the medium changed to remove cell debris and DMSO.   
The culture medium was changed every 2-3 days (depending on the cell density) and 
replaced with fresh pre-warmed complete DMEM +αM (10-12 mL).  
 
3.4.1. Sub-culturing cells 
Cells were sub-cultured (or ‘split’) when ~ 85% confluent. This was approximated by 
examining the flask using a light microscope.  Culture medium was aspirated and the cells 
washed twice with pre-warmed HBSS (4 mL). Warmed trypsin/EDTA (4 mL) was added 
to the flask and gently washed over cells. The flask was returned to incubator until 
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all of the cells had detached (~ 2 min). FBS (0.4 mL or approx 10 % of trypsin volume) 
was added to inhibit the trypsin. The detached cells were aspirated and added to a 50 mL 
centrifuge tube. A cell pellet was prepared by centrifuging the cell suspension for 5 min at 
2000 rpm, 4oC. The supernatant was discarded and the cell pellet resuspended in DMEM 
+αM (10 mL) for sub-culturing, freezing or counting. 
 
3.4.2. Counting cells 
A cell pellet was prepared as described above and resuspended in DMEM +αM (10 
mL).  HBSS (30 µL) and Trypan blue 0.04 % in HBSS (40 µL) were added to a 1.5 mL 
tube. Cell suspension (10 µL) was added and 10µL of this suspension was placed under the 
cover slip of each side of the counting chamber using a pipette. The cells were counted in 8 
of the 4x4 squares. This has a volume equivalent to 0.1 µL. The cell count for 8 squares (n) 
x 10,000 = cells/mL.  
 
3.4.3. Seeding of cells into microtitre plates 
Cells were counted as described and resuspended at predetermined concentrations 
(assay dependent) in DMEM-αM. Using an Eppendorf repeater pipette, 100 µL of the cell 
suspension was added to each well of a sterile Greiner 96 well plate. The gaps around the 
wells at the edge of the plate were filled with 75 µL of sterile H2O to prevent dehydration 
of the external wells. A sterile lid was placed on top and the plate transferred to the 
incubator overnight. 
 115 
3.4.4. Freezing cells in liquid nitrogen for long term storage 
A sterile solution of 5 % (v/v) DMSO in DMEM+αM was prepared. The cell pellet was 
prepared as described above and resuspended in 5 % (v/v) DMSO DMEM+αM (10 mL). 
These were counted and diluted to a density of 1 x 106 cells/mL and frozen in 1 mL 
aliquots in cryotubes labelled with cell type, passage number, initials and date. Cryotubes 
were frozen, at the rate of 1 oC/min (using a ‘freezing pot’ filled with isopropyl alcohol) in 
a – 80 oC freezer for a minimum of 16 h. The following day the cryotubes were transferred 
to a liquid nitrogen cryo-conservation vessel.   
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3.4.5. Development of a standard protocol to measure anti-
Interferon β neutralising antibodies 
3.4.6. Assessment of cell response to IFN β:  Dose response 
Cells were cultured in DMEM+αM at 37 °C and 5 % CO2. Cells were counted and 
seeded into microtitre plates at a density of 40,000 cells per well in DMEM-αM.  The 
plates were incubated overnight at 37 °C and 5 % CO2. Standard interferon solutions were 
prepared with NIBSC human IFNβ 00/572 (reference standard), IFNβ-1a (Avonex, 
Biogen-Idec) and IFNβ-1b (Betaferon, Bayer-Schering).   Doubling dilutions were used to 
prepare standards of concentration 1000 IU/mL to ~0.08 IU/mL and these were added to 
the plates in duplicate. The plates were incubated for 5 hours at 37 °C and 5 % CO2.  The 
‘Promega Steady-Glo Luciferase Assay System’ substrate was warmed to room 
temperature, protected from light and mixed by gentle inversion prior to use. The plate was 
allowed to equilibrate at room temperature for 10 min. The ‘Promega Steady-Glo’ substrate 
was added to each well (50 µL/well). The plate was covered with aluminium foil (to protect 
it from the light) and placed on a plate shaker for 10 minutes. Luminescence was measured 
on a Wallac Victor2 1420 plate reader. A curve was constructed by plotting Log10 IFN 
dilution (x-axis) vs. Log10 LCPS (y-axis) to illustrate the dose-response of the cells to 
stimulation with IFNβ. From these curves the maximal and basal responses were 
determined to be used subsequently as anchor points. Both HL 116 and HEK cell lines 
were evaluated. HL 116 cells were found to be more sensitive to IFNβ stimulation and had 
lower levels of baseline leakage and thus HL 116 cells were used to establish the assay 
[Figure 3-4]. 
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Figure 3-4 Response of HL 116 and HEK 293 cells to IFNβ 
 
 
3.4.7. Inhibition of luciferase induction by commercial Anti-IFNβ 
neutralising antibodies  
Commercial sheep anti-human IFNβ antibody (Serotec AHP294Z) has a known 
neutralising activity of 1 NU/mL neutralising the bioactivity of 1 IU/mL of standard IFNβ. 
This was pre-incubated in known concentrations of 0, 0.1, 1, 10, 100 and 1000 NU/mL 
with IFNβ preparations from (0.5 to 100 IU/mL). These samples were added in duplicate to 
the microtitre plate and incubated for 5 hours. Promega substrate was added, luminescence 
measured and inhibition of activity calculated.  
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3.4.8. Uniformity Experiments  
This experiment was run to determine whether the position of the sample on the plate 
affects the final results.  IFNβ standard (10 LU/mL) was added to each well (100 µL/well) 
and the plate incubated for 5 hours [Figure 3-5].  A second plate [Figure 3-6] was prepared 
with the standard curve in the centre wells and at the edges and the curves and values 
compared. A total of 3 of each uniformity plate were run on 3 different days. The data from 
these experiments was subjected to statistical analysis (ANOVA) to determine putative 
plate effects that may impact on data interpretation.  
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 10 10 10 10 10 10 10 10 10 10 10 10 
B 10 10 10 10 10 10 10 10 10 10 10 10 
C 10 10 10 10 10 10 10 10 10 10 10 10 
D 10 10 10 10 10 10 10 10 10 10 10 10 
E 10 10 10 10 10 10 10 10 10 10 10 10 
F 10 10 10 10 10 10 10 10 10 10 10 10 
G 10 10 10 10 10 10 10 10 10 10 10 10 
H 10 10 10 10 10 10 10 10 10 10 10 10 
Figure 3-5 Uniformity plate layout 1. All wells contain 10 LU IFNβ. 
 
 1* 2* 3** 4** 5* 6* 7** 8** 9* 10* 11** 12** 
A 10 10 QC+ QC+ 10 10 QC+ QC+ 10 10 QC+ QC+ 
B 5 5 100 0 5 5 100 0 5 5 100 0 
C 2.5 2.5 100 0 2.5 2.5 100 0 2.5 2.5 100 0 
D 1.25 1.25 100 0 1.25 1.25 100 0 1.25 1.25 100 0 
E 0.63 0.63 100 0 0.63 0.63 100 0 0.63 0.63 100 0 
F 0.32 0.32 100 0 0.32 0.32 100 0 0.32 0.32 100 0 
G 0.16 0.16 100 0 0.16 0.16 100 0 0.16 0.16 100 0 
H 0.08 0.08 QC- QC- 0.08 0.08 QC- QC- 0.08 0.08 QC- QC- 
Figure 3-6 Uniformity plate layout 2. 
*Columns 1, 2, 5, 6, 9 & 10 contain IFNβ standard curve from 10 LU/mL to ~0.08 LU/mL 
** Columns 3, 4, 7, 8, 11&12 contain QCs and the “maximum” and “minimum” response to IFNβ  
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3.4.8.1. Evaluation of 96 well plates 
Three types of sterile, tissue culture plates were tested for use in the luciferase assay: 96 
well black plates with a transparent bottom (Greiner), black plates with a black bottom 
(Greiner) and all white plates (Greiner).  The three plates were evaluated simultaneously 
with the same calibration curve and samples in each plate. Absolute LCPS, CVs and 50% 
endpoints were compared between plates to determine which was optimal for the assay. 
 
3.4.9. Determination of the 50 % endpoint and Kawade correction 
factor 
The Kawade technique as previously described [3.2], defines the neutralisation potency 
of serum as the titre that reduces IFNβ bioactivity by ten-fold, i.e. the serum titre that 
reduces the activity of IFNβ from 10 LU/mL to 1 LU/mL.  The concentration of IFNβ at 
the 50% endpoint is defined as being 1 LU/mL and is the point at which 50% of the 
biological effect of IFN-beta is lost.  The maximal and basal responses (anchor points) 
were identified from the extended dilution curve and the 50 % endpoint calculated. 
 
50 % endpoint = Average (Log10 Max CPS: Log10 Min CPS) 
 
The undiluted stock of commercial IFNβ-1a (Avonex) is assigned a concentration of 6 
million IU/mL (freeze dried preparation). The dilution factor was calculated for each IFNβ-
1a standard used. The Log mean LCPS (x-axis) vs. Log IFN Dilution (y-axis) was 
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plotted as described above.  The “linear” appearing part of the curve was expanded and a 
trend-line fitted with equation and R2 value.  This equation was used to determine the Log 
IFN dilution at 1LU/mL (i.e. at the 50% endpoint). The IFNβ dilution was then calculated 
(IFNβ dilution = 10^LogIFNDil) and used to calculate the LU/mL used to stimulate the cells 
on the day. 
 
n = (IFNβ Dilution at 1 LU/mL) / (IFNβ Dilution used on cells) 
 
This value (n) was used as a correction factor in the Kawade formula. 
 
t = f (n-1) / 9 (expressed as TRU/mL) 
 
Where:   t = NAbs titre (corrected), f = serum dilution achieving the endpoint, TRU = Ten-
fold Reduction Unit. 
 
3.4.10. Screening IFNβ treated patients’ sera for neutralising 
activity 
Cells were seeded at density of 40,000 per well and incubated overnight as previously 
described. The patients’ sera samples to be tested were thawed at 4 °C. Stock IFNβ was 
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diluted to give a ~20 IU/mL concentration. Samples were screened for presence of any 
neutralising activity by mixing equal volumes of serum at 1:10 dilution with 20 LU/mL 
IFN beta 1a (Avonex) for 1 hour at 37ºC.  A calibration curve of IFN-beta of 
concentrations from 10 LU/mL to 0.08 LU/mL was prepared and a solution of 100 LU/mL 
IFNβ was prepared to detect the maximal saturated response of luciferase induction.  
Known negative and positive patient sera were included in each plate at 1:20 dilution. 
Overnight media was decanted (by inversion and gentle tapping) and the IFNβ dilutions 
and serum/IFNβ preparations added in duplicate to the microtitre plate [Figure 3-7].  Plates 
were incubated at 37 °C in a 5 % CO2 atmosphere for 5 hours. Luciferase substrate 50µL 
was added to the plate and left for 10 minutes before reading in a luminometer.  The LCPS 
obtained by the maximum (100 LU) concentration of IFNβ and minimum (no IFNβ) were 
calculated and the 50 % endpoint identified. The mean LCPS of each sample was 
calculated and those with values below the endpoint were considered positive.  Positive 
samples were analysed further to determine the Nab titre. 
 
  1 * 2 * 3 ** 4 ** 5 *** 6*** 7*** 8*** 9*** 10*** 11*** 12*** 
A 10 10 QC+ QC+ S1 S1 S9 S9 S17 S17 S25 S25 
B 5 5 100 0 S2 S2 S10 S10 S18 S18 S26 S26 
C 2.5 2.5 100 0 S3 S3 S11 S11 S19 S19 S27 S27 
D 1.25 1.25 100 0 S4 S4 S12 S12 S20 S20 S28 S28 
E 0.63 0.63 100 0 S5 S5 S13 S13 S21 S21 S29 S29 
F 0.32 0.32 100 0 S6 S6 S14 S14 S22 S22 S30 S30 
G 0.16 0.16 100 0 S7 S7 S15 S15 S23 S23 S31 S31 
H 0.08 0.08 QC- QC- S8 S8 S16 S16 S24 S24 S32 S32 
Figure 3-7 Screening plate Layout. 
*Columns 1 & 2 IFNβ standard curve from 10 LU/mL to ~0.08 LU/mL 
** Columns 3 & 4 contain QCs and the “maximum” and “minimum” response to IFNβ  
*** Columns 5 to 12 contain screening samples at 1:20 dilution preincubated with 10 LU of IFNβ 
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3.4.11. Nab titre calculation 
IFNβ calibration curve, 20 LU/mL and 100 LU/mL IFNβ solutions and QCs were 
prepared as described above. Serial dilutions of NAb positive samples were prepared, from 
1:20 to 1:2560 (final dilution after IFNβ added) [Table 3-3].  IFNβ solution (125 µL) was 
discarded from the final dilution tube, so that the final volume in all of the tubes was 
125µL. 
 
 
 
DMEM-αM 
Pre-warm 
(37oC) 
Serum 
(or QC) 
IFNβ-1a (20 
LU/mL) 
Final [IFN] 
(LU/mL) 
Final serum 
dilution 
1 225 25 125 10 1:20 
2 125 125 125 10 1:40 
3 125 125 125 10 1:80 
4 125 125 125 10 1:160 
5 125 125 125 10 1:320 
6 125 125 125 10 1:640 
7 125 125 125 10 1:1280 
8 125 125 125 10 1:2560 
Table 3-3 Serum sample dilutions – NAb assay 
 
 
IFNβ solution 20 LU/mL (125 µL) was added to each serum dilution (125 µL) to give a 
final dilution of sera of 1:20 and an IFNβ concentration of 10 LU/mL. The tubes were 
incubated at 37 ºC for 1 hour. Overnight media was decanted from the plates and the IFNβ 
calibration curve, QCs, maximum / minimum controls and samples added in duplicate 
[Figure 3-7]. 
 
 
 123 
 
 1* 2* 3** 4** 5*** 6*** 7*** 8*** 9*** 10*** 11*** 12*** 
A 10 10 QC+ QC+ S1 20 S2 20 S3 20 S4 20 
B 5 5 100 0 S1 40 S2 40 S3 40 S4 40 
C 2.5 2.5 100 0 S1 80 S2 80 S3 80 S4 80 
D 1.25 1.25 100 0 S1 160 S2 160 S3 160 S4 160 
E 0.63 0.63 100 0 S1 320 S2 320 S3 320 S4 320 
F 0.32 0.32 100 0 S1 640 S2 640 S3 640 S4 640 
G 0.16 0.16 100 0 S1 1280 S2 1280 S3 1280 S4 1280 
H 0.08 0.08 QC- QC- S1 2560 S2 2560 S3 2560 S4 2560 
Figure 3-8   Dilution Plate layout. 
 *Columns 1 & 2 IFNβ standard curve from 10 LU/mL to ~0.08 LU/mL 
** Columns 3 & 4 contain QCs and the “maximum” and “minimum” response to IFNβ  
*** Columns 5 to 12 contain diluted samples at 1:20 to 1:2560 dilutions preincubated with 10 LU of 
IFNβ 
 
 
Plates were incubated for 5 hours at 37°C, equilibrated at room temperature for at least 
5 minutes, 50 µL luciferase substrate was then added and the plate was incubated for 10 
minutes on a plate shaker before LCPS was measured. The actual LU of IFNβ used to 
stimulate the cells was calculated using the Kawade technique.  The mean LCPS at each 
dilution of sample, log10 LCPS and CVs were calculated and Log10 LCPS plotted vs. 
Log10 serum dilution to generate a standard curve. The dilution at which the curve crosses 
the 50 % endpoint (1 LU) was determined and the reciprocal of this denotes the unadjusted 
Nab titre.  
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3.4.12. Optimisation of other parameters 
3.4.12.1. Use of Promega Steady-Glo Luciferase Assay System 
The commercial product protocol advised addition of an equal volume of Steady-Glo 
Luciferase assay substrate to the culture medium (i.e. 100µL). This should be incubated for 
10 minutes to ensure complete cell lysis. To optimise the efficiency of the assay, 
performance of 25, 50 and 100 µL of luciferase assay substrate was investigated by 
measuring luminescence counts per second in standard curves of IFNβ- 1a and IFNβ- 1b 
[Figure 3-9, results 3.7.7]. Following addition of substrate, plates were shaken for the 
duration of the incubation period with the substrate to ensure that solutions were fully 
mixed and cells were lysed.  Absolute LCPS data were compared. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0 0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
  
B 0 0 1 1 1 1 1 1 1 1 
  
C   2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
  
D   5 5 5 5 5 5 5 5 
  
E   10 10 10 10 10 10 10 10 
  
F   20 20 20 20 20 20 20 20 
  
G   100 100 100 100 100 100 100 100 
  
H  Units of Avonex /ml  Units of Betaferon / ml 
  
Figure 3-9 Plate layout assessing volume of Luciferase assay substrate required 
Columns in green contain media only, columns in yellow (3 – 6) contain standard curves using Avonex,  
columns in blue (7 to 10) contain standard curves using Betaferon. 
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3.4.12.2. Evaluation of Luminometer parameters 
To ensure optimal reading of the plates, the effects of changing the acquisition time 
settings of the luminometer were investigated. The luminometer was set to read for 0.1, 
0.5, 1 and 2 seconds per well and the raw data compared with respect to absolute values, 
range and CVs of duplicates. The shortest acquisition time giving optimal results was 1 
second and thus was employed in all subsequent work [Figure 3-10]. 
 
 
Figure 3-10 Standard curves with varied aquistion time 
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3.5. Validation of Assay 
The accuracy and precision of the assay was examined by response to NIBSC standard 
IFNβ preparation #00/572, this is the WHO reference standard which acts as a calibrant to 
measure the potency of glycosylated IFNβ derived either from human fibroblasts or from 
CHO cells (commercial IFNβ 1a products).  Repeated testing of NIH anti-human IFNβ 
antibody reference standard #G038-501-572 (pooled human NAbs generated against 
IFNβ1a) was also performed to ensure accuracy of titres obtained using the standard 
operating procedure.  Additional samples with known NAb titres, determined either by a 
validated MxA protein ELISA or cytopathic effect (CPE) assay were obtained from other 
accredited European laboratories – Regional reference laboratory, Orbassano, Italy (CPE & 
MxA ELISA); Karolinska Institute, Stockholm Sweden (MxA ELISA); Biogen Idec, 
Cambridge US (CPE & MxA ELISA); University of Innsbruck, Innsbruck, Austria (MxA 
ELISA). These were tested on 10 occasions to determine assay accuracy and precision. To 
test robustness, sera were tested repeatedly (i) on the same day by two operators and (ii) on 
different days, with different cell passage number, varying pre-incubation / incubation 
times and cell densities.  External validation was performed by blind exchange of samples 
with other European Laboratories using the MxA protein ELISA [Files et al. 1998] and 
cytopathic effect assay [WHO expert committee on Biological Standardisation1985]. 
Samples encompassing a wide range of NAb titres were included. Results were unblinded 
only after testing had taken place. 
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3.6. Statistical analysis 
Statistical analysis and graphs were prepared using Microsoft Office Excel (2003) and 
STATA software (version 9, 2006, Statacorp, Texas, USA). To test for plate effects 
Levene’s test for equality of variances and students T-Test were used. To assess accuracy 
and precision the coefficients of variation for repeated measures were evaluated. To 
compare titres obtained with the Luciferase reporter gene assay and the “gold standard” 
methods, paired combinations and mean-difference plots were assessed using Bland-
Altman method [Bland and Altman 1999]. This method is favoured when comparing 
results measured using a new test with an established one. If the two readings (old test and 
new test) were identical all results would fall upon the mean difference line (which would 
be zero). By plotting the data this gives a visual assessment as to the degree of agreement 
between the two measures and whether this is skewed. The Pearson correlation coefficient 
was used to test association between assay methods. Percentage agreement was calculated 
and inter-rater kappa coefficient used as measure of agreement corrected for chance. A 
value of 0 reflects no agreement and 1 denotes perfect agreement [Kundel and Polansky 
2003; Chan 2003] 
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NAb Assay - Validation procedure summary 
 
 
Dose response of cells to IFNβ 
 
Inhibition of response with commercial NAbs 
 
Uniformity experiments 
 
Evaluate performance of 96 well plates 
 
Application of Kawade technique to determine activity of IFNβ on the day (n) 
 
Screening of patient sera 
 
Dilutions of sera to determine NAb titre 
 
 
 
Optimisation of Assay parameters 
 
Luciferase substrate 
 
Luminometer parameters 
 
Cell density in wells 
 
 
 
Internal Validation 
  
Accuracy – ten known positive patient samples tested on five occasions  
 
Precision - NIH anti-human IFNβ antibody reference standard antibody titres 
 
Repeatibility – NAb titres obtained with repeated testing 
 
Robustmess – effect of varying assay parameters 
 
 
 
External Validation 
 
Blinded sample exchange with 4 other laboratories 
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NAb assay step by step 
 
 
Make solutions and Interferon Calibration standards 
 
 
Count cells and seed in 96 well plate 100µL (40,000 cells) 
 
 
Incubate overnight 
 
 
Prepare serum samples to be tested and controls 
 
 
Preincubate sera with IFNβ (10 LU/mL) for 1 hour 
 
 
Prepare IFNβ standard curve 
 
 
Decant DMEM from 96 well plate 
 
 
Add IFNβ standards to 96 well plate in duplicates 
 
 
Add sera and controls to 96 well plate in duplicate 
 
 
Incubate for 5 hours 
 
 
Add Luciferase substrate to each well 
 
 
Measure luminescent counts per second in Luminometer 
 
 
Calculate value for n and NAb titres as per Kawade method 
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3.7. Results 
3.7.1. Response of cells to IFNβ 
Plates were prepared in accordance with operating procedure. Stock IFNβ was diluted 
uniformly to prepare aliquots of IFNβ with concentrations ranging from 1000 IU/ml 
(dilution factor 6000) to ~0.12 IU/ml (dilution factor 49152000). 100µl of each dilution 
point was added in duplicate to the plate and incubated for 5 hours. Luminescence (as 
measured by luminescent counts per second) was used to detect the presence of the 
luciferase enzyme. The response was equivalent with NIBSC standard IFNβ1a or 1b and 
commercial products Avonex and Betaferon. Plotting the Log10 IFN dilution vs. Log10 
LCPS produced a sigmoidal curve [Figure 3-11] shows the Log10 IFN dilution plotted on 
the x-axis vs. Log10 LCPS on the y-axis (ANOVA, p= 0,53). 
 
 
 
Figure 3-11 Response of cells to IFNβ 
Log IFNβ dilution vs. Log luminescent counts per second measured when  
luciferase substrate added to the cells 
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3.7.2. Inhibition of Luciferase induction by sheep anti human IFN-
beta antibody 
 
Figure 3-12 shows the inhibition of IFNβ by commercial sheep anti-human IFNβ 
antibody. The log IFNβ concentration is plotted on the x-axis and log LCPS on the y-axis. 
Each line represents the concentration of NAb used to inhibit the response of the cells to 
IFNβ. The samples incubated with no NAb, 0.1 NU/mL and 1NU/mL showed a good 
response with all concentrations of IFNβ, the samples with 10 NU/mL of NAb added 
shows some inhibition of response at low IFNβ concentrations but this inhibition is 
overcome at higher IFNβ concentrations, however using 100 NU/mL and 1000 NU/mL of 
NAb the inhibition of response was complete at all IFNβ concentrations. This confirms the 
dose response effect of Nabs. 
 
 
 
Figure 3-12  Inhibition of IFNβ (Avonex) by commercial sheep anti-human IFNβ NAb 
IFNβ concentrations range from 0.5 IU/ml to 100 IU/ml. The bioactivity of IFNβ is inhibited by NAb as 
the NU/ml increases. 
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3.7.3. Application of Kawade method 
3.7.3.1. Calculation of n 
An extended standard IFNβ-1a curve (using doubling dilutions between 100 and 
0.02LU/mL, approximate concentrations) was prepared and incubated [3.4.9]. In the 
example below [Figure 3-13 & Table 3-4] the LCPS at maximum (100LU/mL) was 9574 
(ln 3.98) and at minimum (no IFNβ) was 381 (ln 2.58), thus the log10 LCPS at the 50% 
endpoint was 3.98-2.58 = 3.28. The 50% endpoint reflects 1 LU/mL and the log10 IFN 
dilution at this point was 6.43. Thus the defined interferon concentration of 1LU/mL (50% 
endpoint) would be equivalent to a dilution of 1: 2710834 of the original stock (inverse 
Log 6.43). Each sample to be tested was incubated with ~10LU/mL which was a 1:300,000 
dilution of stock IFNβ. Thus from the standard curve the actual LU value of IFN β 
corresponding to the estimated 10LU/mL could be determined. Thus the n of the Kawade 
equation in the assay on this occasion = 2710834 / 300000 = 9.04. A further example of 
calculation of n is given on page 149 (worksheet from laboratory). 
 
 
 
 133 
Interferon Calibration Curve
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Figure 3-13 Maximum and minimum asymptotes with 50% endpoint 
 
 
Estimated   
LU/mL IFN dil CPS Log CPS 
Log IFN 
Dil 
Log 
CPS 
100.00 30000 9574 3.98 4.48 3.98 
50.00 60000 9520 3.98 4.78 3.98 
25.00 120000 8779 3.94 5.08 3.94 
12.50 240000 7606 3.88 5.38 3.88 
6.25 480000 6518 3.81 5.68 3.81 
3.13 960000 4415 3.64 5.98 3.64 
1.56 1920000 2573 3.41 6.28 3.41 
0.78 3840000 1475 3.17 6.58 3.17 
0.39 7680000 786 2.90 6.89 2.90 
0.20 15360000 545 2.74 7.19 2.74 
0.10 30720000 468 2.67 7.49 2.67 
0.05 61440000 393 2.59 7.79 2.59 
0.02 12288000 381 2.58 8.09 2.58 
0.00  414 2.62   
Table 3-4 IFNβ standard curve in NAb assay (raw data) 
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3.7.3.2. Titre calculation 
To determine whether a test sample was NAb -ve or +ve the mean LCPS from the 
duplicate readings was calculated [3.4.10]. This was converted to ‘Log 10 CPS.’ If this 
value was greater than the 50% endpoint the sample was negative for Nabs. If this value 
was less than the 50% endpoint the sample was positive for NAbs and was therefore 
serially diluted to determine the titre at which the endpoint was reached as decribed in 
3.4.11. The Log 10  LCPS at each serum dilution were plotted on the x-axis vs. the serum 
dilution on the y-axis. A trendline was fitted (using points either side of the 50% endpoint) 
and the trendline equation was used to calculate the serum dilution achieving the 50% 
endpoint. This was the value (f) in the Kawade formula.  Using the Kawade formula above 
the corrected NAbs titre was estimated. A further example of titre calculation is given on 
pages 149 -150 (pages from laboratory worksheet). 
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Figure 3-14 Sample dilution curve 
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3.7.4. Incubation time 
The graph below [Figure 3-15] shows the log10 IFNβ dilution (x-axis) vs. log10 LCPS 
(y-axis). Each line represents the IFNβ standard curve obtained with a specific incubation 
time. Longer incubation times resulted in higher absolute LCPS but did not affect the slope 
of the curve. Saturation was dependent on the IFNβ concentration used. Repeated testing of 
4 samples with different incubation times did not show any significant variation in titre 
with CVs <10.4% [Table 3-5]. 
 
 
 
Figure 3-15 The effect of incubation time on LCPS measured 
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Sample 3 hours 4 hours 5 hours 6 hours mean CV 
1 < 20 < 20 < 20 < 20 < 20 NA 
2 232 252 293 256 258 9.8 
3 782 843 702 898 806 10.4 
4 > 1280 > 1280 > 1280 > 1280 > 1280 NA 
Table 3-5 Nab titres obtained testing four samples using different incubation times        
 
 
3.7.5. Uniformity Experiments 
The LCPS detected in each well when cells were stimulated with 10 LU/mL of standard 
IFNβ were analysed using repeated measures ANOVA, no significant plate effect was 
detected (p = 0.13). Similarly no significant difference was found relating to position of 
standard curve in the plate (p = 0.21). 
 
3.7.6. Evaluation of 96 well plate performance 
The LCPS, performance of standards and titres obtained were not significantly different 
when using black clear bottomed or solid plates. The luminescent counts obtained with 
white plates were higher than those in the black plates; white plates mean IFNβ minimum 
LCPS 234 (range 165-321) black plates minimum LCPS 156 (132 – 176) t-test p=0.0021, 
white plates maximum (100LU IFNβ) LCPS 21354 (range 17634 – 23187) black plates 
mean maximum (100LU IFNβ) 10342 (85679-12753) p < 0.0001. However, NAb titres of 
known positive samples remained unchanged. Thus either black or white, clear bottomed or 
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solid plates are suitable for use in this assay. Black clear bottomed plates were selected for 
use in the standard operating procedure as the cross talk was reduced between wells and the 
cells could be easily visualised. 
 
3.7.7. Optimisation of Promega Steady-Glo Luciferase Assay 
System 
The manufacturers recommend use of 100 µL of substrate in each well for use in the 
Luciferase assay system. The performance of 25, 50 and 100 µL of LAS was evaluated and 
LCPS compared using MANOVA. No significant difference was found in LCPS of 
standard curves using 50 or 100 µL (p = 0.53) but there was a difference when 25 µ µL was 
used p = 0.003. In the interest of cost effectiveness we reduced this volume to 50 µL 
[Figure 3-16] 
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Figure 3-16   Standard curves of IFNβ-1a Avonex  
IFNβ-1a (Avonex) and IFNβ-1b (Betaferon) detected using 25, 50 or 100µL of Luciferase assay 
substrate
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3.7.8. Evaluation of Luminometer parameters 
A single plate was read on 4 occasions altering the duration of measurement of LCPS 
from each well. Readings at 0.1 s/well, 0.5 s/well, 1s/well and 2s/well were obtained. The 
effect on maximum LCPS measured increased significantly from 0.1 to 1 s/well and began 
to plateau after this point [Table 3-6]. Reading times of 0.5 – 2 seconds per well did not 
significantly affect the endpoint and using 1 s/well ensures the total reading time of the 
plate is < 2 minutes which is more convenient when analysing several plates.  
 
s/well Max LCPS Min LCPS 50% endpoint Actual LU 
0.1 1601 24 2.29 17.5 
0.5 4687 15 2.35 15 
1 8834 159 3.07 14.61 
2 9534 177 3.10 14.07 
Table 3-6 Luminometer settings 
Maximum and minimum LCPS obtained varying the duration of measurement from each individual 
well. 
 
3.7.9. Effect of cell density 
Plates were prepared with cell densities ranging from 20,000 to 100,000 cells per well. 
Six samples were tested in each plate to ascertain the effect of cell density on titre obtained. 
No significant difference in titre was found (repeated measures ANOVA p = 0.079), 
coefficients of variation range 0-21% [Table 3-7]. 
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 100,000/well 80,000/well 60,000/well 40,000/well 20,000/well CV 
S1 <20 <20 <20 <20 <20 NA 
S2 69 62 64 67 63 4 
S3 167 180 160 155 200 10 
S4 83 80 75 72 79 6 
S5 600 702 653 590 612 7 
S6 >1280 >1280 >1280 >1280 >1280 NA 
Table 3-7 Cell density effect. 
 
 
3.7.10. Precision, Accuracy, Repeatability and Robustness 
The precision of the assay was assessed by measuring NIH anti-human IFNβ antibody 
reference standard antibody titres. The reference antibody was reconstituted as per NIH 
recommendations. This has an attributed titre of 1:1700 using a CPE assay and titre 
calculated using the Kawade method. This was measured on 10 separate occasions to 
assess accuracy of the Luciferase assay. Figure 3-17 shows the results obtained; mean titre 
1716, CV 8.8 %, [range 1492 – 1989]. 
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Figure 3-17  Repeated testing of NIH NAb reference standard on 10 occassions against IFNβ 1a 
(Avonex). 
  
 
To evaluate accuracy ten known positive patient samples, encompassing a range of 
titres were tested on five occasions on five different days, using cells of different passage 
number. CVs ranged from 8 -23% depending on titre [Table 3-8] Samples with low titres 
were prone to higher % variability although in absolute terms the differences were small. 
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Table 3-8 Repeated testing of 10 known NAb samples 
 
 
Sample 1 2 3 4 5 mean SD CV % 
1 > 1280 > 1280 > 1280 > 1280 > 1280 > 1280 0 NA 
2 647 754 598 671 605 655 80 12 
3 258 238 292 301 275 273 29 11 
4 171 160 183 154 163 166 13 8 
5 93 83 90 75 80 84 8 10 
6 56 58 62 66 49 58 4 8 
7 35 33 34 27 40 34 4 11 
8 36 25 31 22 20 27 6 23 
9 22 12 18 20 25 19 4 22 
10 <20 <20 <20 <20 <20 <20 <20 NA 
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3.7.11. External Validation of Luciferase assay 
Blinded exchange of 200 samples took place between the Neuroimmunology laboratory 
in London and laboratories in Turin, Innsbruck, Stockholm and Biogen Idec (USA). 
Samples were tested using the current Luciferase assay (IoN) and the MxA protein ELISA 
in Turin, Innsbruck and Stockholm. A further 24 samples were also tested using the 
cytopathic effect assay in Turin. Samples were diluted to a factor of either 1:1280 or 
1:2560 depending on the laboratory. For the purpose of calculations, titre values > 1280 or 
> 2560 were considered equal.  
 
3.7.11.1. Turin 
Samples (n=49) were exchanged between Dr. A Bertolotto’s laboratory and IoN. 
Overall agreement – positive vs. negative outcome = 83.7% (41/49) of observed 
agreements. Inter-rater Kappa =0.67. Pearson correlation = 0.83. Of these samples 24 were 
also tested using the CPE. Overall agreement was 87.5% [Table 3-9]. The Kappa inter-rater 
agreement was=0.75 and Pearson correlation = 0.96. Bland Altman plots are shown below 
and shows overall good agreement between the titres obtained as the mean difference line 
sits on the zero line [Figure 3-18]. 
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A. 
 
B. 
 
Figure 3-18 Bland Altman Mean difference plot - Italy 
Figure A shows the agreement between Nab titres obtained using the MxA ELISA in Turin and the 
LUC assay at IoN, UK. Figure B shows the agreement between CPE assay in Turin and LUC assay UK 
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3.7.11.2. Innsbruck 
Samples (n=57) were exchanged. All samples were tested using IFNβ-1b as this is 
always used for Nab assays in Innsbruck irrespective of subject treatment. Overall 
agreement – positive vs. negative outcome = 94.7% (54/57) of observed agreements [Table 
3-9]. The inter-rater Kappa =0.87, Pearson correlation coefficient = 0.90. The Bland 
Altman plot showed that the titres obtained using the Luciferase assay tended to be higher 
than those obtained using the MxA ELISA although when testing for differences these 
were not significant (t test p = 0.067). 
 
 
Figure 3-19 Bland Altman mean difference plot – Austria. 
The figure shows the agreement between the MxA ELISA performed in Innsbruck Austria and the 
luciferase assay in the UK. Samples tend to have higher titres with the Luciferase assay as compared 
with the MxA ELISA as many sit below the zero line.  
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3.7.11.3. Stockholm 
Samples were exchanged on 2 occasions. In total 86 samples were exchanged. Overall 
agreement was 84%, kappa inter-rater agreement was 0.56 and Pearson correlation 
coefficient was 0.83 [Table 3-9]. The Bland Altman plot shows that there is a tendency for 
the titres obtained with the Luciferase assay to be higher than those with the MxA ELISA 
in Stockholm as the mean difference line is at -0.4. This was noted to be related to some 
samples which were negative with the ELISA and low positive using the Luciferase assay. 
 
 
 
Figure 3-20  Bland Altman mean difference plot - Sweden 
The figure shows the agreement between the titres obtained between the MxA ELISA in Sweden and 
the LUC assay UK.  
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3.7.11.4. Biogen Idec  
Biogen Idec supplied 8 samples which were tested. Overall agreement 100%, Inter-
rater kappa 0.86 and Pearson correlation coefficient 0.93 [Table 3-9].  
 
 
 
Turin 
MxA 
Innsbruck 
MxA 
Stockholm 
MxA 
Biogen Idec 
MxA  
LUC 
assay pos neg pos neg pos neg pos neg Total 
Agree 23 18 39 15 55 16 6 2 174/ 200 87% 
Disagree 4 4 2 1 1 14 0 0 26/200 13% 
Table 3-9 Agreement of NAb results with Luciferase assay vs other laboratory. 
The titres obtained using the Luciferase NAb assay at IoN were compared with the “known” results 
obtained using the MxA protein ELISA assay in other accredited European Laboratories. 
 
The overall agreement for the 200 samples exchanged was 87% between MxA ELISA 
and Luciferase assay (n=200) [Table 3-9]. There were a significant number of 
disagreements in the samples exchanged with Stockholm. These were samples which were 
called negative if titre < 20 NU. Of the discordant results the titres measured in Stockholm 
were between 10 – 19 TRU in 9 of 14, but > 20 NU (20 -42 range) when tested using the 
Luciferase assay. Whether difference in low titres make a clinical difference is a moot 
point and will discussed in detail in chapter 5. 
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3.7.12. Quality Control  
Pooled serum samples were stored in small aliquots at – 80o C. A negative and a 
positive control were included on each plate. On dilution plates a moderately positive 
control was diluted to obtain a titre. All samples, QCs and standards were tested in 
duplicate, if samples did not perform as expected the plate was rejected and the analysis 
repeated. IFNβ-1a standards: if the CV for any of the standard points was > 10 %, the 
graph showing a plot of the raw data was examined.  If any one of the plotted points, 
relating to these high CVs, was obviously an outlier it was excluded from the calculations 
relating to the standard curve.  A maximum of two outliers were removed in this manner. If 
more than two were present the assay was repeated.  
Patient samples: If CVs of any dilution points were above 10 %, it was evaluated as to 
whether any of the individual measurements changed the status of the sample, from either 
positive to negative or negative to positive or led to a significant change in titre.  If the 
status was changed the sample was re-analysed.  
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NAb assay worksheet 13/07/2009          
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 3528 3050 118 90 111 110 97 104 106 81 2860 2996 
B 2514 2417 4323 67 205 240 97 119 118 100 1378 1738 
C 1659 1488 4574 80 601 708 121 132 179 237 2567 2580 
D 882 875 4519 58 1623 1812 446 422 876 976 1071 1527 
E 357 395 4287 69 2357 2290 1160 1321 1857 1826 2714 2854 
F 182 197 4289 70 2831 2737 2196 2101 2639 2780 2926 3048 
G 90 113 4561 68 2981 2999 3142 3023 3343 3180 2985 3029 
H 83 50 2067 1736 3035 3203 3252 3174 3607 3372 3290 3266 
 
1 2 3 4 5 6 7 8 9 10 11 12 
     
 
 
 
       
LU/mL IFN Diln CPS 
Log 
CPS LogIFNDil         
10.00 300000 3289 3.52 5.48         
5.00 600000 2466 3.39 5.78         
2.50 1200000 1574 3.20 6.08         
1.25 2400000 879 2.94 6.38         
0.63 4800000 376 2.58 6.68         
0.31 9600000 190 2.28 6.98         
0.16 19200000 102 2.01 7.28         
0.08 38400000 67 1.82 7.58         
             
 CPS 
Log 
CPS LU/mL 
Log IFN 
Dil IFN Diln 
       
Maximum 4426 3.65           
Minimum 69 1.84           
50% Endpoint 2.74 1.0 6.54 3447562        
 
 
           
 
 
     
QA 
        
LU used to stimulate 
cells n= 11.49 
 
300000 
 
  
Av CPS SD CV 
  
 
 
     Maximum 4426 140 3   
 
 (n-1)/9= 1.17 
   Minimum 69 7 10   
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Samples LCPS  1 LCPS 2 Average SD CV 
Log 
CPS Diln 
Serum 
Dil (f) NAb titre  Result 
Sample 
ID Report 
10.00 3528 3050 3289 338 10 3.52   Report   P SQ 
5.00 2514 2417 2466 69 3 3.39       
2.50 1659 1488 1574 121 8 3.20       
1.25 882 875 879 5 1 2.94       
0.63 357 395 376 27 7 2.58       
0.31 182 197 190 11 6 2.28       
0.16 90 113 102 16 16 2.01       
0.08 83 50 67 23 35 1.82             
Positive QC 118 90 104 20 19 2.02 20   Positive QC Pool Pass 
Negative 
QC 2067 1736 1902 234 12 3.28 20     Negative QC Pool Pass 
       Sample 1      
Sample 1 111 110 111 1 1 2.04 20 76 88 Low positive 
 205 240 223 25 11 2.35 40  corrected   
 601 708 655 76 12 2.82 80     
 1623 1812 1718 134 8 3.23 160     
 2357 2290 2324 47 2 3.37 320     
 2831 2737 2784 66 2 3.44 640     
 2981 2999 2990 13 0 3.48 1280     
  3035 3203 3119 119 4 3.49 2560         
       Sample 2     
Sample 2 97 104 101 5 5 2.00 20 192 224 Positive 
 97 119 108 16 14 2.03 40  corrected   
 121 132 127 8 6 2.10 80     
 446 422 434 17 4 2.64 160     
 1160 1321 1241 114 9 3.09 320     
 2196 2101 2149 67 3 3.33 640     
 3142 3023 3083 84 3 3.49 1280   :  
  3252 3174 3213 55 2 3.51 2560         
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3.8. Conclusions 
The Luciferase assay fulfils the international need of a reliable cost and time efficient 
NAb assay which can be incorporated easily into routine use. Reporter gene assays are 
frequently used in bioassay systems as markers of biological activity of a substrate. In this 
context the luciferase gene was linked downstream to the ISRE and reliably expressed 
when IFNβ binds to the cell surface receptor and initiates the cell signalling pathway which 
results in activation of ISRE transcription of the luciferase gene. To validate the assay 
parameters specific to assay conditions, accuracy, reliability and precision were examined 
and samples were exchanged with four other validated laboratories to compare titres 
obtained with the Luciferase assay and existing assays. The assay was found to be highly 
robust in relation to incubation times and cell density. High throughput screening is 
possible as 32 samples can be evaluated on a single plate and dilutions are only required for 
those which reach the 50% endpoint. Unlike existing assays it is easily completed in less 
than 24 hours and does not require expensive or patented materials. The cells employed 
were already in the public domain and with the permission of Dr Gilles Uze could be 
distributed to independent validated laboratories for use. As part of the NABINMS 
consortium the Luciferase assay was distributed to other consortium members and 
established in their laboratories. Results relating to distribution of the assay will be reported 
in chapter 7. 
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Chapter 4  
Evaluation of the frequency and clinical effects of NAbs 
in subjects receiving IFNβ 
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4 Evaluation of the frequency and clinical effects of 
Neutralising Anti-Interferon beta antibodies in subjects 
receiving IFNβ  
 
4.1. Background 
As described in chapter 1 IFNβ is a biological therapy which is known to be 
immunogenic, inducing anti-IFNβ neutralising antibodies in a proportion of subjects. The 
frequency of NAbs varies depending on IFNβ product and the NAb assay used. The 
objective in this chapter was to assess the frequency of NAbs using the newly established 
luciferase reporter gene assay, to evaluate their association with relapses, occurrence of 
side effects and to compare the results in our cohort with that of published data.  
 
4.2. Materials and methods 
BAbs were measured using the cELISA as described in chapter 2 and NAbs were 
measured using the Luciferase assay described in chapter 3. Testing was performed in 
accordance with the standard operating procedures described in earlier chapters. 
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4.2.1. Subject acquisition 
All subjects attending the NHNN receiving interferon beta who were being followed in 
the outpatient department on a regular basis were eligible for inclusion in the study. Since 
1996 most subjects had serum samples stored for future NAb analysis. These samples were 
coded with a β-IFN number and recorded in an electronic database. This was accessed to 
identify those who had received treatment for ≥ 2 years as of 31st January 2006. Those on 
treatment for a shorter period were excluded as were those who stopped therapy or 
switched to an alternative (non IFNβ) treatment, such as Copaxone or Mitoxantrone, during 
this period. Those who stopped or switched treatment after 2 years of IFNβ therapy were 
included. 
Case notes of each subject included in the study were requested from medical records 
in the hospital. Those which were located were reviewed for clinical information: date of 
birth, sex, MS subtype at time treatment commenced, IFNβ product chosen, number of 
relapses in 24 months prior to treatment, relapse rate on treatment, side effects experienced, 
treatment cessation or switching to alternative product.  
 
4.2.2. Samples 
As NAbs generally appear between 6 – 18 months time points [Sorensen et al. 2005] 12 
and 24 months were selected for testing. Those who had been on treatment for a further 
year had an additional “follow up” sample included. These samples were tested for the 
presence of binding antibodies to IFNβ by capture ELISA and also for the presence of 
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neutralising antibodies using the Luciferase assay as previously described in Chapter 3.   
 
4.2.3. Statistical Analysis 
The percentage of subjects who developed NAbs at each time point was calculated to 
determine the incidence in each treatment group. All analyses were performed using 
Stata™ Version 9.2, 2006 (StataCorp Texas USA). Difference between groups was 
analysed using Chi-squared test. Measure of association between NAb status, relapse rate, 
side effects, treatment cessation were analysed using Pearson Chi-squared test or Fisher’s 
exact test as appropriate. All reported p values were based on two tailed statistical tests and 
a significance level of 0.05. 
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4.3. Results 
After reviewing the database of samples 348 subjects were identified who had 
commenced therapy prior to January 2004. A further 21 subjects were excluded due to 
early treatment cessation or switching to non IFNβ product, leaving 327 subjects included 
in the analysis. The female: male ratio was 2.56:1, 71.9% being female n = 238 and 28.1% 
being male n = 93. The mean age at time of study was 41.8 years (range 19-68), the mean 
time from disease diagnosis to treatment commencement was 5.56 years (median 4 years, 
range < 12 months – 28 years). The mean relapse rate prior to treatment was 1.53 / year. 
Eighty eight percent of subjects had RRMS at the time treatment was commenced; the 
remaining 12% had SPMS. 
 
4.3.1. Product breakdown 
Of the 327 subjects included 119 subjects (37.3%) were treated with IFNβ-1a IM 
(Avonex®), 55 subjects (16.2%) with IFNβ-1b SC (Betaferon®) and 149 subjects (46.5%) 
with IFNβ-1a SC (Rebif®) either the 22 or 44 µg dose. In total  649 samples were available 
for testing;  260 at 12 months, 200 at 24 months and 189 subjects had samples available for 
follow up testing. 238 subjects had ≥2 samples available for testing, 23% had only one 
sample available and with regards to data analysis these were included in the “anytime 
positive” analysis and NAb rates at a particular time point but were excluded from the 
longitudinal analysis regarding Nab persistence.  
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4.3.2. BAb and NAb analysis per sample. 
All samples were screened for BAbs and subsequently tested for NAbs, 331 samples 
were BAb +ve (51% of samples tested), 317 (49%) samples were BAb -ve and NAb –ve, 
174 (27%) BAb +ve NAb –ve and 156 were BAb +ve NAb +ve. There were two samples 
which tested positive for NAbs but were negative for BAbs. Both of these had low NAb 
titres (24 and 36). The percentage of BAb +ve samples by product was: 24% Avonex, 50% 
Betaferon, 47.6% Rebif. The total number of NAb positive samples was 156 (24 % of all 
samples tested). The percentages of NAb positive samples at each time point tested are 
illustrated below [Table 4-1]. 
  
 
 
 1 year 2 years > 3 years  
Product positive negative positive negative positive negative total 
Avonex 8 (8.84%) 
87 
(91.6%) 
6 
(7.7%) 
72 
(92.3%) 
4 
(5.8%) 
65 
(94.2%) 242 
Betaferon 15 (38.5%) 
24 
(61.5%) 
11 
(30.6%) 
26 
(69.4%) 
11 
(28.2%) 
28 
(71.8%) 115 
Rebif 45 (35.7%) 
81 
(64.3%) 
32 
(37.6%) 
53 
(62.4%) 
24 
(29.6%) 
57 
(70.4%) 292 
total 68 192 49 151 39 150 649 
Table 4-1 Percentage of samples tested which were NAb positive at 12 and 24 months and in the follow 
up period 
 
 
Table 4-2 depicts NAb status and titre per product of all subjects and reflects the 
samples that were available for testing. Samples were not available for all subjects 
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at each time-point. Titres were highest in the NAb positive samples of subjects treated with 
Rebif. Of those testing positive, 50% of those on Rebif had titres > 320 NU as compared to 
only 31% of those treated with Betaferon and 11% of those on Avonex. 
 
 
 
 
Titre of positive 
samples 
Avonex 
n=242 
Betaferon 
n=115 
Rebif 
n=292 
< 20 NU 
(negative) 
92.6% 
(224) 
69.55% 
(80) 
65.4% 
(191) 
Total > 20 NU 
(positive) 
7.4% 
(18) 
30.45% 
(35) 
34.6% 
(101) 
20 – 99 NU 4.4 % (10) 13.9% (16) 11.0% (32) 
100-320 NU 2.6% (6) 7.0% (8) 6.5% (19) 
> 320 NU 0.9% (2) 9.6% (11) 17.1% (50) 
Table 4-2 NAb status and titres per product 
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4.3.3. NAb analysis by subject 
Three hundred and twenty seven subjects were included in the study. Of these, 130 
subjects (40%) were BAb positive and 89 (27%) subjects were NAb positive at anytime. 
The risk of being NAb +ve at 12 months was: 8% IFNβ-1a IM (Avonex), 39% IFNβ-1b 
(Betaferon) and 33% IFNβ-1a SC (Rebif), p<10-5. The risk at 24 months was 8% (Avonex), 
31% (Betaferon) and 27% (Rebif) respectively, p=0.002 [Figure 4-1]. Only 4 subjects 
(2.1%) who were NAb –ve at 24 months subsequently became NAb +ve in the follow up 
period. There was no difference in NAb rates seen in women (27% NAb +ve) or men (31% 
NAb +ve) p=0.377. 
 
 
Figure 4-1 Percentage of subjects who are BAb or NAb positive 
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4.3.4. NAb persistence. 
As 23% of subjects had only one sample available for testing they were excluded from 
the analysis of NAb persistence. 251 subjects had a 12 or 24 month sample and a 
follow up sample (greater than 3 years). Of these, 84 subjects were NAb +ve at either 
12 or 24 months 61% remained NAb +ve at follow up (mean 4.3 years; 2-8 years), 39% 
reverted to NAb –ve status. Of those receiving Betaferon 37.5% (9/24) reverted, 
Avonex 50% (5/10) and 38% of those receiving Rebif (19/50) [Table 4-3]. Most 
subjects who reverted had titres < 100 NU and all were < 320 NU. The mean titre of 
reverters was 85 (SD 79) vs 374 (SD 167), p < 0.0001. These titres are illustrated in 
Figure 4-2. 
  
 
 Avonex Betaferon Rebif 
Persistent Neg 88.5% 44.5% 53.7% 
Persistent Pos 5.8% 34.1% 28.7% 
Reverters 
% all subjects, 
(% NAb +ve subjects) 
 
5.8% 
(50%) 
 
20.5% 
(37.5%) 
 
17.6% 
(38%) 
Table 4-3 Percentage of subjects who reverted to NAb negative status during follow up period 
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Figure 4-2 Nab titres by product in reverters vs non-reverters 
Mean and 95% CI of mean shown.   
A = Avonex, B = Betaferon and R = Rebif 
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4.3.5. Effect of NAbs on relapse rate 
Medical notes were requested on all 327 subjects, of which 288 were available for 
retrospective review. Reliable data regarding relapse rates was available on 228 subjects, 
32 % of whom had no documented relapses since treatment commenced. Pre treatment 
annualised relapse rate (ARR) was 1.53/year (range 1 – 12). The post treatment ARR was 
0.55/year (range 0 – 5.9) for all subjects. The ARR in NAb –ve subjects was 0.50 and was 
0.67 in the NAb +ve cohort (chi-squared p=0.04). There was a higher total number of 
relapses in subjects who were persistently NAb +ve in the follow up period as opposed to 
those who tested positive on only one occasion and reverted to negative status (0.27 vs. 
1.58 relapses, p < 0.0005). Of those who were documented as relapse free (75 subjects), 61 
(81.3%) were NAb –ve throughout, 11 (14.7%) were NAb +ve at any time and 3 (4%) were 
persistently NAb +ve, all having Nab titres < 100 NU. 
0.49
0.35
0.62
1.53
0.44
0.3 0.27
0.52 0.42
0.79
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
Pre IFN year 1 year 2 after 2 years
Mean RR all 
subjects
RR Nab -ve
RR Nab +ve
  
Figure 4-3 Relapse rates in subjects depending on NAb status. 
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The mean relapse rate during the first year of therapy was 0.49 (range 0-3) and 0.35 
(range 0-2) in the second year. The mean number of relapses in the follow up period (i.e. > 
2 years) was 0.62 range (0 – 6). NAb status at 12 months was not a predictor of  relapses in 
the following 12 months, relative risk 1.13 (95% CI 0.9 – 1.4, chi2 p=0.45), however NAb 
status at 12 months was found to predict relapses in the period 2 years after treatment 
commenced, relative risk 1.55 (95% CI 1.05 – 2.42, p=0.012). Similarly there was a strong 
association between NAb status at 24 months and subsequent relapses (occurring after 24 
month) relative risk 1.3 (95% CI 1.01 – 1.56 p=0.002). Thus the effect of NAbs on relapse 
rate lags behind their initial appearance.  
 
The frequency of relapse was calculated with regards to the actual NAb titre measured. 
Titres were divided into NAb –ve, titre 0 – 19 NU, low positive 20-99 NU, moderate 
positive 100 – 319 and high positive titre > 320 NU. The NAb status at 24 months 
correlated with relapses. 27% of subjects whom were NAb –ve at 24 months had a 
subsequent relapse during follow up as compared with 52% of those with low positive, 
62% of those with moderate positive titres and 65% of those with titres > 320 [Figure 4-4]. 
This showed that subjects with higher titres (> 100NU) were at greater risk of relapse. 
Higher relapse rates were also found in subjects who were persistently NAb +ve as 
opposed to those who tested positive on only one occasion and reverted to negative status, 
0.27 vs. 1.58 (ANOVA, p<0.005). 
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Figure 4-4 Percentage of subjects experiencing a relapse depending on NAb titre 
 
 
4.3.6. Side Effects 
Charts were reviewed retrospectively for the presence or absence of side effects related 
to IFNβ therapy – including flu-like symptoms, skin reactions, and headache. Of the 238 
NAb –ve subjects 135 had a record regarding side effects with 108 (46%) reporting 
ongoing troublesome side effects. In the NAb +ve cohort (89 subjects) a record was found 
in 56 subjects with 32 (36%) reporting troublesome side effects. Analysing those who 
reported troublesome side effects (140) 113 (81%) were NAb negative and 27 (19%) NAb 
positive. Reporting side effects was found to be a predictor of NAb -ve status (Pearson chi2 
p= 0.046). Of the 51 subjects who reported an absence of side effects 24 were NAb +ve 
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and 27 NAb –ve. Evaluating side effects as a predictor of NAb status revealed that a 
positive report has a specificity of 81% in identifying those who remained NAb negative, 
but sensitivity of only 47%.  
 
4.3.7. Treatment Cessation 
Medical notes and the IFNβ treatment database were reviewed to ascertain subjects’ 
treatment status at the time the review was conducted. Data was available for 310 cases. Of 
these 196 were still on treatment, 91 had stopped treatment, 17 were lost to follow up and 6 
had stopped in order to conceive. The 91 cases that stopped treatment included those who 
switched to Copaxone® or Mitoxantrone due to IFNβ treatment failure, persistent relapses 
and those who met other criteria for treatment cessation (EDSS > 6.5). Of those who 
stopped treatment 42% were NAb +ve as compared to 33% of those continuing treatment, 
however this difference was not significant  p=0.565.  Similarly correlating NAb status at 
24 months with treatment cessation, no significant difference in NAb status was found 
between those who continued treatment and those who had stopped (22% NAb -ve vs. 29% 
NAb +ve, p=.057). 
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4.4. Conclusions 
In this cohort of 327 subjects, 649 time points were tested for BAbs and NAbs. The rate 
of NAb positivity in our cohort reflects that in the published literature and further supports 
the validity of the Luciferase reporter gene NAb assay. Rates quoted in other studies for 
Avonex, Rebif and Betaferon are reported as ~ 2-6%, 15-44%, 25-47% respectively 
(chapter 1) and depends on the sensitivity of the assay used [Rudick et al 1998, Jacobs et al 
2000, PRISMS 1998, Interferon β MS study group 1996, Francis et al 2005, Bertolotto et 
al 2002]. As samples were not available for all subjects at each time-point analysis per 
sample shows NAb frequencies at each time point that was dependent on the individuals 
who had samples available. This accounts for the difference in the NAb frequencies 
reported per sample as compared to per subject.  Analysis of  the data by subject the risk of 
being NAb +ve at 12 months was 8%, 33%, 39% (Avonex, Rebif, Betaferon) and at 24 
months was 8%, 27%, 31%. These values are similar to those published, showing that 
Avonex is less immunogenic than the two high frequency, higher dose preparations. 
Betaferon appears to have the highest frequency of NAbs but the difference between 
Betaferon and Rebif is small. Absolute NAb titres were highest in those subjects treated 
with Rebif, 50% of whom had titres >320 NU as compared to only 33% of those on 
Betaferon and 11% of those treated with Avonex. Many studies consider the two doses; 22 
µg and 44µg of Rebif independently and have reported higher NAb frequencies in the 
Rebif 22 µg dose [Francis et al. 2005]. In this cohort it was difficult to ascertain from 
retrospective case note review which subjects remained on 22 µg and if and when subjects 
were switched to the higher dose. In view of this the two doses were analysed together. 
Only two subjects were BAb –ve and NAb +ve (both treated with Rebif and NAbs < 100 
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NU). This would suggest that in view of the luciferase assay being both cost and time 
efficient BAb screening is not essential prior to Nab testing and that simple screening for 
neutralising activity should be the first step. 
Clinical information with regards to side effects was only available in 191 subjects.  In 
those where a record was made it was more likely that troublesome side effects were 
reported (positive bias), this may account for the low sensitivity. The predictive value of 
side effects reflecting NAb negativity and the significant association found between NAbs 
and side effects are useful when following a subject in the clinical setting but NAb testing 
is still required to confirm this.  
The pre-treatment relapse rate of 1.53/year was high compared to the relapse rates 
quoted in most clinical trials. This was due to local guidelines determining eligibility for 
disease modifying therapy. Subjects in the UK are only deemed eligible for treatment with 
a DMD if they have experienced ≥ 2 relapses in the previous 2 years. Due to this all 
relapsing remitting subjects (88%) in this study had a baseline annualised relapse rate ≥ 
1/year. The apparent relapse rate reduction (0.55/year overall) in relation to treatment may 
over estimate the treatment effect as it is likely not all relapses were documented or 
required medical review after therapy commenced. The natural history of MS is for 
relapses to reduce overtime so regression to the mean is also a factor to account for 
reduction in relapse rates of the entire cohort. Subjects who continued to relapse or 
progress rapidly after starting IFNβ may have been switched to either Copaxone or 
Mitoxantrone during the first 2 years of treatment and were therefore excluded from the 
analysis, biasing the cohort in favour of responders or those with less severe disease. A 
difference was found in the annualised relapse rates of those who were persistently NAb –
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ve and those who were NAb +ve at any time (0.5  vs. 0.67 p = 0.04). NAb +ve status at 12 
and 24 months was significantly associated with relapses after 24 months of treatment 
showing the effect of NAbs on efficacy of IFNβ lags behind the appearance of NAbs. This 
has been described previously and may reflect the length of time it takes for the biological 
efficacy of Interferon-beta to be lost [Kappos et al. 2005; Francis et al. 2005].  A 
longitudinal MRI study, following 2 subjects who discontinued treatment, has shown that 
disease activity begins to increase 6 months after treatment has stopped and returns to 
baseline ~ 10 months after treatment cessation [Richert et al. 2000]. We have also shown 
that higher NAb titres are associated with increased risk of relapse. 
Over 100 subjects had stopped treatment during the follow up period, many of whom 
stopped due to disease progression. Those who had persistently active disease on IFNβ 
were considered for Copaxone or Mitoxantrone therapy. As the medical notes did not 
specify the reason in many cases all were considered together. This may contribute to the 
lack of association seen between NAb positivity and treatment cessation/failure. In 
addition, patients who are destined to become NAb positive have a greater reduction in 
relapse rate than those who remain NAb negative in the first 6 months of starting treatment 
[PRISMS 2001; Francis et al. 2005; Kappos et al. 2005, Sorensen et al. 2007] this 
biological effect reduces the impact of NAbs on relapse rate after 6 months of treatment 
[Giovannoni and Goodman 2005]. The results in this study would support implementation 
of guidelines which recommend routine Nab testing with the view that persistent NAb 
positivity is a herald of treatment failure and increased relapse rates. 
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5 Validation of a novel anti-Interferon beta antibody 
assay: Correlation with induction of peripheral 
biomarkers  
5.1. Background 
As previously discussed [chapter 1] IFNβ alters the expression of several hundred 
genes at the nuclear level and the downstream production of mRNA and proteins. These 
confer the anti-viral, anti-proliferative and immunomodulatory actions of IFNβ.  Many of 
these can also be induced by other factors and are thus not specific markers of IFN activity. 
Some however, have been identified as being relatively specific to type 1 IFNs. Myxovirus 
resistance protein A (MxA) is a good example of this [Deisenhammer et al. 2000; Pachner 
at al. 2003 b]. Other useful biomarkers include 2-5 oligoadenylate synthetase [Pachner at 
al. 2003 b], neopterin [Cook et al. 2001]  β2-microglobulin [Francis et al. 2005] and 
TRAIL (tumor necrosis factor apoptosis inducing ligand) [Wandinger et al. 2003;Gilli et 
al. 2006], but these are not exclusively induced by interferons.  These have been used to 
show that the presence of NAbs reduces the bioactivity of IFNβ. Bertolotto et al have 
shown that there is a significant rise in MxA mRNA and protein in response to IFNβ 
administration and that this response is lost in the presence of NAbs [Bertolotto et al. 2003; 
Gilli et al. 2005, Hesse et al. 2009]. In the case of MxA mRNA levels, this response has 
been shown to be maximal at 12 hours. Similarly the MSCRG (1998) showed failure to 
induce neopterin in the NAb positive cohort [Rudick et al. 1998]. This finding has also 
been replicated in several other papers. Neutralising antibodies were measured in relation 
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to induction of β-2 microglobulin and neopterin. In the presence of Nabs failure to show 
any significant response to IFNβ was shown [Francis et al. 2005]. The second study 
measured the in vivo response to IFNβ by measuring pre and post dose levels of MxA 
mRNA, neopterin and β2- microglobulin [Scagnolari et al. 2007]. Responses were 
compared between NAb +ve and NAb –ve cohorts. Both pre and post dose levels were 
lower in NAb +ve subjects and a significant inverse correlation was found between Nab 
titre and pre dose levels in particular. They showed that the steady state levels were 
significantly suppressed in NAb +ve patients and in a titre dependent fashion.  
Some Neurologists argue that some bioactivity may be preserved in patients with NAbs 
despite lack of induction of MxA in response to IFNβ injection. The Danish group have 
measured gene expression by gene chip analysis in 12 NAb -ve and 12 NAb +ve patients to 
test that hypothesis. They were not able to detect differential expression of any of the 
interferon (IFN) beta-regulated genes identified in NAb -ve patients in the NAb +ve cohort, 
thus suggesting no residual bioactivity [Hesse el al. 2009]. Other studies have shown 
attenuation of the induction of TRAIL in response to IFNβ administration [Wandinger et 
al. 2003; Gilli et al. 2006].  
Until the development of the Luciferase NAb assay [Farrell et al. 2008; Farrell and 
Lam et al. 2008] there has not been a readily available assay in the UK to measure NAbs. 
To further validate this assay we sought to measure biomarker induction (MxA) in a cohort 
of subjects with MS who were treated with IFNβ and use this to establish a “cut-off” or 
NAb titre, determined by the Luciferase assay, at which no detectable in vivo bioactivity of 
IFNβ is found. This would help develop better guidelines for interpretation of NAb results 
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using the luciferase assay and thus subsequent patient management. We anticipated that ~ 
25% of subjects recruited would have detectable NAbs, but in only half of these the titre 
would be significant, i.e. at a level that inhibits the induction of the biomarkers. Patients on 
Avonex were excluded because the vast majority (> 95%) would be NAb negative. By 
measuring MxA before and after the administration of IFNβ we would be able to quantify 
the relative increase in each subject in response to the injection. In this way we correlated 
the NAb titre with relative attenuation of biomarker response and thus defined a threshold 
at which no IFNβ bioactivity is found.  
 
5.2. Hypothesis 
Peripheral biomarker induction after IFNβ administration would be attenuated in a 
predictable fashion in the presence of NAbs. By quantifying this we would determine the 
titre (as measured by Luciferase reporter gene assay) at which partial and complete loss of 
INFβ bioactivity is seen and thus generate improved guidelines for clinical practice. 
 173 
5.3. Materials 
5.3.1. Sample collection  
Plastic venous blood tubes 8mL EDTA  Hemogard® closure, 8.5mL Serum tube with 
clot activator and gel for serum separation BD Vacutainer®, venepuncture kit, centrifuge, 
sterile 1.5 mL microtubes Sarsdedt®. 
5.3.2. Processing and storage  
Centrifuge, sterile 1.5 mL microtubes Sarsdedt®, sterile pipettes and tips, -80°C freezer 
5.3.3. RNA preparation and quantification 
PAXgene Blood RNA Tubes (cat. no. 762165), Ethanol (96–100%) for molecular 
biology Sigma Aldrich®, Pipettes: 2µL, 10 µL, 200 µL, 1000 µL, adjustable volume 
pipettes - Eppendorf Research®, Sterile, aerosol-barrier, RNase-free pipette tips, 0.1 - 
10µL, 200 µL, 1000 µL (extralong) STARLAB® TipOne, Graduated cylinder, Centrifuge, 
Vortex mixer, micro-centrifuge, Incubator, Crushed ice, Nanodrop™ 3.1 Thermo 
Scientific. 
5.3.4. Reverse transcription  
 High capacity cDNA reverse transcriptase kit (with RNase inhibitor) Applied 
Biosystems™ cat # 4374966, Nuclease free water, 0.2ml 8 Strip PCR Tubes, Individual 
attached domed caps STARLAB®, thermal cycler, microcentrifuge, pipettes and tips as 
before.   
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5.3.5. PCR 
TaqMan Universal master mix Applied Biosystems™ cat #4304437, ABI gene 
expression kit MxA and GAPDH,  MicroAmp® Optical 96-Well Reaction Plate Applied 
Biosystems™ #4316813, Optical adhesive  cover Applied Biosystems™ #4311971, 
Assays-on-demand™ Gene expression products; Mx1 assay id Hs00182073_m1, GAPDH 
assay id Hs99999905_m1 Applied Biosystems™, Nuclease free water, Taqman 7500 Real-
Time PCR system Applied Biosystems™. 
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5.4. Methods  
5.4.1. Subjects 
Previous evaluation of subjects attending the NHNN revealed that ~ 25% of subjects 
treated with Rebif or Betaferon were NAb positive. NAb frequency in subjects treated with 
Avonex are < 8 % using the Luciferase assay, thus we elected to exclude those treated with 
Avonex to enrich the capture of NAb +ve subjects. Of those who were NAb +ve, the 
majority had low positive titres < 100 NU (~ 50%) and another ~ 40% had high positive 
titres > 320 NU. Other groups have also shown that ~ 10% of subjects have some 
neutralising activity but do not reach the 20 NU cut-off. It was estimated that by recruiting 
150 subjects we would have ~ 50 subjects who would be NAb positive, with sufficient 
numbers of low to moderate titres to establish a cut-off level. Ethical approval to conduct 
the study was awarded in all sites prior to recruitment and subjects with MS treated with 
either Rebif or Betaferon, who regularly attended the one of several sites including the 
National Hospital for Neurology and Neurosurgery (NHNN), Barts and the London NHS 
Trust, Basildon hospital, Southend hospital and St Thomas’ hospital were recruited. 
Recruitment began in July 2008 and was stopped in January 2010 when 144 subjects had 
completed the study. Recruitment was stopped before 150 subjects had been identified due 
to time and financial constraints related to completing the project. 
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5.4.2. Samples 
Blood samples were obtained on the day that IFNβ would be administered and again 12 
hours after injection. Each day 4 PAXgene® tubes, 1 x 8.5 mL serum tube and 1 x 8 ml 
EDTA tube were taken. PAXgene® tubes were used to ensure the stability of mRNA for 
storage and future use. These have been commercially validated and shown to protect RNA 
molecules from degradation by RNases and also minimises further gene expression 
(www.preanalytix.com). Each PAXgene tube allows collection of 2.5 mLs of blood and 
should yield approximately 3µg RNA (eluted in 80µL). The PAXgene tubes were kept at 
room temperature for a minimum of 2 hours and were subsequently frozen at minus 80°C 
until use. A whole blood sample was aliqouted from the EDTA tube, the serum and 
remaining EDTA tubes were centrifuged for 10 minutes at 3000 rpm and serum and plasma 
aliquots were taken and frozen at -80°C until use. All of the samples were processed and 
stored at the Blizard Institute of Cell and Molecular Science, Barts and The London School 
of Medicine and Dentistry.  
 
5.4.3.  Neutralising Antibody Quantification 
Pre and post injection samples were tested for NAbs using the Luciferase NAb assay in 
the neuroimmunology laboratory as described in chapter 3. Titres were expressed in 
Neutralising Units (NU). 
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5.4.4.  MxA quantification 
5.4.4.1. RNA extraction and purification 
Two Paxgene® tubes taken prior to IFNβ injection and two taken 12 hours post IFNβ 
injection were used to extract and purify mRNA from each participant. Extraction was 
performed as using the PreAnalytix PAXgene Blood RNA system and following the 
manual extraction protocol. In brief the PAXgene Blood RNA Tubes were centrifuged for 
10 minutes at 3000 x g. The supernatant was decanted and 2 mLs RNase-free water was 
added to each tube. The two PAXgene tubes from the same time point were combined at 
this stage creating a 4mL volume in one tube.  The tube was closed using a fresh secondary 
BD Haemogard closure. The sample was vortexed until the pellet was visibly dissolved, 
and was centrifuged for another 10 minutes at 3000x g. The supernatant was decanted and 
350 µL of buffer (BR1) was added. This was vortexed until the pellet was visibly dissolved 
and the sample was pipetted into a 1.5 ml microcentrifuge tube. 
To this 300 µL of buffer (BR2) and 40 µL of proteinase K were added. This was mixed 
and incubated for 10 minutes at 55°C. The lysate was pipetted directly into the PAXgene 
shredder spin column, placed in a 2 ml processing tube, and centrifuged for 3 minutes. The 
entire supernatant of the flow-through was transferred into a fresh tube and 350 µL of 
ethanol (96–100%) was added. This was mixed and added in aliquots to the PAXgene 
RNA spin column which was centrifuged for 1 minute at 8000–20,000 x g. The flow 
through was discarded and the column placed in a new 2 ml processing tube.  
At this stage the mRNA was bound to the column and the following steps are to purify 
and elute the mRNA. 350 µL of buffer (BR3) was added into the PAXgene RNA 
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spin column and centrifuged for 1 minute. The spin column was placed in a new 2 ml 
processing tube. For each spin column 10 µL of DNase stock solution was added to 70 µL 
buffer RDD and mixed before adding 80 µL to each column.  This was incubated at room 
temperature (20–30°C) for 15 minutes. A further 350 µL of buffer (BR3) was added into 
the spin column, and centrifuged for 1 minute at 8000–20,000 x g, the old processing tube 
and flow-through was discarded. 500 µL of buffer (BR4 – containing ethanol) was then 
added and the spin column centrifuged for 1 minute. Another 500 µL of buffer (BR4) was 
added and centrifuged for 3 minutes.  
Finally the mRNA was eluted by pipetting 40 µL of elution buffer BR5 directly onto 
the PAXgene RNA spin column membrane. Again this was centrifuged for 1 minute at 
8000–20,000 x g and the step repeated with another 40 µL of buffer BR5 to generate an 
elution volume of 80 µL. The eluate was incubated at 65°C for 5 minutes and samples 
immediately chilled on ice. 
 
5.4.4.2. Reverse transcription (cDNA) 
RNA was quantified using the Nanodrop™ 3.1. The quality of the RNA material was 
monitored by recording the OD ratio 230:260 and 260:280. Samples with values 1.9 – 2.1 
were consided of good quality however all samples were used to generate cDNA. Most 
extracts contained > 30 ng/µL of RNA and thus all samples were diluted in nuclease free 
water to a standard concentration of 30µg/mL. Master mix was prepared as described in 
Table 5-1. The master mix (6.8 µL) was added to the 0.2 µL microtube and 13.2 µL of 
template RNA was added to each individual tube. The master mix / RNA template 
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mixture (20 µL per reaction) was incubated using the thermal cycling conditions described 
in Table 5-2. The cDNA was stored at -80°C until use. 
 
 
Component Volume / Reaction 
10 x RT Buffer 2 µL 
25 x dNTP Mix (100mM) 0.8 µL 
10 x RT Random Primers 2 µL 
Multiscribe Reverse Transcriptase 1 µL 
Rnase Inhibitor 1 µL 
Total Volume 6.8 µL 
Table 5-1 Components of Master Mix for reverse transcription 
 
 
 
 Step 1 Step 2 Step 3 Step 4 
Temperature °C 25°C 37°C 85 °C 4°C 
Time 10 min 120 min 5 sec ∞ 
Table 5-2 Thermal cycling conditions for reverse transcription 
 
 
 
5.4.5.  Standard Curve  
To generate a standard curve of MxA and GAPDH for use in the PCR, HL-116 (ISRE-
Luc) cells were stimulated overnight with IFNβ 1a (Avonex), 1000 IU/mL which was 
added to DMEM in which cells were cultured. The cells were harvested and pelleted and 
resuspended into 2 mLs HBSS. This was added to a PAXGene tube for extraction of RNA 
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and cDNA generation as described above. 
 
5.4.5.1. PCR 
Real time PCR was used to quantify MxA [Bertolotto et al. 2007] gene expression in 
response to administration of IFNβ. Real time PCR reactions are characterised by the point 
in time at which amplification of a target is first detected rather than the total amount 
accumulated at the end of the PCR run. Five serial dilutions of cDNA generated from IFNβ 
stimulated HL-116 cells were prepared to generate both MxA and GAPDH standard 
curves. Values were attributed to each standard in accordance with the amount of RNA 
which was used to generate cDNA (100, 10, 1, 0.1 and 0.01 ng).  Fresh master mix for (i) 
MxA and (ii) GAPDH reactions were prepared using 10µL Taqman Universal Master Mix, 
8 µL molecular grade water and 1µL of ABI gene expression mix (either MxA or 
GAPDH), 19 µL of master mix added to each well in the reaction plate. Half of the wells 
contained master mix to detect MxA and the other half for GAPDH. To each well 1 µL of 
template cDNA was added. The plate was loaded into the Taqman® 7500 system and the 
PCR was run with the following conditions; 
2 minutes at 50°C + 10 minutes at 95°C + [15 sec @ 95°C + 60 sec @ 60°C] x 40 cycles 
 
After the run was completed samples were analysed using the SDS programme 
(Taqman® 7500).  
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 1 2 3 4 5 6 7 8 9 10 11 12 
A S 1 S 1 S 2 S 2 S 3 S 3 S 4 S 4 S 5 S 5 NTC NTC 
B U U U U U U U U U U U U 
C U U U U U U U U U U U U 
D U U U U U U U U U U U U 
E U U U U U U U U U U U U 
F U U U U U U U U U U U U 
G U U U U U U U U U U U U 
H S 1 S 1 S 2 S 2 S 3 S 3 S 4 S 4 S 5 S 5 NTC NTC 
Figure 5-1 PCR plate layout.   
Wells A-D (Green) MxA , wells E-H (Red) GAPDH 
S – standard, NCT – negative control, U –unknown sample 
 
 
5.4.6. Analysis of PCR results 
The assay was validated by standardising the standard curve obtained for MxA. The 
position of the threshold line was set at the point where the highest MxA standard (S1 100 
ng RNA) crossed the vertical line denoting the 25th cycle. The MxA standard curve was 
automatically generated where the slope was optimised at -3.3 (-3.0 to -3.6) with the y 
intercept at 24.5 to 25.0. Similarly the GAPDH standard curve was generated where the 
slope was optimised at -3.3 (-3.0 to -3.6) with the y intercept at 15.5 to 16.0. Relative 
quantification of the expression of MxA and GAPDH was thus calculated. The relative 
amount of MxA induction in each individual was calculated by dividing the amount of 
MxA detected by the amount of GAPDH in the same sample. Variation in RNA extraction 
and efficiency of reverse transcription were compensated for in this was by normalising all 
MxA values to GAPDH and then calculating the difference between the amount of MxA in 
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pre IFNβ administration sample and the post dose sample. 
 
MxA pre/GAPDH pre = corrected MxA level pre IFNβ administration 
MxA post /GAPDH post = corrected MxA level post IFNβ administration 
 
 
MxA corr post – MxA corr pre = MxA induction in response to IFNβ administration 
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5.5. Statistical Analysis 
The Student T test was used to determine differences between baseline demographics 
of participants. ANOVA was used to compare means of NAb groups and non-parametric 
tests i.e., Mann-Whitney U test, Kruskal-Wallis test with post Dunn correction for multiple 
comparison and Spearman correlation were performed where appropriate using GraphPad 
Prism version 4.00 for Windows (GraphPad Software, San Diego California USA, 
www.graphpad.com). 
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5.6. Results 
5.6.1. Demographics 
144 subjects were recruited into the study. Of these 91 were female (64%) and 53 male 
(36%). Of those included 19 were treated with Rebif® 22µg TTW, 89 were treated with 
Rebif® 44 µg TTW and 36 with Betaferon® 250 µg EOD. Of the 144 sets of samples, 132 
had complete and valid NAb and MxA / GAPDH results. The average timing of the post 
IFNβ administration sample was 12.6 hours (range 10 – 15 hours). Baseline characteristics 
of participants are given below [  Table 5-3]. There were significantly more females 
recruited than males, in keeping with the sex distribution of MS, and the age at recruitment, 
duration of treatment and post treatment annualised relapse rates were higher in the female 
cohort. Females were also more likely to report side effects. 
 
 
Sex 
Female 
n = 91 (64%) 
Male 
n = 53 (36%) 
 
Age (at recruitment) 45.6 (27 – 65) 41.6 (19 – 61) p< 0.001 
Duration of disease 
(years 12.4 (1 – 35) 8.9 (1 – 23) p< 0.001 
Years on treatment 6.68 (0.6 – 22) 5.7 (1 – 15) p< 0.001 
Annualised relapse rate 
post treatment 0.32 (0 – 3) 0.44 (0 – 1.67) p< 0.001 
Side effects reported 76% 68% p< 0.001 
NAb negative 
Neutralising activity  (> 5 
NU) 
66 ( 72% ) 
25 ( 28%) 
30 (57%) 
23 (43%) 
 
  Table 5-3 Demographics of participants 
 185 
5.6.2. NAb frequency per product 
Of the 144 subjects who took part 138 had valid NAb results at the time of submission. 
As predicted approximately one in every four participants were NAb positive (titre > 20 
NU, 24.8 %) and a further 8 % (n=11) had evidence of sub-threshold neutralising activity 
(titres 5 – 19 NU). The number of NAb positive subjects was different depending on which 
product they were treated with [Table 5-4]. Subjects treated with Betaferon had the highest 
frequency of NAbs (42%) as compared with Rebif 22µg (32%) and Rebif 44 µg (25%). 
There was no significant difference in NAb titre obtained when testing the pre or post IFNβ 
administration samples (t test p = 0.643). 
 
 
 
Nab negative 
< 20 
No 
neutralising 
activity 
Neutralising 
activity 
> 5 NU 
Titre 
5 - 19 
Titre 
20 -99 
Titre 
100 - 600 
Titre 
> 600 
Rebif 22 
n=19 
13 
(68%) 
13 
(68%) 
6 
(32%) 
0 
(0%) 
4 
(21%) 
1 
(5%) 
1 
(5%) 
Rebif 44 
n=84 
67 
(79%) 
59 
(70%) 
24 
(30%) 
8 
(10%) 
5 
(6%) 
4 
(5%) 
7 
(8%) 
Betaferon 
n=35 
22 
(63%) 
18 
(51%) 
17 
(49%) 
4 
(11%) 
3 
(9%) 
10 
(29%) 
0 
(0%) 
Total 
n=138 
102 
(73%) 
90 
(65%) 
47 
(35%) 
12 
(8.7%) 
12 
(9%) 
15 
(11%) 
8 
(6%) 
Table 5-4 Nab status depending on product. 
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5.6.3. MxA induction 
MxA was measured by generating a standard curve from IFNβ stimulated HL-116 
cells. Arbitrary values of 100, 10, 1, 0.1 and 0.01 were assigned to each point on the curve. 
The MxA level for each sample was thus calculated with reference to the standard curve 
and normalised to GAPDH. The MxA level pre and post IFNβ administration and the 
difference (MxA induction) were calculated. Data is illustrated in Figure 5-2. 
Baseline MxA: Mean baseline levels of MxA expression pre IFNβ administration in 
NAb titre group were; NAb negative 778.4 (95% CI 643-913), NAb 5 – 19 NU 624 (95% 
CI 442 – 805), NAb 20-99 NU 555 (95% CI 242 – 868), NAb 100 – 600 NU 390 (95% CI 
20 – 659) and NAb >600 NU 44.75 (95% CI 12 – 77). The MxA value at baseline in the 
NAb > 600 NU group was significantly different to all other groups (ANOVA p < 0.001).  
MxA post dose: Mean MxA level post IFNβ administration was also calculated; NAb 
negative 2330 (95% CI 1940 – 2719), NAb 5 – 19 NU 1883 (95% CI 1335 – 2431), NAb 
20 – 99 NU 1533 (95% CI 741 – 2324), NAb 100 – 600 NU 832 (186 – 1478) and NAb > 
600 NU 101 (95% CI 0 – 224). The MxA value 12 hours post IFNβ administration in the 
NAb 100 – 600 NU and > 600 NU group were significantly different to all other groups 
(ANOVA p = 0.0014).  
MxA induction: Mean induction of MxA in each group was; NAb negative 1762 (95% 
CI 1411 – 2113), NAb 5 – 19 NU 1259 (95% CI 764 – 1754), NAb 20 – 99 NU 1168 (569 
– 1768), NAb 100 – 600 NU 442 (95% CI 0 – 885), NAb > 600 NU 46 (95% CI 0 – 128). 
MxA induction was lower in the NAb 100- 600 NU and NAb > 600 NU groups as 
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compared with the lower NAb + and NAb negative groups (p=0.0012, p < 0.0001). [Table 
5-5, Figure 5-2]. 
 
 
 
Mean MxA Nab 
negative Titre 5 - 19 Titre 20 - 99 
Titre 100 - 
600 Titre > 600 
Pre dose 778 624 555 390 45 
Post dose 
(12hrs) 2330 1883 1533 832 101 
MxA 
induction 1762 1259 1168 442 46 
Table 5-5 Mean values of MxA pre and post IFNβ administration and MxA induction 
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Figure 5-2 Scatterplot of Log 10 MxA level dependent on NAb group 
Mean and 95% CI shown. A. MxA level in each subject before IFNβ administration. B. MxA level post 
IFNβ administration.  MxA levels at baseline andpost injection  value were significantly different in the 
NAbs > 600 NU group as compared with the other groups. 
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Figure 5-3 Scatterplot of Log
 10 MxA induction  in each subject depending on NAb titre. 
Mean and 95% CI shown. MxA induction  levels were significantly different in the NAbs 100 – 600 NU 
and  > 600 NU group as compared with the other groups. 
 
 
5.6.3.1. MxA induction post IFNβ administration. 
To assess whether there was a difference in MxA response and inhibition by NAbs in 
all treatment groups, samples were divided into groups by product – Rebif 22µg, Rebif 44 
µg and Betaferon. The diffence in MxA level after IFNβ injection is illustrated in Figure 5-
3.  Regarding the post injection sample significant differences were found in MxA level 
between the NAb negative and NAb positive (>20 NU) cohorts (Mann Whitney test) in 
each product group.   
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Figure 5-4 Scatterplot of Log10 MxA level post IFNβ administration. 
Mean and 95% CI depicted, significant differences were found between NAb positive and NAb 
negative subjects in each treatment group. 
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5.6.4. MxA expression in relation to NAb titre 
In subjects with any neutralising activity (i.e. titre > 5 NU, n = 49) NAb titre was 
negatively correlated with MxA level at baseline, post IFNβ administration and also MxA 
induction [Figure 5-5].. In subjects with NAb titre 5 – 19 NU (n = 12) a correlation existed 
with baseline MxA level (spearman r = -0.69, p<0.0001) MxA post injection (spearman r = 
- 0.74, p < 0.0001) and MxA induction (spearman r = - 0.70, p< 0.0001) Similarly in 
subjects with clinically defined NAb +ve titres (i.e. NAb titre > 20 NU, n = 37) a 
correlation existed between titre and baseline MxA level (spearman r = -0.72, p<0.0001), 
MxA post injection (spearman r = - 0.79, p < 0.0001) and MxA induction (spearman r = - 
0.67, p = 0.0004) [Figure 5-6]. This indicated that NAb titre is an accurate predictor of 
MxA level either pre or post IFNβ administration and confirms a titre (dose) dependent 
suppresson of MxA induction in the presence of NAbs. Using a ROC analysis of Log 10 
MxA post and Nabs the sensitivity and specificity of being NAb negative setting the 
threshold at Log 10  MxA > 2 (ie MxA >100) is sensitivity 98 % & specificity 86% (area 
under curve 0.951 and p<0.0001). Adjusting the threshold to Log10 MxA > 2.5 (ie MxA = 
316) as a cut point, the sensitivity remains 99 % and specificity falls to 84%. Therefore a 
single post dose sample would be sufficient to predict IFNβ bioactivity in clinical practice; 
provided the subject injected themself with bioactive IFNβ 
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Figure 5-5 Correlation of NAb titre (sample > 5 NU) with MxA level. 
Pre IFNβ injection, B. Post IFNβ injection and C. MxA induction 
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Figure 5-6 Correlation of NAb titre (samples > 20 NU) with MxA level. 
A.  Pre IFNβ injection, B. Post IFNβ injection and C. MxA induction 
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5.7. Discussion 
The effect of NAbs at a group level is generally well understood and has been shown to 
be associated with increased relapse rates and increased disease activity on MRI. What this 
means however for the individual with NAbs had remained somewhat unclear. Other 
groups [Sominanda et al. 2008] have shown a titre dependent loss of MxA induction after 
IFNβ administration in subjects with NAbs. In this work the luciferase NAb assay was used 
to determine NAb status and MxA expression at baseline and after IFNβ administration 
was quantified. We have found that there is a clear correlation between NAb titre and MxA 
level in both the pre injection and 12 hours post injection samples. The post dose MxA 
level had the best correlation with NAb titre and therefore could be a useful adjunct in 
clinical practice to predict IFNβ bioactivity. Those with low positive NAbs  < 100 NU did 
not show significant loss of bioactivity (as measured by MxA) as compared with those with 
titres 100 - 600 NU whom experienced a reduction of activity and those > 600 NU who 
showed little / no response to IFNβ administration (mean post dose MxA expression 101, 
95% CI 0 – 224). These results were consistent in those treated with either IFNβ-1a SC 
(both 22 and 44µg doses) or IFNβ 1b SC. There was no significant difference in NAb titre 
obtained in samples before or after IFNβ injection and thus a single 12 hour post dose 
sample would suffice to assess both NAbs and MxA expression. Those with NAbs > 600 
NU show significant loss of biological effect and those with NAbs 100 – 600 NU should 
have MxA expression measured to assess bioactivity. At present it is difficult to determine 
an exact NAb titre at which one can predict with > 95% both sensitivity and specificity that 
there is no biological response due to the small numbers of subjects who were in this 
category. However using the mean MxA levels post IFNβ administration it is 
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apparent that a good response is inferred by a level > 1000. If the value is lower than this it 
probably represents abrogated in vivo bioactivity and a sample should be repeated 6 – 12 
weeks later to reassess response. In those with significantly reduced MxA response and 
persistently positive NAbs consideration should be given to changing to an alternative 
treatment. 
A further consensus paper from the members of the NABINMS consortium will be 
published in the near future and their recommendations are that patients doing well 
clinically, NAb and/or MxA bioactivity assessments should be performed. In those with 
sustained high titer NAbs and/or lack of MxA bioactivity switching to a non-IFNβ therapy 
should be considered.  In patients with intermediate disease activity, continuation of IFNβ 
therapy could be considered in NAb negative patients, whereas high NAb titers and/or lack 
of MxA bioactivity should suggest a switch to a non-IFNβ. Patients who are clinically 
failing therapy should have a change in treatment irrespective of NAb or MxA bioactivity 
outcomes. The data generated from our study highlights this grey zone and the need for a 
personalised approach to managing NAbs in people with moderate NAb titres.  
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Chapter 6  
Evolution of the anti-IFNβ antibody response 
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6 Evolution of the anti-IFNβ antibody response  
 
6.1. Background 
As biological products are known to provoke the production of anti-drug antibodies we 
sought to understand the maturation process of antibodies to IFNβ and thus provide 
insights into prevention or treatment of NAbs.  Antibodies (immunoglobulins) form the 
major component of the humoral immune response, serving to protect the extracellular 
component. They serve two main purposes (i) to bind specifically to molecules from the 
antigen that elicited the response, (ii) to recruit cells and molecules to destroy the antigen 
(pathogen) once antibody is bound to it. The immunoglobulin molecule is produced by B 
cells and consists of four polypeptide chains -two heavy and two light chains, forming a Y 
shaped structure. Together the light and heavy chains form two antigen binding sites at the 
tips of the Y. Each molecule has a constant region (C region) which determines its class 
and a variable region (V region) which determines its antigen specificity. After a B cell is 
exposed to antigen it must express a receptor which will bind this antigen, as the cells 
proliferate they undergo somatic hyper-mutation of the variable region genes to improve 
specificity (clonal selection). The stronger the binding the more likely it is that the B cell 
clone will survive and proliferate – also called “affinity maturation”. Affinity maturation 
describes the process by which selection of the antibodies with the highest affinity for an 
antigen occurs.  
There are five human immunoglobulin isotypes – IgM, IgG, IgD, IgE and IgA, which 
are specialised to activate different immune effector mechanisms. The environment 
 198 
determines the specific antibodies that are produced. IgM is always the first antibody 
produced in a humoral immune response and is of low affinity. Thus class switching to an 
antibody of higher affinity; IgG, IgA and IgE, occurs shortly after the initial response. IgG 
is the principal isotype in the blood and extracellular fluid, whereas IgA is abundant in 
secretions – mucous epithelium. IgE is bound avidly by receptors on mast cells but is in 
low volume in the blood. IgG and IgA can also be divided into subclasses; IgG (IgG1, 
IgG2, IgG3 and IgG4) and IgA (IgA1, IgA2) that differ in structure based on unique 
sequences in their heavy chain constant regions. In healthy individuals, the proportion of 
each subclass is maintained within relatively narrow ranges; IgG1, 60–65%; IgG2, 20–
25%; IgG3, 5–10%; IgG4, 3–6% [French and Harrison 1984]. However, in an antigen 
specific response, the distribution of IgG subclasses differs from their proportions in 
normal sera. This IgG distribution depends in part on the nature of the antigen, with 
proteins generally eliciting IgG1 and IgG3 subclasses, while IgG2 predominates in 
responses against carbohydrates [Ferrante et al. 1990; Siber et al. 1980]. Immune responses 
with substantial IL-4 production (Th2 cytokines) result in IgG4 induction, whilst IFNγ and 
IL-10 induce the production of IgG2 and IgG1/IgG3 respectively [Briere et al. 1994; 
Kawano and Noma 1996]. Type I interferons induce IL-10 secretion by PBMCs which 
enhances proliferation and immunoglobulin production by B cells [Rousset et al. 1992].  
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6.2. Oligoclonal Antibody response 
Oligoclonal bands are discrete bands of immunoglobulins with decreased 
electrophoretic mobility which may be detected in the serum or CSF in response to any 
process which generates an immune reaction such as infection (e.g. measles, herpes 
simples), autoimmunity (e.g. lupus cerebritis), neoplasia (e.g. paraneoplastic syndromes). 
When the source is systemic these antibodies cross the blood brain barrier and may also be 
detected in the CSF. Bands may be detected by isoelectric focusing or agarose gel 
electrophoresis, which separate proteins of different charge and size [Error! Reference 
source not found.]. By using these methods we can see evidence of a (poly) specific 
humoral immune response to the antigen in question.  
Anode + Cathode  -
pH
Distance in Gel
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Basic
+
-
Isoelectric focusing
pI
O
O
 
Figure 6-1 Schematic of isoelectric focusing 
The motion of a protein as it approaches it’s isoelectric point (pI). The pH gradient and motion 
of the protein are controlled by the electric field.  At a pH lower than pI the protein is 
positively charged (+) and moves towards the Cathode. Above the pI the protein is negativelt 
charged (-) and moves towards the Anode. There is no electrical force at the pI. 
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6.2.1. Antibodies to IFNβ 
The antibodies generated against IFNβ, as with the majority of protein based biological 
products, are generally of the IgG isotype. There are conflicting reports in the literature as 
to which IgG subclass predominates. In one study, in patients treated with IFNβ-1b who 
developed NAbs, IgG2 and IgG4 were found to occur more frequently than in patients with 
only BAbs (30% vs. 3%, p = 0.05, and 55% vs. 18%, p = 0.003, respectively). The NAb 
titre correlated strongly with the IgG4 titre (r = 0.53, p = 0.02) [Deisenhammer et al. 2001]. 
Another group reported that the IgG subclass depended on IFNβ product administered and 
was predominantly IgG1 and IgG3 within the first 6 months of treatment followed by a 
progressive decline, while IgG4 levels increased and peaked later after 24 months [Gibbs 
and Oger 2007]. Regardless of the treatment received, NAb +ve patients had higher levels 
of IgG4 subclass-specific antibodies than NAb −ve patients. These studies suggest that as a 
result of a high protein therapy (especially those prone to aggregation) the antibody 
response to IFNβ matures over time with increased IgG4 fractions and may develop a 
mono or oligoclonal response to specific IFNβ epitopes.  
 
 
6.2.2. Immunoblotting 
This technique was initially used to investigate antigen specific oligoclonal 
immunoglobulin G patterns in subacute sclerosing panencephalitis and herpes simplex 
encephalitis [Moyle et al. 1984]. It makes use of the affinity maturation process which 
selects a few highly specific clones which recognise the antigen in question. Thus by using 
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isoelectric focusing to separate the protein bands these antibodies can be transferred by 
passive blotting onto a membrane impregnated with the antigen in question and can then be 
detected immunologically. If the response to IFNβ is specific, one would expect that one or 
a few high affinity clones would emerge and be detectable as mono / oligoclonal bands on  
immunoblots. 
 
Hypothesis 
The aim of this chapter was to:  
1. Explore the hypothesis of affinity maturation of the anti-IFNβ antibody response 
and determine if the anti-IFNβ antibody response is oligoclonal using iso-electric 
focusing and immunoblotting techniques.  
 
2. Quantify the IgG subtypes in NAb +ve and BAb +ve samples and evaluate the role 
of IgG4 in neutralising activity by subtracting IgG4 fraction from sera and re-
evaluating neutralising capacity. 
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6.3. High Affinity immunoblot 
[This method was developed by Dr Miles Chapman as part of his doctoral thesis 
[Chapman et al 2006]. All blots were performed with Dr Miles Chapman- 
Neuroimmunology Dept, Institute of Neurology, London]. 
 
6.3.1. Materials 
Ultrabind 450 membrane (Gelman, UK), IFNβ – albumin-free protein (courtesy of Ed 
Croze, Schering) IFNβ-1b stock (Betaferon® Bayer-Schering), 0.9% Saline (9g sodium 
chloride (Sigma) in 1 L de-ionised water),  trizma base (Sigma) , non-fat dry milk powder 
(skimmed milk), 0.05M sulphuric acid, 1 M sodium hydroxide,  methanol, Goat anti-
human IgG (Diasorin),  Rabbit anti-goat IgG- HRP conjugate (Dako), 3-amino-9-
ethylcarbazole (Sigma), ethanol, acetate buffer,  hydrogen peroxide, mouse monoclonal 
anti-human IFN-β #B-02 Yamasa SAM-260871-1, polypropylene universal 50ml tubes 
(Sarstedt), slow rocker (Stuart), electrophoresis tank (GE Healthcare), blotting paper 
(Hollingsworth and Vose), scalpel blade. 
 
6.3.2. Methods 
6.3.2.1. Coating the membrane 
Ultrabind 450 membrane (Gelman, UK) 8cm x 4cm (32cm2) was coated with IFNβ 
solution (5ug/cm2 = 160ug of IFNβ in 11 mls 0.9% saline) and placed in a dry 
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polypropelene universal tube. This was sealed and placed on a slow rocker overnight at 
4ºC. The following morning the saline was decanted and the membrane washed twice in 
tap water. This was blocked in 50mL of 0.9% saline/2% skimmed milk/1% TRIS for at 
least 1 hour. The blocking solution was decanted and the membrane washed in saline and 
allowed to air dry. These could be frozen in a sealed plastic bag at -20ºC for up to a week.  
 
6.3.2.2. Isoelectric focusing 
The prepared gel was allowed to equilibrate to room temperature. The electrophoresis 
tank (GE Healthcare) was coupled to a circulating water cooler at 12ºC. This was started ~ 
30 minutes before focusing was run to reach temperature. Wicks of blotting paper had been 
prepared; one was soaked in 0.05 M sulphuric acid and the other in 1 M sodium hydroxide. 
The cooling plate was coated with ~ 1ml of 50 % methanol/50 % water solution prior to 
placing the gel onto it to ensure an airtight seal between the gelbond and the plate. Excess 
methanol was blotted away with dry tissue. The edges of the gel were trimmed using a 
scalpel blade to remove any “meniscus effect”. An application foil was laid on the gel 
approximately 3cm from the bottom edge of the gel. This was pressed firmly onto the gel 
to ensure an airtight seal so that when samples were applied they would not be drawn away 
from the wells. Samples were diluted 1:100 in de-ionised water and applied from right to 
left. Blank wells were filled with deionised water. The wicks were then placed on the gel; 
the sulphuric acid-soaked wick at the anode and the sodium hydroxide-soaked wick at the 
cathode. Paper towels were placed at the edges of the gel to absorb any moisture generated. 
The electrodes were secured in place using screw clamps and those on the glass plate 
were adjusted so the wire ran along the centre of the wick. The leads from the electrodes 
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were connected and the lid of the apparatus put in place. The gel was run at 800 volts, 
maximum 150 watts and 20 mA for 900 volt hours. During the run a pause was made to 
remove the application foil, replace the soaked blotting paper and remove any moisture. 
 
6.3.2.3. Blotting the gel 
After IEF of samples was complete the blotting paper and wicks were discarded. 
Excess water was removed with nitrocellulose. A membrane either pre-impregnated with 
IFNβ or only with block (as control) was then placed on the gel, ensuring no air bubbles 
were trapped. Once in place 6 sheets of blotting paper were placed on top, followed by a 
glass plate and 1kg weight, for 10 minutes. 
 
6.3.2.4. Development of the membrane 
A 1:1000 dilution of goat anti-human IgG was made by adding 25µL of the antibody to 
25 mls of 0.2% milk in 0.9% saline. The membrane was immersed in this and incubated, 
covered, overnight at 4ºC on a slow rocker. The following day the membrane was washed 
six times with 0.01% Tween/0.2 % milk/0.9 % saline. The membrane was then incubated 
with 25 ml rabbit anti-goat IgG- HRP conjugate (diluted 1:1000 in 0.2 % milk/0.9 % 
saline) for 2 hours and visualised using ethylaminocarbazole (50µg of 3-amino-9-
ethylcarbazole (Sigma)) dissolved in 20ml ethanol, 100ml working strength acetate buffer 
and 100µL 30% v/v hydrogen peroxide added before use). The membrane was developed 
for at least 10 minutes after which it was removed, washed in tap water to prevent further 
colour development and dried between two sheets of blotting paper under a hairdryer. 
 205 
6.3.3. Sample identification 
10 samples were identified from 8 subjects, which had been screened for BAbs and 
NAbs. The first set of 5 sera consisted samples which were high BAb +ve / NAb +ve. The 
second set of 5 sera were included one which was BAb -ve/NAb -ve , one BAb +ve/NAb -
ve and 3 BAb +ve / NAb +ve of different titres from the same individual. Six subjects were 
treated with Rebif® and two with Betaferon®. The results of BAb and NAb testing and 
immunoblot of patient sera are shown [Table 6-1 & Figure 6-1]. 
 
 
 
 
 
 
Sample no Product Patient no BAb titre NAb titre 
724 R 1 234 >2560 
876 B 2 132 >2560 
888 R 3 165 2435 
893 B 4 197 >2560 
964 R 5 126 3550 
3751 R 6 <3 negative 
5202 R 7 8 37 
2733 R 8 21 56 
3737 R 8 64 785 
3486 R 8 265 >2560 
Table 6-1 Patient samples used in immunoblots 
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Figure 6-2 Immunoblot of patient sera (I) 
A. Patient sera. Note bands in far left sample.  
B. Blot using antigen free membrane  
C. Blot with IFNβ impregnated membrane – no bands visable  
 
 
Oligoclonal bands 
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6.4. Results 
On three occasions blots were performed with minor modifications to the method as 
follows; 
The initial immunoblot [Figure 6-3] was performed using commercial IFNβ 
(Betaferon®) and samples 1-5 (all high positive NAbs). This showed a polyclonal response 
with no clear band(s) of anti-IFNβ antibodies. The blot was repeated in the same way with 
samples 6-10 using albumin free IFNβ but the result was similar and no clear clonal 
response was found in the sera and no binding to the IFNβ protein was detected [Figure 
6-4]. This was repeated (blot not shown) but again did not detect an oligoclonal pattern in 
NAb sera or any binding to the IFNβ protein. 
These results suggest that either the antibody response to IFNβ is polyclonal or that the 
method with which we tried to show an oligoclonal response is not sufficiently optimised 
or sensitive. The commercial product of IFNβ contains albumin which may encourage 
aggregation and interfere with the binding of IFNβ molecules to the membrane. IFNβ itself 
is highly prone to aggregation in high concentration (>250µg/ml) thus limiting the 
concentration we could impregnate the membrane with. In view of this the experiment was 
repeated using albumin-free protein; however, a polyclonal response was still detected. The 
method was further altered to focus the patients’ sera in duplicate and blot directly to the 
membrane. One copy was blotted onto a membrane which was coated with IFNβ which 
would bind to any adherent anti-IFNβ antibodies, however no binding was detected.  
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Figure 6-3 Immunoblot patient sera (II) 
A. Focused sera of IFNβ treated patients with known high positive NAbs 
B. Immunoblot with membrane impregnated with commercial IFNβ (Betaferon®) 
C. Blot using an antigen free membrane (control) 
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Figure 6-4 Immunoblot of patient sera (III) 
A. immunoblot of patient sera   
B. no binding to IFNβ protein 
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6.5. Immunoglobulin subclass quantification 
The purpose of these experiments was to measure the neutralising capacity of a sample 
pre and post IgG4 extraction to evaluate if IgG4 subclass was largely responsible to 
neutralising capacity: 
• IgG4 extraction column preparation 
• IgG4 extraction 
• Measurement of IgG subtypes in pre and post IgG4 extraction, sera 
• NAb quantification in pre and post IgG4 extraction, sera 
 
 
6.5.1. Materials  
MicroLink™ Protein Coupling Kit (PIERCE #20475) contains: 
AminoLink Plus Coupling Gel spin columns, coupling buffer: BupH™ phosphate 
buffered saline pack (0.1M sodium phosphate, 0.15M NaCl; pH 7.2), µLtrapure water, 
quenching buffer, 1M Tris HCl 0.05% NaN3, pH 7.4, Sodium cyanoborohydride (5M), 
0.01M NaOH, wash solution 1M NaCl, 0.05% NaN3, elution buffer pH 2.8 (contains 
primary amine), microcentrifuge collection tubes. Bindarid™ Human IgG subclass single 
dilution kits: Radioimmune diffusion plates (specific for IgG 1, 2, 3 or 4), calibrators IgG 
1, 2, 3 and 4, 7% bovine serum albumin (BSA) solution, control serum, gel dividers 
Additional materials: Pipettes: 10 µL, 200 µL, 1000 µL, 30-300 µL multichannel 
adjustable volume pipettes - Eppendorf Research®, pipette tips 10 µL, 20 -200  µL, 1000 
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µL, centrifuge, slow rocker, polypropylene universal 50ml tubes, polypropylene 1.5mL 
microtubes, plastic ruler to measure to 0.1mm. Mouse monoclonal antibody to human IgG4 
(ZYMED laboratories) 
 
6.5.2. Methods - IgG4 immuno-subtraction 
 
 
Figure 6-5 Protein coupling to subtract IgG4 
Adapted from Pierce microprotein coupling kit information sheet (www.piercenet.com) 
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6.5.2.1. Column Preparation 
All reagents were equilibrated to room temperature. The coupling buffer was prepared 
by dissolving the dry-blend buffer with 500mls ultrapure water. 50 µL of mouse 
monoclonal anti- IgG4 antibody was added to 150 µL of coupling buffer.  The column cap 
was loosened and the bottom plug removed. The column was then placed in collection tube 
and spun at 1000g for 2 minutes. The column cap was removed and plug re-inserted. To re-
suspend the gel 300µL coupling buffer was added. Again the plug was removed and 
column placed in a collection tube. This was centrifuged @ 1000g for 1 minute and flow 
through was discarded. This was repeated twice. 
The column was plugged and 200 µL of sample was added directly onto the gel. The 
cap was replaced and gently vortexed. 2 µL of sodium cyanoborohydride solution was 
added to the column in fume hood, the cap replaced and mixed again. The column was 
incubated at room temperature for 4 hours, vortexing gently every hour (gentle end over 
end mixing). The column cap was loosened and plug removed. The column was placed in a 
fresh collection tube and centrifuged.  The column was uncapped and plug re-inserted. 
300µL of coupling buffer was added, the cap replaced and mixed. The column was placed 
in a collection tube and centrifuged twice.  
To block remaining active binding sites 300µL of quenching buffer was added onto the 
gel and mixed. The column cap was loosened and plug removed. The column was placed in 
a collection tube and centrifuged. This step was repeated again. The column plug was re-
inserted and 200µL of quenching buffer directly added onto gel. The cap was replaced and 
column vortexed gently again. 4 µL of sodium cyanoborohydride solution was added to the 
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column in the fume hood. This was mixed again and incubated at room temperature for 30 
minutes mixing every 15 mins. The cap and plug were removed and the column placed in a 
collection tube and centrifuged. 
 
6.5.2.2. Wash and store  
300µL of wash solution was added to the column and plug reinserted. The cap was 
replaced and solutions mixed. The cap and plug were removed and the column placed in a 
collection tube which was centrifuged and the flow through discarded. This was performed 
twice more.  
The column was plugged and 300 µL of coupling buffer added, the cap was replaced 
and column was mixed. The cap and plug were removed and the column was centrifuged, 
the flow through was discarded. Again this was repeated twice. Finally the column was 
plugged and 300µL coupling buffer added along the sides of column to wash down gel. 
The cap was replaced and the column stored at 4˚C for up to 2 weeks. 
Thereafter the serum sample was placed in the column and incubated on a rocker for 2 
hours at room temperature.  The column was centrifuged to yield the IgG4 depleted 
sample.  
 
6.5.2.3. Quantification of IgG subclasses 
The principle of radial immunodiffusion is based on the ability of antigen to diffuse 
through an agarose gel containing an appropriate mono-specific antibody. The antigen-
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antibody complexes are formed and a precipitin ring forms. The ring size increases until 
the equilibrium between complex formation and breakdown is reached. At this stage a 
linear relationship between the ring diametre and antigen concentration exists. A 
concentration curve was produced with known antigen concentrations and thus the antigen 
content of unknown samples was calculated. 
 
 
Figure 6-6 Principle of Radial immunodiffusion. 
Equilibrium of antigen-antibody complexes forming precipitant rings 
 
 
6.5.2.4. Methods 
The four RID plates (IgG1, 2, 3, 4) were removed from the foil pouches and 
equilibrated for ~ 15 minutes to room temperature to ensure no condensation was present. 
These were kept upside-down until any moisture had evaporated. The plates were 
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partitioned into 4 sections with gel dividers. Calibrators and controls were mixed gently 
before use. Dilutions of 60% (moderate) and 10% (low) of the calibrators were made to 
create a standard curve. Due to the expected higher concentrations of IgG1 and 2, a 1:10 
dilution of control IgG1 and IgG2 were prepared using 25µL control serum with 225µL of 
diluent to maintain accuracy. Dilution of IgG3 and IgG4 controls was not required.  
 
Point of curve Calibrator µL Diluent µL 
High 100 0 
Moderate 60 40 
Low 25 225 
               Table 6-2 Standard curve radial immunodiffusion assay 
 
 
6.5.2.5. Patient serum samples 
8 patient samples were chosen, 1 pooled normal serum and one treatment naive patient 
were tested. The neat patient sample and the serum post IgG4 subtraction were prepared for 
use in the RID plates. A 1:10 dilution of the patient’s samples were made for application to 
the IgG1 and 2 plates, neat sera was added to IgG3 and 4 plates.  
 
6.5.2.6. IgG 1 and 2 plates 
5 µL of calibrator dilutions – neat, moderate and low, were added to the first 3 wells (1-
3). The next well (4) was filled with 5 µL of control sera @ 1:10 dilution. The remaining 
wells were filled with patient samples @ 1:10 dilutions. 
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6.5.2.7. IgG 3 and 4 plates 
5 µL of calibrator dilutions – neat, moderate and low, were added to the first 3 wells (1-
3). The next well (4) was filled with 5 µL of neat control sera. The remaining wells were 
filled with neat patient samples. 
 
The lids were replaced tightly on the 4 plates and were incubated at room temperature 
for 72 hours to incubate and the diffusion rings to appear.  
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6.5.3. Calculation of results 
Lids were removed and using a ruler and magnifying glass the diameter of the precipitin 
rings were measured. Figure 6-7 shows an example of the appearance of the precipitin 
rings. The ring diameters were measured to the nearest 0.1mm using a magnifying glass. 
The squares of the diameters (mm2) of the rings were calculated. The known concentration 
f the IgG subclass was plotted on the x-axis vs. the D2 of calibrators (3 dilutions) on the y-
axis vs). A trendline was applied and the IgG concentrations of each sample were 
calculated from the equation [Figure 6-8]. 
 
 
 
Figure 6-7 Radial immunodiffusion plate with IgG precipitant rings 
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Figure 6-8 Standard curves of each IgG subclass with trendline equation. 
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6.5.4. Results 
Paired samples (pre and post IgG4 subtraction) of 4 patients were run on each plate. 
The concentration of IgG1, 2, 3 and 4 was calculated in each case to evaluate if IgG4 had 
been specifically extracted [Table 6-3]. Paired samples (pre and post IgG4 subtraction) of 4 
patients were run on each plate. The mean proportion of amount of IgG4 extracted was 
90% range [53 - 100]. Although only IgG4 should have been extracted in the column 
reductions were seen in other IgG subtypes also; IgG1 22% [13 – 33], IgG2 15% [0 - 50], 
IgG3 47% [0 – 98]. The pre and post IgG4 extraction samples were then tested for 
neutralising activity using the procedure detailed in chapter 3. Although reduction of 
neutralising antibody titre was noted in most samples this showed no correlation to the 
reduction of total IgG4 [Figure 6-9].  
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Sample IgG1 IgG2 IgG3 IgG4 
Control 1      
% reduction 
 
23 0.2 21 94 
Control 2 
% reduction 
 
26 4.7 25 85 
S 1 
% reduction 
 
33 18 82 100 
S 2 
% reduction 
 
16 0 98 100 
S 3 
% reduction 
 
13 24 0 53 
S 4 
% reduction 
 
17 50 32 100 
S 5 
% reduction 
 
27 5 24 94 
S 6 
% reduction 
 
35 21 83 100 
S 7 
% reduction 
 
13 5 98 100 
S 8 
% reduction 
 
16 26 4 75 
Table 6-3 Percentage reduction of Immunoglobulin subclass. 
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Neutralising 
activity 
PRE 
Neutralising 
activity 
POST 
Reduction in 
neutralising 
activity (%) 
Reduction in 
IgG4 (%) 
1 3928 1180 70 100 
2 2092 558 73 100 
3 13051 6494 50 53 
4 >10240 >10240 NA 100 
5 438 321 27 94 
6 1572 976 38 100 
7 4239 3290 22 100 
8 970 548 44 75 
Table 6-4 Neutralising antibody titre for each sample pre and post IgG4 extraction. 
 
 
 
Figure 6-9 Correlation of neutralising activity and IgG4 subtraction 
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6.6. Conclusions 
In this work we were unable to detect an oligoclonal response to IFNβ. This might 
indicate that (i) the antibody response to IFNβ is indeed polyclonal (ii) that the method 
with which we tried to show an oligoclonal response is not sufficiently optimised or 
sensitive. The commercial product of IFNβ contains albumin which may encourage 
aggregation and interfere with the binding of IFNβ molecules to the membrane. IFNβ itself 
is highly prone to aggregation in high concentration (>250µg/ml) thus limiting the 
concentration we could impregnate the membrane with. In view of this the experiment was 
repeated using albumin-free protein; however, a polyclonal response was still detected. We 
therefore chose to alter the method to focus the patients’ sera and blot directly to the 
membrane. We then incubated one copy with IFNβ which would bind to any anti-IFNβ 
antibodies adherent to the membrane, however no binding was detected. It may be that the 
response is oligoclonal but due to the limitations of the techniques and the nature of the 
IFNβ molecule we were unable to show this.  
It is possible however that the phenomenon known as “scrambling” of the IgG4 
antibody fraction is the reason that we are unable to detect the oligoclonal immune 
response using immunoblotting techniques. An antibody is composed of two identical 
dimers with identical Fab binding arms. However IgG4 subtype antibodies are able to 
exchange dimer partners to form antibodies which have different Fab arms and thus 
crosslink different antigens. This switch of Fab arms is called scrambling [Burton and 
Wilson 2007].  
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Regarding the effect of IgG4 subclass extraction we were unable to specifically remove 
IgG 4 without also reducing the amount of other subclasses. In view of this any apparent 
reduction of neutralising capacity of the patient’s sera could not be attributed to IgG 4. No 
correlation was found between the reduced neutralsing capacity and the reduction in IgG 4. 
It would be of interest to extract IFNβ specific antibodies thereafter subtract the IgG4 
fraction.  Further work to evaluate affinity maturation and the role of individual IgG 
subtypes in neutralising IFNβ activity is required but was not undertaken within the remit 
of this thesis. 
In conclusion, it appears that NAbs are found in the IgG4 and non-IgG4 components of 
the IgG response. Although we showed that the NAb response to IFNβ was polyclonal this 
is likely to be due to the biology of IgG4. Technical factors in relation to the chemistry of 
recombinant human IFNβ may explain our inability to detect oligoclonal bands in the other 
IgG subtypes.  
 
 
 
 
 
 
 224 
 
Chapter 7  
Incorporating NAbs and NAb testing into 
clinical practice 
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7  Incorporating NAbs and NAb testing into clinical 
practice 
 
7.1. Diffusion of innovation 
Diffusion of innovation is a theory of “how, why, and at what rate new ideas and 
technology spread through cultures”. Everett Rogers introduced this theory in 1962 in his 
book, “Diffusion of Innovations”, writing that "Diffusion is the process by which an 
innovation is communicated through certain channels over time among the members of a 
social system”. Rogers theorised that innovations would spread through a community in a 
sigmoidal curve.  The early adopters select the innovation first (which may be a technology 
or in the scientific world the cause of a disease), followed by the majority, until a 
technology or innovation (or opinion) has reached its saturation point in a community. He 
also described the process of innovation adoption as a process that occurs over time 
through five stages: Knowledge, Persuasion, Decision, Implementation and Confirmation. 
Accordingly, the innovation-decision process is the process through which an individual or 
other decision-making unit passes (i) from first knowledge of an innovation, (ii) to forming 
an attitude toward the innovation, (iii) to a decision to adopt or reject, 4, (iv) to 
implementation of the new idea and (v) to confirmation of this decision [Rogers 2003]. 
This theory can be applied easily to medical practice and also to the response of the MS 
community to NAbs.  
Interferon beta (IFNβ) has been widely used for more than ten years in patients with 
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relapsing multiple sclerosis (MS). Funding of disease modifying treatments such as 
interferons and glatiramer acetate have been controversial in many countries, especially in 
the UK [Pickin et al. 2009]. The unpredictable course of MS and its potential to cause 
severe disability explains the high demand for disease-modifying agents – but independent 
bodies such as Cochrane and the National Institute of Clinical Excellence (NICE) 
www.nice.org.uk/TA32) have highlighted the lack of clear-cut evidence of their clinical 
efficacy. Over 560 papers are currently indexed on PubMed when search terms “interferon 
beta & neutralizing antibodies” are entered. Conflicting results of clinical trials are 
reflected in equivocal guidelines regarding NAbs issued by European, American and 
British Neurological bodies [EFNS, AAN ABN guidelines]. There has been much 
controversy with respect to the significance of these antibodies in patients with multiple 
sclerosis treated with IFNβ and how to manage them [Hartung and Munschauer, III 2004; 
Farrell and Giovannoni 2007]. Ambivalent data underpins the controversy relating to NAbs 
and this is largely due to highly variable methodology between trials, many of which are of 
insufficient duration to show an effect on primary endpoints. The influence of the 
pharmaceutical industry should not be underestimated as they have certainly played a large 
role in encouraging doubt over the relevance of NAbs.  
What are the “known facts” relating to NAbs? The detrimental effect on clinical outcomes 
is only seen in patients followed for more than two years. The frequency of NAbs is 
product dependent with IFNβ-1b SC being more immunogenic than IFNβ-1a SC and IFNβ-
1a IM [Jacobs et al. 1996; Francis et al. 2005; IFNβ MS Study group 1996]. The loss of 
clinical effect is titre dependent [Sominanda et al. 2008; Pachner et al. 2009b] (and 
confirmed in this thesis) and those with low titres may revert to NAb negative status over 
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time. This was shown in the IFNβ-1b follow-up study in which 80% of NAb positive 
patients converted to antibody-negative status after 8 years despite continued therapy [Rice 
et al. 2001]. Another known fact is that NAbs to one IFNβ product cross-react with the 
others, so switching therapy to another IFNβ is not likely to be an effective strategy in the 
NAb positive patient [Khan and Dhib-Jalbut 1998; Bertolotto et al. 2000] .  
In the UK no NAb testing was readily available and those who wished to test would send 
samples to research laboratories or elsewhere in Europe. Thus using the Rogers model of 
diffusion of innovation adoption of routine testing for NAbs has been arrested in the 3rd or 
4th phase in the UK and indeed many other countries. Early adopters have championed the 
significance of NAbs but there remain many who oppose incorporating them into clinical 
decision making and routine testing has only appeared in a handful of countries.  
 
7.2. Existing guidelines.  
7.2.1. American Academy of Neurology (AAN) 
The AAN reported in 2007 their recommendations focusing on the effect of NAbs on 
clinical and radiologic outcomes [Goodin et al. 2007].  The committee concurred that there 
is probably a reduction in efficacy of treatment because of NAbs and there is likely to be 
greater antibody production in response to IFNβ-1b than to IFNβ-1a, and that IM IFNβ-1a 
is clearly less immunogenic than other interferon therapies. Despite the consistent finding 
of NAb levels greater than 1:200 being associated with a reduction of efficacy, the 
committee was unable to make definite recommendations for changing therapy.  
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7.2.2. European Federation of Neurological Societies (EFNS) 
The EFNS recommended that patients treated with IFNβ are tested for the presence of 
NAbs at 12 and 24 months of therapy (Level A recommendation). In those whom remain 
NAb negative at 18 – 24 months further testing is not routinely required (Level B 
recommendation). There is class I evidence that the presence of NAbs significantly reduces 
the effect of IFNβ on relapse rate and active lesions and burden of disease seen with MRI. 
In patients who are NAb+ve measurements should be repeated at intervals of 3–6 months 
and therapeutic options should be re-evaluated (Level A recommendation). Therapy with 
IFNβ should be discontinued in patients with high titres of NAbs at repeated measurements 
with 3- to 6-month intervals (Level A recommendation) [Sorensen et al. 2005a]. New 
guidelines are currently in preparation. 
 
7.2.3. Association of British Neurologists (ABN) 
Recently the ABN have issued updated guidelines pertaining to use of IFNβ in subjects 
with RRMS and CIS superseding those published in 2001. This included a statement 
relating to NAbs stating that positive tests for NAbs to beta-interferon strengthen the case 
for discontinuation of treatment when clinical or MRI features of treatment failure are 
present. NAb testing should be performed in a competent lab using a reliable assay 
www.theabn.org . 
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Despite the body of evidence confirming the impact of NAbs on treatment efficacy 
opinions regarding NAbs differ greatly. In Denmark since IFNβ became available NAbs 
have been routinely tested in all subjects and much of what we know has been published by 
this group [Ross et al. 2000; Sorensen et al. 2003c; Vartanian et al. 2004; Ross et al. 2006; 
Hesse et al. 2009;  Sellebjerg et al. 2009].  In the UK and USA however opinion is less 
certain with many doubting the significance of NAbs. The modest average efficacy of IFNβ 
in MS (~ 30% reduction of relapses) also contributes to the uncertainty as MS is a disease 
of relapses and remissions in the majority of patients, the natural history being that relapses 
decrease with time, thus apparent treatment response may occur in the presence of NAbs 
and may be a model of benign MS rather than treatment efficacy. 
 
7.3. Delivery 
The purpose of this work was to address the need to develop a simple, time and cost 
efficient assay, which could be reliably used in clinical practice. For this purpose we have 
developed the Luciferase assay which has been validated against gold standard assays in 
Europe [chapter 3]. The assay has been used to illustrate the increased relapse rate and 
treatment failure in subjects who are NAb positive [chapter 4] and titres obtained with this 
assay predict bioactivity of IFNβ as predicted by MxA expression [chapter 5]. As part of 
the European consortium to standardise Nab testing 40 blinded samples were exchanged 
between laboratories in the UK, Denmark and Canada. The three laboratories showed 
excellent agreement with the “gold standard” assay (CPE in Dr Antonio Bertolotto’s lab in 
Italy) and the Luciferase assay showed excelled interlaboratory validity [Figure 7-1]. 
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Figure 7-1 Agreement of Luciferase assay with CPE 
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7.3.1. Clinical practice 
The luciferase NAb assay [chapter 3] was initially developed in 2006 and was approved for 
routine NHS use in June 2007, and became available to all prescribing centres. To assess 
the opinion of Neurologists to NAbs we performed an anonymous online survey using 
SurveyOnNet www.surveyonnet.com initially surveying opinion in the UK. Thereafter we 
extended the survey to North American and European countries using surveymonkey 
www.surveymonkey.com [chapter 7.3.2]. Neurologists involved in NAb testing in 17 
countries were invited to take part and 9 agreed to circulate the questionnaire. However 
after three months only the UK, USA, Canada and Austria had generated sufficient data.  
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7.3.2. Questionnnaire - Neutralising anti-interferon beta 
antibodies (Nabs) in patients with Multiple Sclerosis. 
1. Do you treat patients with MS? 
 
2. Do you prescribe disease modifying therapies (please tick relevant treatments): 
A. Interferon beta 
B. Glatiramer Acetate 
C. Mitoxantrome 
D. Natalizumab     
E. None 
F. Others (please list)……………………                                                                
                                                                                                                                                               
3. Have you heard about neutralising antibodies (NAbs) to Interferon beta? 
A. Yes 
B. No 
 
4. Are you aware of International Guidelines pertaining to NAbs? 
A. Yes - EFNS 
B. Yes - AAN 
C. Yes - Both 
D. No 
        
5. Do you counsel patients about NAbs when educating them about treatment 
options? 
A. Yes 
B. No 
 
 
6. Do you take NAbs into consideration when starting an Interferon beta preparation?  
A. Yes 
B. No 
C. Some times 
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7. Do you think that high levels of NAbs abrogate the efficacy of the drug:  
A. Yes 
B. Probably 
C. No 
D. Don’t know 
                                                                                                                                                                                                                                                              
8. Which statement best describes your practice with respect to NAbs? 
A. I test for NAbs routinely in all patients receiving IFNβ 
B. I only test for NAbs in those who have relapses 
C. I never test for NAbs 
D. I test for NAbs when the patient specifically requests it. 
 
9. If a patient is NAb positive do you: 
A. Do nothing 
B. Retest in 3 months, with view to changing therapy 
C. Discuss change of therapy with patient. 
D. Acknowledge result but only change therapy if patient is actively relapsing 
E. Request MRI and change therapy if Gadolinium enhancing lesions present. 
 
10. Are you aware that NAb testing is available in ………… 
A. Yes 
B. No 
 
11. In which city / country do you practice? 
              
12. Please add any further comments with regards to your views on NAbs to IFNβ      
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7.3.3. Survey Results 
UK: One hundred and three British neurologists responded, representing all regions of the 
UK and Northern Ireland. All were regular prescribers of IFNβ and aware of NAbs (100%) 
but only 78% were aware that NAb testing was available in the UK funded by the NHS. 
When commencing IFNβ treatment 61% of neurologists counselled patients about NAbs 
and 24% felt it influenced product choice.  When asked if NAbs abrogate the efficacy of 
IFNβ 48% of neurologists answered “yes”, 48% answered “probably” and only 4% said 
that they thought NAbs have no effect.  To assess the testing patterns of neurologists we 
asked when they usually tested for NAbs; 17% routinely screened all subjects for NAbs, 
38% only tested following a relapse and 11% when specifically requested by the patient, 
35% of respondents never tested patients for NAbs. Concerning action following a positive 
result; 35% re-tested 3 months later to assess persistence, 30% discussed alternative 
treatments and 42% would only recommend change if patient actively relapsing.  
 
USA: One hundred and thirty two people replied, 95% of whom regularly prescribed 
disease modifying drugs. Of these 99.1% were aware of NAbs and 56% believe they 
abrogate the efficacy of IFNβ treatment and 36% replied “probably”. In total 87% were 
aware of guidelines from AAN +/- EFNS and 86% generally counselled patients about 
NAbs before initiating treatment. Only 13% routinely tested all patients for NAbs, 70% in 
those who were actively relapsing and 15% never tested. In response to a positive test 46% 
will retest to evaluate persistence with a view to changing treatment, 24% discuss 
alternative treatments amd 10% will request and MRI to assess lesion load basing treatment 
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change on this. 
 
Canada: Twenty three neurologists replied and all (100%) regularly prescribed disease 
modifying drugs and all were aware of NAbs (100%). 100% believed NAbs do (63.6%) or 
probably (36.4%) abrogate the efficacy of IFNβ treatment. In total 82% were aware of 
guidelines from AAN +/- EFNS and 90% generally counselled patients about NAbs before 
initiating treatment, but generally this did not influence product choice. Routine testing of 
all patients was described by 30%, 55% tested those who were actively relapsing and 15% 
never tested. In response to a positive test 48% would retest to evaluate persistence with a 
view to changing treatment, 19% discuss alternative treatments amd 10% will request and 
MRI to assess lesion load basing treatment change on this. 
 
Austria: Seventy seven neurologists answered however only 90% prescribed DMDs. Of 
these 96% were aware of NAbs and 95% thought Nabs do (37%) or probably (48%) affect 
the efficacy of IFNβ. Routine testing was performed in 25% with a further 67% testing in 
actively relapsing patients, only 5% said they never test for NAbs. In response to a positive 
test 39% would repeat the test to evaluste persistence and then consider treatment change. 
33% would only consider an alternative treatment if the patient was actively relapsing and 
7.4% would base the choice on an MRI.  
 
When comparing responses of all 4 counties awareness regarding Nabs was high and most 
thought they play a role in reducing the efficacy of the drug. However routine testing was 
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rarely pursued and most only tested if a patient was actively relapsing. In the UK 35% of 
those who answered never test for NAbs. This is over double the proportion in other 
countries surveyed. Results are summarised in Table 7-1. 
 
 
 UK USA CANADA AUSTRIA 
Prescribe IFNβ 100% 95% 96% 90% 
Aware of NAbs 100% 99% 100% 96% 
NAbs reduce IFNβ efficacy 
Yes 
Probably 
No 
 
48% 
48% 
4% 
 
56% 
36% 
2.6% 
 
63.3% 
36.4% 
0% 
 
37% 
48% 
5.4% 
NAb testing 
All 
Relapsing only 
Never 
 
17% 
38% 
35% 
 
13% 
70% 
15% 
 
30% 
55% 
15% 
 
25% 
67% 
5% 
Table 7-1 Results of NAbs survey 
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7.3.4. Uptake of the Luciferase Assay in the UK 
It is estimated that more than 10,000 people with MS are treated with IFNβ in the UK. 
Since the Luciferase assay became available, 3478 samples (representing 2853 individuals) 
from 117 centres have been tested in our unit (figures from 25th January 2010). Of these 
2283 (66%) were negative [titre < 20] and 1185 (34%) positive [327 (9.4%) were low, 331 
(9.5%) moderate and 523 (15%) high positive]. This reflects the probable number of 
patients screened for NAbs in the UK and highlights that only ~ 15% of subjects are in the 
category that predicts no biological response to the IFNβ injection.  
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Chapter 8 
Conclusions 
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8 Conclusions  
The purpose of this work was to address the need to develop a simple, time and cost 
efficient assay, which could be reliably used in clinical practice both here in the UK but 
also to distribute it to other laboratories. We have achieved this in developing the luciferase 
assay which has been validated against gold standard assays in Europe [chapter 3]. The 
assay has also been widely distributed thoughout Europe and North America and has 
shown excellent inter-laboratory validity. The assay has been used to investigate the 
association of NAbs with clinical status and in chapter 4 the increased relapse rate and 
treatment failure in subjects who are NAb positive was shown. The reduced clinical 
efficacy was also shown to be titre dependent and those with highest NAb titres having the 
greatest risk of relapse. One hundred and fourty four subjects were recruited prospectively 
whom were treated for a minimum of 6 months with IFNβ [Chapter 5]. Samples were taken 
before and after IFNβ administration and MxA was measured as an established marker of 
IFNβ bioactivity.  The NAb titres obtained with the Luciferase assaywere found to predict 
the MxA response with those who were NAb positive showing a reduced MxA induction in 
a titre dependent fashion.   
Over the past two years after validation of the assay this work has been presented at several 
conferences and the assay methods published [Farrell et al. 2008; Farrell & Lam et al. 
2008]. After submission of a successful business case to UCLH the luciferase assay 
became the routine assay used in the Neuroimmunology laboratory at the NHNN, London 
for routine NAb testing on the NHS. We have distributed the assay to several countries 
including Germany, Austria, Sweden, Denmark, Canada, Italy, Poland, Switzerland, 
Hungary and in many countries it has become the National Reference Assay.  
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As we have found in several cohorts of patients tested at NHNN ~ 25 % of all subjects 
have NAbs. In many these are at a low level and unlikely to affect the bioactivity of the 
drug significantly. However consideration should be given to identifying those who are 
responders and non-responders to IFNβ, and alter management accordingly. Problems arise 
making treatment decisions in patients who are NAb +ve but are doing well clinically. In 
these cases NAb status should be used as a predictive marker of risk of future relapse and 
to identify subjects who are more likely to fail IFNβ therapy. The odds of having a relapse 
in a NAb +ve period compared to NAb -ve is between 1.51 and 1.58 (p< 0.03) and the time 
to first relapse is prolonged by an average of 244 days in subjects who are NAb -ve at 12 
months (p<0.009) [Sorensen et al. 2003]. Some clinicians argue that due to the high 
reversion rates seen in subjects treated with IFNβ-1b in particular, there is no need to stop 
treatment. It is important to note however that not all will revert and that it is generally only 
seen in those with low titres. During the period of NAb positivity they will also be at 
increased risk of relapse and may incur further disability through incomplete recovery. As 
NAbs are known to be cross-reactive across IFNβ products switching between 1a and 1b is 
not sufficient [Antonelli et al. 1999; Bertolotto et al. 2000].  It is due to this that we 
recommend that those with persistently high titres should be considered for alternative 
therapy. 
An alternative strategy to manage NAbs is to consider directly targeting them by either 
preventing their formation or treating them after they have developed. Recently studies 
have explored the effect of corticosteroids in preventing the development of neutralising 
anti-IFNβ antibodies (NAbs) or minimising their levels. It has been shown that treatment 
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with concomitant steroids delays the appearance of NAbs and lower titres develop when 
they do appear [Pozzilli et al. 2002; Pozzilli et al. 2004]. Concomitant use of 
immunosuppressive therapies in combination with various biological products is associated 
with a lower rate or the reversal of NAbs. In an open labelled study of 161 MS patients, 
receiving IFNβ-1b (Betaferon®, 8MIU s.c. on alternate days), randomised to receive either 
intravenous methyl-prednisolone 1g monthly for 12 months compared to no corticosteroids 
the prevalence of NAbs at 15 months in the prednisone treated group was 12.1% compared 
to 26.8% in untreated group, a relative reduction of 54.9% [Pozzilli et al. 2002b].  However 
results from a number of studies have not shown consistent results [Calabresi et al. 2002; 
Patti et al. 2001]. The most feasible option however is to switch to another class of DMD 
altogether: Glatiramer Acetate, Natalizumab and Mitoxantrone are well established 
available treatments and it is anticipated that in the next 12 months new oral agents should 
be available. 
We recommend that once a person is established on IFNβ treatment they should be 
routinely screened for NAbs at 12 and 24 months. If a person is NAb -ve at 24 months it is 
unlikely that they will become NAb +ve in the future and therefore further routine testing 
will not be of benefit. In those with titre ~ 100 – 600 NU quantification of MxA expression 
is useful in determining the individual’s response to IFNβ administration. Those who show 
expression of MxA are likely to be partial responders despite NAbs whereas those will very 
low levels of MxA suggest the drug is not inducing the required biological response. New 
guidelines are anticipated for the Eurpoean consortium regarding NAbs and should also be 
adopted in the UK. 
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Future research planned following the work described in this thesis will focus on 
establishing a combined NAb and MxA induction assay as part of routine NAb testing for 
NHS patients. As sample numbers increase it will enable us to further define the Nab titre 
at which the biological response is reduced and the titre at which no response is found. Due 
to the small number of subjects with titres > 600 NU in the cohort described here, the study 
was underpowered to establish a sensitive and specific “cut point”. We must stress that a 
specific cut-point may not exist and in vivo bioactivity and NAb titre may need to be 
interepreted together. We also plan to use NAbs as a tool to investigate the treatment effect 
of IFNβ on viruses which have been linked to MS (eg EBV, HHV6) either in relation to 
aetiology or disease activity. Longitudinal and cross-sectional studies are underway 
evaluating the serological response to and reactivation of viruses in subjects which were 
recruited in the NAb studies described. 
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